10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

Form 10-Q

☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended September 30, 2017

OR

☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from               to               

Commission File Number 1-7293

_________________________________________

TENET HEALTHCARE CORPORATION

(Exact name of Registrant as specified in its charter)

_________________________________________

Nevada (State of Incorporation) 95-2557091 (IRS Employer Identification No.)

1445 Ross Avenue, Suite 1400

Dallas, TX 75202

(Address of principal executive offices, including zip code)

(469) 893-2200

(Registrant’s telephone number, including area code)

_________________________________________

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months, and (2) has been subject to such filing requirements for the past 90 days.   Yes ☒ No ☐

Indicate by check mark whether the Registrant has submitted electronically and posted on its corporate website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months.   Yes ☒ No ☐

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company (each as defined in Exchange Act Rule 12b-2).

Large accelerated filer ☒	Accelerated filer ☐	Non-accelerated filer ☐
Smaller reporting company ☐		Emerging growth company ☐

If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the Registrant is a shell company (as defined in Exchange Act Rule 12b-2).   Yes ☐ No ☒

At October 31, 2017, there were 100,936,869 shares of the Registrant’s common stock, $0.05 par value, outstanding.

TENET HEALTHCARE CORPORATION

TABLE OF CONTENTS

		Page
PART I. FINANCIAL INFORMATION
Item 1.	Financial Statements (Unaudited)
	Condensed Consolidated Financial Statements	1
	Notes to Condensed Consolidated Financial Statements	5
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	26
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	57
Item 4.	Controls and Procedures	57
PART II. OTHER INFORMATION
Item 1.	Legal Proceedings	58
Item 1A.	Risk Factors	58
Item 6.	Exhibits	59

i

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

TENET HEALTHCARE CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

Dollars in Millions

(Unaudited)

	September 30,			December 31,
	2017			2016
ASSETS
Current assets:
Cash and cash equivalents	$	429		$	716
Accounts receivable, less allowance for doubtful accounts ($934 at September 30, 2017 and $1,031 at December 31, 2016)	2,567			2,897
Inventories of supplies, at cost	297			326
Income tax receivable	14			4
Assets held for sale	842			29
Other current assets	1,160			1,285
Total current assets	5,309			5,257
Investments and other assets	1,253			1,250
Deferred income taxes	783			871
Property and equipment, at cost, less accumulated depreciation and amortization ($4,750 at September 30, 2017 and $4,974 at December 31, 2016)	7,077			8,053
Goodwill	7,022			7,425
Other intangible assets, at cost, less accumulated amortization ($841 at September 30, 2017 and $772 at December 31, 2016)	1,764			1,845
Total assets	$	23,208		$	24,701
LIABILITIES AND EQUITY
Current liabilities:
Current portion of long-term debt	$	140		$	191
Accounts payable	1,100			1,329
Accrued compensation and benefits	800			872
Professional and general liability reserves	210			181
Accrued interest payable	336			210
Liabilities held for sale	407			9
Other current liabilities	1,146			1,242
Total current liabilities	4,139			4,034
Long-term debt, net of current portion	14,741			15,064
Professional and general liability reserves	617			613
Defined benefit plan obligations	596			626
Deferred income taxes	—			279
Other long-term liabilities	604			610
Total liabilities	20,697			21,226
Commitments and contingencies
Redeemable noncontrolling interests in equity of consolidated subsidiaries	1,816			2,393
Equity:
Shareholders’ equity:
Common stock, $0.05 par value; authorized 262,500,000 shares; 149,244,229 shares issued at September 30, 2017 and 148,106,249 shares issued at December 31, 2016	7			7
Additional paid-in capital	4,835			4,827
Accumulated other comprehensive loss	(238		)	(258		)
Accumulated deficit	(2,161		)	(1,742		)
Common stock in treasury, at cost, 48,413,280 shares at September 30, 2017 and 48,420,650 shares at December 31, 2016	(2,419		)	(2,417		)
Total shareholders’ equity	24			417
Noncontrolling interests	671			665
Total equity	695			1,082
Total liabilities and equity	$	23,208		$	24,701

See accompanying Notes to Condensed Consolidated Financial Statements.

TENET HEALTHCARE CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

Dollars in Millions, Except Per-Share Amounts

(Unaudited)

	Three Months Ended September 30,						Nine Months Ended September 30,
	2017			2016			2017			2016
Net operating revenues:
Net operating revenues before provision for doubtful accounts	$	4,941		$	5,216		$	15,310		$	15,856
Less: Provision for doubtful accounts	355			367			1,109			1,095
Net operating revenues	4,586			4,849			14,201			14,761
Equity in earnings of unconsolidated affiliates	38			31			95			85
Operating expenses:
Salaries, wages and benefits	2,264			2,308			6,990			7,012
Supplies	740			767			2,285			2,351
Other operating expenses, net	1,120			1,231			3,466			3,686
Electronic health record incentives	(1		)	(2		)	(8		)	(23		)
Depreciation and amortization	219			205			662			632
Impairment and restructuring charges, and acquisition-related costs	329			31			403			81
Litigation and investigation costs	6			4			12			291
Gains on sales, consolidation and deconsolidation of facilities	(104		)	(3		)	(142		)	(151		)
Operating income	51			339			628			967
Interest expense	(257		)	(243		)	(775		)	(730		)
Other non-operating expense, net	(4		)	(7		)	(14		)	(18		)
Loss from early extinguishment of debt	(138		)	—			(164		)	—
Net income (loss) from continuing operations, before income taxes	(348		)	89			(325		)	219
Income tax benefit (expense)	60			(10		)	105			(61		)
Net income (loss) from continuing operations, before discontinued operations	(288		)	79			(220		)	158
Discontinued operations:
Income (loss) from operations	(1		)	2			(1		)	(5		)
Income tax benefit (expense)	—			(1		)	—			—
Net income (loss) from discontinued operations	(1		)	1			(1		)	(5		)
Net income (loss)	(289		)	80			(221		)	153
Less: Net income attributable to noncontrolling interests	78			88			254			266
Net loss attributable to Tenet Healthcare Corporation common shareholders	$	(367	)	$	(8	)	$	(475	)	$	(113	)
Amounts attributable to Tenet Healthcare Corporation common shareholders
Net loss from continuing operations, net of tax	$	(366	)	$	(9	)	$	(474	)	$	(108	)
Net income (loss) from discontinued operations, net of tax	(1		)	1			(1		)	(5		)
Net loss attributable to Tenet Healthcare Corporation common shareholders	$	(367	)	$	(8	)	$	(475	)	$	(113	)
Earnings (loss) per share available (attributable) to Tenet Healthcare Corporation common shareholders:
Basic
Continuing operations	$	(3.63	)	$	(0.09	)	$	(4.72	)	$	(1.09	)
Discontinued operations	(0.01		)	0.01			(0.01		)	(0.05		)
	$	(3.64	)	$	(0.08	)	$	(4.73	)	$	(1.14	)
Diluted
Continuing operations	$	(3.63	)	$	(0.09	)	$	(4.72	)	$	(1.09	)
Discontinued operations	(0.01		)	0.01			(0.01		)	(0.05		)
	$	(3.64	)	$	(0.08	)	$	(4.73	)	$	(1.14	)
Weighted average shares and dilutive securities outstanding (in thousands):
Basic	100,812			99,523			100,475			99,210
Diluted	100,812			99,523			100,475			99,210

See accompanying Notes to Condensed Consolidated Financial Statements.

2

TENET HEALTHCARE CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OTHER COMPREHENSIVE INCOME (LOSS)

Dollars in Millions

(Unaudited)

	Three Months Ended September 30,						Nine Months Ended September 30,
	2017			2016			2017			2016
Net income (loss)	$	(289	)	$	80		$	(221	)	$	153
Other comprehensive income (loss):
Amortization of net actuarial loss included in other non-operating expense, net	4			5			12			8
Unrealized gains on securities held as available-for-sale	2			2			5			3
Foreign currency translation adjustments	5			(3		)	14			(44		)
Other comprehensive income (loss) before income taxes	11			4			31			(33		)
Income tax expense related to items of other comprehensive income (loss)	(7		)	(1		)	(11		)	(3		)
Total other comprehensive income (loss), net of tax	4			3			20			(36		)
Comprehensive net income (loss)	(285		)	83			(201		)	117
Less: Comprehensive income attributable to noncontrolling interests	78			88			254			266
Comprehensive loss attributable to Tenet Healthcare Corporation common shareholders	$	(363	)	$	(5	)	$	(455	)	$	(149	)

See accompanying Notes to Condensed Consolidated Financial Statements.

3

TENET HEALTHCARE CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

Dollars in Millions

(Unaudited)

	Nine Months Ended September 30,
	2017			2016
Net income (loss)	$	(221	)	$	153
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	662			632
Provision for doubtful accounts	1,109			1,095
Deferred income tax expense (benefit)	(145		)	32
Stock-based compensation expense	44			51
Impairment and restructuring charges, and acquisition-related costs	403			81
Litigation and investigation costs	12			291
Gains on sales, consolidation and deconsolidation of facilities	(142		)	(151		)
Loss from early extinguishment of debt	164			—
Equity in earnings of unconsolidated affiliates, net of distributions received	(4		)	2
Amortization of debt discount and debt issuance costs	33			33
Pre-tax loss from discontinued operations	1			5
Other items, net	(19		)	(3		)
Changes in cash from operating assets and liabilities:
Accounts receivable	(1,046		)	(1,156		)
Inventories and other current assets	97			(95		)
Income taxes	(14		)	(1		)
Accounts payable, accrued expenses and other current liabilities	(141		)	(35		)
Other long-term liabilities	7			48
Payments for restructuring charges, acquisition-related costs, and litigation costs and settlements	(88		)	(132		)
Net cash provided by (used in) operating activities from discontinued operations, excluding income taxes	(3		)	1
Net cash provided by operating activities	709			851
Cash flows from investing activities:
Purchases of property and equipment — continuing operations	(492		)	(614		)
Purchases of businesses or joint venture interests, net of cash acquired	(41		)	(96		)
Proceeds from sales of facilities and other assets	826			573
Proceeds from sales of marketable securities, long-term investments and other assets	20			36
Purchases of equity investments	(64		)	(37		)
Other long-term assets	(16		)	(15		)
Other items, net	(6		)	3
Net cash provided by (used in) investing activities	227			(150		)
Cash flows from financing activities:
Repayments of borrowings under credit facility	(850		)	(1,195		)
Proceeds from borrowings under credit facility	850			1,195
Repayments of other borrowings	(4,099		)	(112		)
Proceeds from other borrowings	3,788			4
Debt issuance costs	(62		)	(1		)
Distributions paid to noncontrolling interests	(178		)	(151		)
Proceeds from sales of noncontrolling interests	29			19
Purchases of noncontrolling interests	(722		)	(180		)
Proceeds from employee stock plan purchases	5			4
Other items, net	16			9
Net cash used in financing activities	(1,223		)	(408		)
Net increase (decrease) in cash and cash equivalents	(287		)	293
Cash and cash equivalents at beginning of period	716			356
Cash and cash equivalents at end of period	$	429		$	649
Supplemental disclosures:
Interest paid, net of capitalized interest	$	(617	)	$	(596	)
Income tax payments, net	$	(54	)	$	(33	)

See accompanying Notes to Condensed Consolidated Financial Statements.

4

TENET HEALTHCARE CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1. BASIS OF PRESENTATION

Description of Business and Basis of Presentation

Tenet Healthcare Corporation (together with our subsidiaries, referred to herein as “Tenet,” “we” or “us”) is a diversified healthcare services company. At September 30, 2017, we operated 77 hospitals, 20 surgical hospitals and over 460 outpatient centers in the United States, as well as nine facilities in the United Kingdom, through our subsidiaries, partnerships and joint ventures, including USPI Holding Company, Inc. (“USPI joint venture”). Our Conifer Holdings, Inc. (“Conifer”) subsidiary provides healthcare business process services in the areas of hospital and physician revenue cycle management and value-based care solutions to healthcare systems, as well as individual hospitals, physician practices, self-insured organizations, health plans and other entities.

This quarterly report supplements our Annual Report on Form 10-K for the year ended December 31, 2016 (“Annual Report”). As permitted by the Securities and Exchange Commission for interim reporting, we have omitted certain notes and disclosures that substantially duplicate those in our Annual Report. For further information, refer to the audited Consolidated Financial Statements and notes included in our Annual Report. Unless otherwise indicated, all financial and statistical data included in these notes to our Condensed Consolidated Financial Statements relate to our continuing operations, with dollar amounts expressed in millions (except per-share amounts).  In addition to the impact of the new accounting standards discussed below, certain prior-year amounts have also been reclassified to conform to the current-year presentation, primarily related to the detail of other intangible assets in Note 1 and the line items presented in the changes in shareholders’ equity table in Note 8.

Effective January 1, 2017, we adopted the Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) 2016-09, “Compensation—Stock Compensation (Topic 718) Improvements to Employee Share-Based Payment Accounting” (“ASU 2016-09”), which affects all entities that issue share-based payment awards to their employees. The guidance in ASU 2016-09 simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. Upon adoption of ASU 2016-09, we recorded previously unrecognized excess tax benefits of approximately $56 million as a deferred tax asset and a cumulative effect adjustment to retained earnings as of January 1, 2017. Prospectively, all excess tax benefits and deficiencies will be recognized as income tax benefit or expense in our consolidated statement of operations when awards vest.

Also effective January 1, 2017, we early adopted ASU 2017-07, “Compensation—Retirement Benefits (Topic 715) Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost” (“ASU 2017-07”), which the FASB issued in March 2017. The amendments in ASU 2017-07 apply to all employers that offer to their employees defined benefit pension plans, other postretirement benefit plans, or other types of benefits accounted for under Topic 715 of the FASB Accounting Standards Codification. The guidance in ASU 2017-07 requires that an employer report the service cost component in the same line item or items as other compensation costs arising from services rendered by the pertinent employees during the period. The other components of net benefit cost are required to be presented in the statement of operations separately from the service cost component and outside a subtotal of income from operations. The line item or items used in the statement of operations to present the other components of net benefit cost must be disclosed. The amendments in ASU 2017-07 must be applied retrospectively for the presentation of the service cost component and the other components of net periodic pension cost and net periodic postretirement benefit cost in the statement of operations. As a result of the adoption of ASU 2017-07, we reclassified approximately $20 million of net benefit cost from salaries, wages and benefits expense to other non-operating income (expense), net, in the accompanying Condensed Consolidated Statement of Operations for both of the nine month periods ended September 30, 2017 and 2016. Upon adoption of ASU 2017-07, we also reclassified approximately $8 million of net benefit cost from salaries, wages and benefits expense to other non-operating income (expense), net for the three months ended December 31, 2016, and we reclassified approximately $21 million of net benefit cost from salaries, wages and benefits expense to other non-operating income (expense), net for the year ended December 31, 2015.

Although the Condensed Consolidated Financial Statements and related notes within this document are unaudited, we believe all adjustments considered necessary for a fair presentation have been included and are of a normal recurring nature. In preparing our financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”), we are required to make estimates and assumptions that affect the amounts reported in our Condensed Consolidated Financial Statements and these accompanying notes. We regularly evaluate the accounting policies and estimates we use. In general, we base the estimates on historical experience and on assumptions that we believe to be reasonable given the particular circumstances in which we operate. Actual results may vary from those estimates. Financial and statistical information we

5

report to other regulatory agencies may be prepared on a basis other than GAAP or using different assumptions or reporting periods and, therefore, may vary from amounts presented herein. Although we make every effort to ensure that the information we report to those agencies is accurate, complete and consistent with applicable reporting guidelines, we cannot be responsible for the accuracy of the information they make available to the public.

Operating results for the three and nine month periods ended September 30, 2017 are not necessarily indicative of the results that may be expected for the full year. Reasons for this include, but are not limited to: overall revenue and cost trends, particularly the timing and magnitude of price changes; fluctuations in contractual allowances and cost report settlements and valuation allowances; managed care contract negotiations, settlements or terminations and payer consolidations; changes in Medicare and Medicaid regulations; Medicaid and other supplemental funding levels set by the states in which we operate; the timing of approval by the Centers for Medicare and Medicaid Services of Medicaid provider fee revenue programs; trends in patient accounts receivable collectability and associated provisions for doubtful accounts; fluctuations in interest rates; levels of malpractice insurance expense and settlement trends; the timing of when we meet the criteria to recognize electronic health record incentives; impairment of long-lived assets and goodwill; restructuring charges; losses, costs and insurance recoveries related to natural disasters and other weather-related occurrences; litigation and investigation costs; gains (losses) on sales, consolidation and deconsolidation of facilities; income tax rates and deferred tax asset valuation allowance activity; changes in estimates of accruals for annual incentive compensation; the timing and amounts of stock option and restricted stock unit grants to employees and directors; gains or losses from early extinguishment of debt; and changes in occupancy levels and patient volumes. Factors that affect patient volumes and, thereby, the results of operations at our hospitals and related healthcare facilities include, but are not limited to: the business environment, economic conditions and demographics of local communities in which we operate; the number of uninsured and underinsured individuals in local communities treated at our hospitals; seasonal cycles of illness; climate and weather conditions; physician recruitment, retention and attrition; advances in technology and treatments that reduce length of stay; local healthcare competitors; managed care contract negotiations or terminations; the number of patients with high-deductible health insurance plans; any unfavorable publicity about us, or our joint venture partners, that impacts our relationships with physicians and patients; changes in healthcare regulations and the participation of individual states in federal programs; and the timing of elective procedures. These considerations apply to year-to-year comparisons as well.

Translation of Foreign Currencies

The accounts of European Surgical Partners Limited (“Aspen”) were measured in its local currency (the pound sterling) and then translated into U.S. dollars. All assets and liabilities were translated using the current rate of exchange at the balance sheet date. Results of operations were translated using the average rates prevailing throughout the period of operations. Translation gains or losses resulting from changes in exchange rates are accumulated in shareholders’ equity.

Net Operating Revenues Before Provision for Doubtful Accounts

We recognize net operating revenues before provision for doubtful accounts in the period in which our services are performed. Net operating revenues before provision for doubtful accounts primarily consist of net patient service revenues that are recorded based on established billing rates (i.e., gross charges), less estimated discounts for contractual and other allowances, principally for patients covered by Medicare, Medicaid, managed care and other health plans, as well as certain uninsured patients under our Compact with Uninsured Patients and other uninsured discount and charity programs.

6

The table below shows the sources of net operating revenues before provision for doubtful accounts from continuing operations:

	Three Months Ended September 30,						Nine Months Ended September 30,
	2017			2016			2017			2016
Hospital Operations and other:
Net patient revenues from acute care hospitals, related outpatient facilities and physician practices
Medicare	$	809		$	844		$	2,563		$	2,658
Medicaid	256			339			822			1,009
Managed care	2,524			2,729			7,867			8,031
Indemnity, self-pay and other	442			328			1,316			1,264
Net patient revenues(1)	4,031			4,240			12,568			12,962
Health plans	10			122			100			385
Revenue from other sources	171			158			480			482
Hospital Operations and other total prior to inter-segment eliminations	4,212			4,520			13,148			13,829
Ambulatory Care	477			457			1,422			1,346
Conifer	401			398			1,203			1,169
Inter-segment eliminations	(149		)	(159		)	(463		)	(488		)
Net operating revenues before provision for doubtful accounts	$	4,941		$	5,216		$	15,310		$	15,856

(1) Net patient revenues include revenues from physician practices of $171 million and $179 million for the three months ended September 30, 2017 and 2016, respectively, and $551 million and $558 million for the nine months ended September 30, 2017 and 2016, respectively.

Cash and Cash Equivalents

We treat highly liquid investments with original maturities of three months or less as cash equivalents. Cash and cash equivalents were approximately $429 million and $716 million at September 30, 2017 and December 31, 2016, respectively. At September 30, 2017 and December 31, 2016, our book overdrafts were approximately $240 million and $279 million, respectively, which were classified as accounts payable.

At September 30, 2017 and December 31, 2016, approximately $167 million and $147 million, respectively, of total cash and cash equivalents in the accompanying Condensed Consolidated Balance Sheets were intended for the operations of our captive insurance subsidiaries, and approximately $62 million and $85 million, respectively, of total cash and cash equivalents in the accompanying Condensed Consolidated Balance Sheets were intended for the operations of our health plan-related businesses.

Also at September 30, 2017 and December 31, 2016, we had $89 million and $179 million, respectively, of property and equipment purchases accrued for items received but not yet paid. Of these amounts, $57 million and $141 million, respectively, were included in accounts payable.

During the nine months ended September 30, 2017 and 2016, we entered into non-cancellable capital leases of approximately $82 million and $110 million, respectively, primarily for equipment.

Other Intangible Assets

The following tables provide information regarding other intangible assets, which are included in the accompanying Condensed Consolidated Balance Sheets at September 30, 2017 and December 31, 2016:

	Gross Carrying Amount		Accumulated Amortization			Net Book Value
At September 30, 2017:
Capitalized software costs	$	1,537	$	(721	)	$	816
Trade names	105		—			105
Contracts	855		(55		)	800
Other	108		(65		)	43
Total	$	2,605	$	(841	)	$	1,764

7

	Gross Carrying Amount		Accumulated Amortization			Net Book Value
At December 31, 2016:
Capitalized software costs	$	1,572	$	(681	)	$	891
Trade names	106		—			106
Contracts	845		(43		)	802
Other	94		(48		)	46
Total	$	2,617	$	(772	)	$	1,845

Estimated future amortization of intangibles with finite useful lives at September 30, 2017 is as follows:

			Three Months Ending		Years Ending								Later Years
			December 31,
	Total		2017		2018		2019		2020		2021
Amortization of intangible assets	$	1,097	$	47	$	152	$	135	$	104	$	92	$	567

We recognized amortization expense of $125 million and $111 million in the accompanying Condensed Consolidated Statements of Operations for the nine months ended September 30, 2017 and 2016, respectively.

Investments in Unconsolidated Affiliates

We control 220 of the facilities within our Ambulatory Care segment and, therefore, consolidate their results. We account for many of the facilities our Ambulatory Care segment operates (109 of 329 at September 30, 2017) and four of the hospitals our Hospital Operations and other segment operates, as well as 11 additional facilities in which our Hospital Operations and other segment holds ownership interests, under the equity method as investments in unconsolidated affiliates and report only our share of net income attributable to the investee as equity in earnings of unconsolidated affiliates in the accompanying Condensed Consolidated Statements of Operations. Summarized financial information for the equity method investees within our Ambulatory Care segment and the four equity method investee hospitals operated by our Hospital Operations and other segment are included in the following table. For investments acquired during the reported periods, amounts reflect 100% of the investee’s results beginning on the date of our acquisition of the investment.

	Three Months Ended September 30,				Nine Months Ended September 30,
	2017		2016		2017		2016
Net operating revenues	$	635	$	610	$	1,819	$	1,803
Net income	$	143	$	129	$	376	$	364
Net income attributable to the investees	$	93	$	83	$	242	$	241

NOTE 2. ACCOUNTS RECEIVABLE AND ALLOWANCE FOR DOUBTFUL ACCOUNTS

The principal components of accounts receivable are shown in the table below: 

	September 30, 2017			December 31, 2016
Continuing operations:
Patient accounts receivable	$	3,371		$	3,799
Allowance for doubtful accounts	(934		)	(1,031		)
Estimated future recoveries	130			141
Net cost reports and settlements payable and valuation allowances	(2		)	(14		)
	2,565			2,895
Discontinued operations	2			2
Accounts receivable, net	$	2,567		$	2,897

At September 30, 2017 and December 31, 2016, our allowance for doubtful accounts was 27.7% and 27.1%, respectively, of our patient accounts receivable. Accounts that are pursued for collection through Conifer’s business offices are maintained on our hospitals’ books and reflected in patient accounts receivable with an allowance for doubtful accounts established to reduce the carrying value of such receivables to their estimated net realizable value. Generally, we estimate this allowance based on the aging of our accounts receivable by hospital, our historical collection experience by hospital and for each type of payer, and other relevant factors.

8

We also provide charity care to patients who are unable to pay for the healthcare services they receive. Most patients who qualify for charity care are charged a per-diem amount for services received, subject to a cap. Except for the per-diem amounts, our policy is not to pursue collection of amounts determined to qualify as charity care; therefore, we do not report these amounts in net operating revenues. Most states include an estimate of the cost of charity care in the determination of a hospital’s eligibility for Medicaid disproportionate share hospital (“DSH”) payments. These payments are intended to mitigate our cost of uncompensated care, as well as reduced Medicaid funding levels. The table below shows our estimated costs (based on selected operating expenses, which include salaries, wages and benefits, supplies and other operating expenses and which exclude the costs of our health plan businesses) of caring for our self-pay patients and charity care patients, and revenues attributable to Medicaid DSH and other supplemental revenues we recognized in three and nine months ended September 30, 2017 and 2016:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2017		2016		2017		2016
Estimated costs for:
Self-pay patients	$	164	$	158	$	484	$	453
Charity care patients	29		36		92		104
Total	$	193	$	194	$	576	$	557
Medicaid DSH and other supplemental revenues	$	140	$	249	$	462	$	691

At September 30, 2017 and December 31, 2016, we had approximately $375 million and $537 million, respectively, of receivables recorded in other current assets and approximately $56 million and $139 million, respectively, of payables recorded in other current liabilities in the accompanying Condensed Consolidated Balance Sheets related to California’s provider fee program.

NOTE 3. ASSETS AND LIABILITIES HELD FOR SALE

In the three months ended September 30, 2017, we entered into a definitive agreement for the sale of our hospitals, physician practices and related assets in Philadelphia, Pennsylvania and the surrounding area. In accordance with the guidance in the FASB’s Accounting Standards Codification (“ASC”) 360, “Property, Plant and Equipment,” we classified $222 million of our Philadelphia-area assets as “assets held for sale” in current assets and the related liabilities of $52 million as “liabilities held for sale” in current liabilities in the accompanying Condensed Consolidated Balance Sheet at September 30, 2017. These assets and liabilities, which are in our Hospital Operations and other segment, were recorded at the lower of their carrying amount or their fair value less estimated costs to sell. We recorded impairment charges of $235 million for the write-down of assets held for sale to their estimated fair value, less estimated costs to sell, as a result of this anticipated transaction.

Also in the three months ended September 30, 2017, MacNeal Hospital, which is located in a suburb of Chicago, as well as other operations affiliated with the hospital, met the criteria to be classified as held for sale. As a result, we classified these assets totaling $222 million as “assets held for sale” in current assets and the related liabilities of $33 million as “liabilities held for sale” in current liabilities in the accompanying Condensed Consolidated Balance Sheet at September 30, 2017. These assets and liabilities, which are in our Hospital Operations and other segment, were recorded at the lower of their carrying amount or their fair value less estimated costs to sell. There was no impairment recorded for the write-down of assets held for sale to their estimated fair value, less estimated costs to sell, as a result of the planned divestiture of these assets.

Additionally, our nine Aspen facilities in the United Kingdom met the criteria to be classified as held for sale in the three months ended September 30, 2017. We classified $398 million of our United Kingdom assets as “assets held for sale” in current assets and the related liabilities of $322 million as “liabilities held for sale” in current liabilities in the accompanying Condensed Consolidated Balance Sheet at September 30, 2017. These assets and liabilities, which are in our Ambulatory Care segment, were recorded at the lower of their carrying amount or their fair value less estimated costs to sell. We recorded impairment charges of $59 million for the write-down of assets held for sale to their estimated fair value, less estimated costs to sell.

9

Assets and liabilities classified as held for sale at September 30, 2017 were comprised of the following:

Accounts receivable	$	178
Other current assets	100
Investments and other long-term assets	20
Property and equipment	456
Other intangible assets	8
Goodwill	80
Current liabilities	(107		)
Long-term liabilities	(300		)
Net assets held for sale	$	435

In the three months ended June 30, 2017, we entered into a definitive agreement for the sale of our hospitals, physician practices and related assets in Houston, Texas and the surrounding area, and we classified these assets and liabilities as held for sale. Effective August 1, 2017, we completed the sale for net proceeds of approximately $750 million and recognized a gain on sale of approximately $111 million.

In the three months ended September 30, 2016, certain of our health plan assets and liabilities met the criteria to be classified as held for sale. In the nine months ended September 30, 2017, we completed the sales of certain of our health plan businesses in Michigan, Arizona and Texas at transaction prices of approximately $20 million, $13 million and $12 million, respectively, and recognized gains on the sales of approximately $3 million, $13 million and $10 million, respectively.

Our hospitals, physician practices and related assets in Georgia met the criteria to be classified as assets held for sale in the three months ended June 30, 2015. We completed the sale of our Georgia assets on March 31, 2016 at a transaction price of approximately $575 million and recognized a gain on sale of approximately $113 million. Because we did not sell the related accounts receivable with respect to the pre-closing period, net receivables of approximately $17 million are included in accounts receivable, less allowance for doubtful accounts, in the accompanying Condensed Consolidated Balance Sheet at September 30, 2017.

NOTE 4. IMPAIRMENT AND RESTRUCTURING CHARGES, AND ACQUISITION-RELATED COSTS

During the nine months ended September 30, 2017, we recorded impairment and restructuring charges and acquisition-related costs of $403 million, consisting of approximately $294 million of charges to write-down assets held for sale to their estimated fair value, less estimated costs to sell, for our Aspen and Philadelphia-area facilities, $29 million of impairment of two equity method investments, $40 million of employee severance costs, $8 million of contract and lease termination fees, $3 million to write-down intangible assets, $13 million of other restructuring costs, and $16 million in acquisition-related costs, which include $5 million of transaction costs and $11 million of acquisition integration charges. Our impairment and restructuring charges and acquisition-related costs for the nine months ended September 30, 2017 were comprised of $319 million from our Hospital Operations and other segment, $70 million from our Ambulatory Care segment and $14 million from our Conifer segment.

During the nine months ended September 30, 2016, we recorded impairment and restructuring charges and acquisition-related costs of $81 million primarily related to our Hospital Operations and other segment, consisting of approximately $26 million of employee severance costs, $4 million of contract and lease termination fees, $2 million to write-down intangible assets, $9 million of other restructuring costs, and $40 million in acquisition-related costs, which include $5 million of transaction costs and $35 million of acquisition integration charges.

Our impairment tests presume stable, improving or, in some cases, declining operating results in our facilities, which are based on programs and initiatives being implemented that are designed to achieve the facility’s most recent projections. If these projections are not met, or if in the future negative trends occur that impact our future outlook, impairments of long-lived assets and goodwill may occur, and we may incur additional restructuring charges, which could be material.

At September 30, 2017, our continuing operations consisted of three reportable segments, Hospital Operations and other, Ambulatory Care and Conifer. Our Hospital Operations and other segment was structured as follows at September 30, 2017:

• Our Eastern region included all of our segment operations in Alabama, Florida, Illinois, Massachusetts, Michigan, Missouri, Pennsylvania, South Carolina and Tennessee;

10

• Our Texas region included all of our segment operations in New Mexico and Texas; and 

• Our Western region included all of our segment operations in Arizona and California.

These regions are reporting units used to perform our goodwill impairment analysis and are one level below our reportable business segments. We also perform a goodwill impairment analysis for our Ambulatory Care and Conifer reporting units.

We periodically incur costs to implement restructuring efforts for specific operations, which are recorded in our consolidated statements of operations as they are incurred. Our restructuring plans focus on various aspects of operations, including aligning our operations in the most strategic and cost-effective structure. Certain restructuring and acquisition-related costs are based on estimates. Changes in estimates are recognized as they occur.

NOTE 5. LONG-TERM DEBT AND LEASE OBLIGATIONS

The table below shows our long-term debt at September 30, 2017 and December 31, 2016:

	September 30, 2017			December 31, 2016
Senior unsecured notes:
5.000% due 2019	$	—		$	1,100
5.500% due 2019	500			500
6.750% due 2020	300			300
8.000% due 2020	—			750
8.125% due 2022	2,800			2,800
6.750% due 2023	1,900			1,900
7.000% due 2025	500			—
6.875% due 2031	430			430
Senior secured notes:
6.250% due 2018	—			1,041
4.750% due 2020	500			500
6.000% due 2020	1,800			1,800
Floating % due 2020	—			900
4.500% due 2021	850			850
4.375% due 2021	1,050			1,050
7.500% due 2022	750			750
4.625% due 2024	1,870			—
5.125% due 2025	1,410			—
Capital leases	377			735
Mortgage notes	85			84
Unamortized issue costs, note discounts and premiums	(241		)	(235		)
Total long-term debt	14,881			15,255
Less current portion	140			191
Long-term debt, net of current portion	$	14,741		$	15,064

Senior Secured and Senior Unsecured Notes

On June 14, 2017, we sold $830 million aggregate principal amount of our 4.625% senior secured first lien notes, which will mature on July 15, 2024 (the “2024 Secured First Lien Notes”). We will pay interest on the 2024 Secured First Lien Notes semi-annually in arrears on January 15 and July 15 of each year, commencing on January 15, 2018. The proceeds from the sale of the 2024 Secured First Lien Notes were used, after payment of fees and expenses, together with cash on hand, to deposit with the trustee an amount sufficient to fund the redemption of all $900 million in aggregate principal amount of ourfloating rate senior secured notes due 2020 (the “2020 Floating Rate Notes”) on July 14, 2017, thereby fully discharging the 2020 Floating Rate Notes as of June 14, 2017. In connection with the redemption, we recorded a loss from early extinguishment of debt of approximately $26 million in the three months ended June 30, 2017, primarily related to the difference between the redemption price and the par value of the notes, as well as the write-off of associated unamortized note discounts and issuance costs.

Also on June 14, 2017, THC Escrow Corporation III (“Escrow Corp.”), a Delaware corporation established for the purpose of issuing the securities referred to in this paragraph, issued $1.040 billion in aggregate principal amount of

11

4.625% senior secured first lien notes due 2024 (the “Escrow Secured First Lien Notes”), $1.410 billion in aggregate principal amount of 5.125% senior secured second lien notes due 2025 (the “Escrow Secured Second Lien Notes”) and $500 million in aggregate principal amount of 7.000% senior unsecured notes due 2025 (the “Escrow Unsecured Notes”).

On July 14, 2017, we (i) assumed Escrow Corp.’s obligations with respect to the Escrow Secured Second Lien Notes and (ii) effected a mandatory exchange of all outstanding Escrow Secured First Lien Notes for a like principal amount of our newly issued 2024 Secured First Lien Notes. The proceeds from the sale of the Escrow Secured Second Lien Notes and Escrow Secured First Lien Notes were released from escrow on July 14, 2017 and were used, after payment of fees and expenses, to finance our redemption on July 14, 2017 of $1.041 billion aggregate principal amount of our outstanding 6.250% senior secured notes due 2018 and $1.100 billion aggregate principal amount of our outstanding 5.000% senior unsecured notes due 2019.

On August 1, 2017, we assumed Escrow Corp.’s obligations with respect to the Escrow Unsecured Notes. The proceeds from the sale of the Escrow Unsecured Notes were released from escrow on August 1, 2017 and were used, after payment of fees and expenses, to finance our redemption on August 1, 2017 of $500 million aggregate principal amount of our 8.000% senior unsecured notes due 2020.

On September 11, 2017, we redeemed the remaining $250 million aggregate principal amount of our 8.000% senior unsecured notes due 2020 using cash on hand.

As a result of the redemption activities in the three months ended September 30, 2017 discussed above, we recorded a loss from early extinguishment of debt of approximately $138 million in the period, primarily related to the difference between the redemption price and the par value of the notes, as well as the write-off of associated unamortized note discounts and issuance costs.

Credit Agreement

We have a senior secured revolving credit facility (as amended, the “Credit Agreement”) that provides, subject to borrowing availability, for revolving loans in an aggregate principal amount of up to $1 billion, with a $300 million subfacility for standby letters of credit. Obligations under the Credit Agreement, which has a scheduled maturity date of December 4, 2020, are guaranteed by substantially all of our domestic wholly owned hospital subsidiaries and are secured by a first-priority lien on the accounts receivable owned by us and the subsidiary guarantors. Outstanding revolving loans accrue interest at a base rate plus a margin ranging from 0.25% to 0.75% per annum or the London Interbank Offered Rate (“LIBOR”) plus a margin ranging from 1.25% to 1.75% per annum, in each case based on available credit. An unused commitment fee payable on the undrawn portion of the revolving loans ranges from 0.25% to 0.375% per annum based on available credit. Our borrowing availability is based on a specified percentage of eligible accounts receivable, including self-pay accounts. At September 30, 2017, we had no cash borrowings outstanding under the Credit Agreement, and we had approximately $2 million of standby letters of credit outstanding. Based on our eligible receivables, approximately $998 million was available for borrowing under the Credit Agreement at September 30, 2017.

Letter of Credit Facility

We have a letter of credit facility (as amended, the “LC Facility”) that provides for the issuance of standby and documentary letters of credit, from time to time, in an aggregate principal amount of up to $180 million (subject to increase to up to $200 million). Obligations under the LC Facility are guaranteed and secured by a first-priority pledge of the capital stock and other ownership interests of certain of our wholly owned domestic hospital subsidiaries on an equal ranking basis with our senior secured first lien notes. On September 15, 2016, we entered into an amendment to the existing letter of credit facility agreement in order to, among other things, (i) extend the scheduled maturity date of the LC Facility to March 7, 2021, (ii) reduce the margin payable with respect to unreimbursed drawings under letters of credit and undrawn letters of credit issued under the LC Facility, and (iii) reduce the commitment fee payable with respect to the undrawn portion of the commitments under the LC Facility.

Drawings under any letter of credit issued under the LC Facility that we have not reimbursed within three business days after notice thereof will accrue interest at a base rate plus a margin equal to 0.50% per annum. An unused commitment fee is payable at an initial rate of 0.25% per annum with a step up to 0.375% per annum should our secured-debt-to-EBITDA ratio equal or exceed 3.00 to 1.00 at the end of any fiscal quarter. A fee on the aggregate outstanding amount of issued but undrawn letters of credit will accrue at a rate of 1.50% per annum. An issuance fee equal to 0.125% per annum of the aggregate face amount of each outstanding letter of credit is payable to the account of the issuer of the related letter of credit. At September 30, 2017, we had approximately $105 million of standby letters of credit outstanding under the LC Facility.

12

NOTE 6. GUARANTEES

At September 30, 2017, the maximum potential amount of future payments under our income guarantees to certain physicians who agree to relocate and revenue collection guarantees to hospital-based physician groups providing certain services at our hospitals was $172 million. We had a total liability of $139 million recorded for these guarantees included in other current liabilities at September 30, 2017.

At September 30, 2017, we also had issued guarantees of the indebtedness and other obligations of our investees to third parties, the maximum potential amount of future payments under which was approximately $23 million. Of the total, $17 million relates to the obligations of consolidated subsidiaries, which obligations are recorded in the accompanying Condensed Consolidated Balance Sheet at September 30, 2017.

NOTE 7. EMPLOYEE BENEFIT PLANS

In recent years, we have granted both options and restricted stock units to certain of our employees. Options have an exercise price equal to the fair market value of the shares on the date of grant and generally expire 10 years from the date of grant. A restricted stock unit is a contractual right to receive one share of our common stock or the equivalent value in cash in the future. Typically, options and time-based restricted stock units vest one-third on each of the first three anniversary dates of the grant; however, certain special retention awards may have longer vesting periods. In addition, we grant performance-based restricted stock units and performance-based options that vest subject to the achievement of specified performance goals within a specified time frame. At September 30, 2017, assuming outstanding performance-based restricted stock units and options for which performance has not yet been determined will achieve target performance, approximately 5.6 million shares of common stock were available under our 2008 Stock Incentive Plan for future stock option grants and other incentive awards, including restricted stock units (approximately 4.6 million shares remain available if we assume maximum performance for outstanding performance-based restricted stock units and options for which performance has not yet been determined).

Our Condensed Consolidated Statements of Operations for the nine months ended September 30, 2017 and 2016 include $44 million and $46 million, respectively, of pre-tax compensation costs related to our stock-based compensation arrangements.

Stock Options

The following table summarizes stock option activity during the nine months ended September 30, 2017:

	Options		Weighted Average Exercise Price Per Share		Aggregate Intrinsic Value		Weighted Average Remaining Life
					(In Millions)
Outstanding at December 31, 2016	1,435,921		$	22.87
Granted	1,396,307		18.24
Exercised	(16,525	)	4.56
Forfeited/Expired	(187,458	)	26.07
Outstanding at September 30, 2017	2,628,245		$	20.30	$	2	5.1 years
Vested and expected to vest at September 30, 2017	2,628,245		$	20.30	$	2	5.1 years
Exercisable at September 30, 2017	1,231,938		$	22.63	$	2	1.7 years

There were 16,525 and 110,715 stock options exercised during the nine months ended September 30, 2017 and 2016, respectively, with aggregate intrinsic values of less than $1 million and approximately $1 million, respectively.

At September 30, 2017, there were $9 million of total unrecognized compensation costs related to stock options. These costs are expected to be recognized over a weighted average period of 2.1 years.

In the three months ended March 31, 2017, we granted an aggregate of 987,781 stock options under our 2008 Stock Incentive Plan to certain of our senior officers. The stock options will all vest on the third anniversary of the grant date, subject to achieving a closing stock price of at least $23.74 (a 25% premium above the March 1, 2017 grant-date closing stock price of $18.99) for at least 20 consecutive trading days within three years of the grant date, and will expire on the tenth anniversary of the grant date. In the nine months ended September 30, 2016, there were no stock options granted.

13

The weighted average estimated fair value of stock options we granted in the three months ended March 31, 2017 was $8.52 per share. The fair values were calculated based on the grant date, using a Monte Carlo simulation with the following assumptions:

	Three Months Ended March 31, 2017
Expected volatility	49%
Expected dividend yield	0%
Expected life	6.2 years
Expected forfeiture rate	0%
Risk-free interest rate	2.15%

The expected volatility used in the Monte Carlo simulation incorporates historical and implied share-price volatility and is based on an analysis of historical prices of our stock and open-market exchanged options. The expected volatility reflects the historical volatility for a duration consistent with the contractual life of the options, and the volatility implied by the trading of options to purchase our stock on open-market exchanges. The historical share-price volatility excludes the movements in our stock price on two dates (April 8, 2011 and April 11, 2011) with unusual volatility due to an unsolicited acquisition proposal. The expected life of options granted is derived from Tenet’s historical stock option exercise behavior, adjusted for the exercisable period (i.e., from the third anniversary through the tenth anniversary of the grant date). The risk-free interest rates are based on zero-coupon United States Treasury yields in effect at the date of grant consistent with the expected exercise time frames.

On September 29, 2017, we granted our executive chairman 408,526 performance-based stock options with a grant date fair value of $5.63. The options vest on the first anniversary of the grant date and become exercisable only if the average closing price per share of the Company’s common stock, calculated over any period of 30 sequential trading days during the four-year period following the grant date, equals or exceeds $20.53.

The following table summarizes information about our outstanding stock options at September 30, 2017:

	Options Outstanding				Options Exercisable
Range of Exercise Prices	Number of Options	Weighted Average Remaining Contractual Life	Weighted Average Exercise Price		Number of Options	Weighted Average Exercise Price
$0.00 to $4.569	154,361	1.4 years	$	4.56	154,361	$	4.56
$4.57 to $19.759	1,396,607	8.1 years	18.24		300	14.52
$19.76 to $32.569	822,890	2.1 years	20.87		822,890	20.87
$32.57 to $42.529	254,387	0.4 years	39.31		254,387	39.31
	2,628,245	5.1 years	$	20.30	1,231,938	$	22.63

Restricted Stock Units

The following table summarizes restricted stock unit activity during the nine months ended September 30, 2017: 

	Restricted Stock Units		Weighted Average Grant Date Fair Value Per Unit
Unvested at December 31, 2016	3,174,533		$	38.75
Granted	643,329		18.65
Vested	(1,302,503	)	35.99
Forfeited	(93,618	)	37.62
Unvested at September 30, 2017	2,421,741		$	35.16

In the nine months ended September 30, 2017, we granted 643,329 restricted stock units, of which 630,426 will vest and be settled ratably over a three-year period from the grant date. The vesting of the remaining 12,903 restricted stock units is contingent on our achievement of specified performance goals for the years 2017 to 2019. Provided the goals are achieved, the performance-based restricted stock units will vest and settle on the third anniversary of the grant date. The actual number of performance-based restricted stock units that could vest will range from 0% to 200% of the 12,903 units granted, depending on our level of achievement with respect to the performance goals.

14

At September 30, 2017, there were $44 million of total unrecognized compensation costs related to restricted stock units. These costs are expected to be recognized over a weighted average period of 1.8 years.

Employee Retirement Plans

In both of the nine-month periods ended September 30, 2017 and 2016, we recognized (i) service cost related to one of our frozen nonqualified defined benefit pension plans of approximately $1 million in salaries, wages and benefits expense, and (ii) other components of net periodic pension cost and net periodic postretirement benefit cost related to our frozen qualified and nonqualified defined benefit plans of approximately $20 million in other non-operating income (expense), net, in the accompanying Condensed Consolidated Statements of Operations.

NOTE 8. EQUITY

Changes in Shareholders’ Equity

The following table shows the changes in consolidated equity during the nine months ended September 30, 2017 and 2016 (dollars in millions, share amounts in thousands):

	Tenet Healthcare Corporation Shareholders’ Equity
	Common Stock			Additional Paid-In Capital			Accumulated Other Comprehensive Loss			Accumulated Deficit			Treasury Stock			Noncontrolling Interests			Total Equity
	Shares Outstanding	Issued Par Amount
Balances at December 31, 2016	99,686	$	7	$	4,827		$	(258	)	$	(1,742	)	$	(2,417	)	$	665		$	1,082
Net income (loss)	—	—		—			—			(475		)	—			99			(376		)
Distributions paid to noncontrolling interests	—	—		—			—			—			—			(93		)	(93		)
Other comprehensive income	—	—		—			20			—			—			—			20
Accretion of redeemable noncontrolling interests	—	—		(32		)	—			—			—			—			(32		)
Purchases (sales) of businesses and noncontrolling interests	—	—		(4		)	—			—			—			—			(4		)
Cumulative effect of accounting change	—	—		—			—			56			—			—			56
Stock-based compensation expense, tax benefit and issuance of common stock	1,145	—		44			—			—			(2		)	—			42
Balances at September 30, 2017	100,831	$	7	$	4,835		$	(238	)	$	(2,161	)	$	(2,419	)	$	671		$	695
Balances at December 31, 2015	98,495	$	7	$	4,815		$	(164	)	$	(1,550	)	$	(2,417	)	$	267		$	958
Net income (loss)	—	—		—			—			(113		)	—			96			(17		)
Distributions paid to noncontrolling interests	—	—		—			—			—			—			(82		)	(82		)
Other comprehensive loss	—	—		—			(36		)	—			—			—			(36		)
Purchases (sales) of businesses and noncontrolling interests	—	—		(43		)	—			—			—			119			76
Purchase accounting adjustments	—	—		—			—			—			—			237			237
Stock-based compensation expense and issuance of common stock	1,033	—		29			—			—			—			—			29
Balances at September 30, 2016	99,528	$	7	$	4,801		$	(200	)	$	(1,663	)	$	(2,417	)	$	637		$	1,165

Our noncontrolling interests balances at September 30, 2017 and December 31, 2016 were comprised of $70 million and $89 million, respectively, from our Hospital Operations and other segment, and $601 million and $576 million, respectively, from our Ambulatory Care segment. Our net income attributable to noncontrolling interests for the nine months ended September 30, 2017 and 2016 in the table above were comprised of $9 million and $8 million, respectively, from our Hospital Operations and other segment, and $90 million and $88 million, respectively, from our Ambulatory Care segment.

15

NOTE 9. PROPERTY AND PROFESSIONAL AND GENERAL LIABILITY INSURANCE

Property Insurance

We have property, business interruption and related insurance coverage to mitigate the financial impact of catastrophic events or perils that is subject to deductible provisions based on the terms of the policies. These policies are on an occurrence basis. For the policy period April 1, 2017 through March 31, 2018, we have coverage totaling $850 million per occurrence, after deductibles and exclusions, with annual aggregate sub-limits of $100 million for floods, $200 million for earthquakes and a per-occurrence sub-limit of $200 million for named windstorms with no annual aggregate. With respect to fires and other perils, excluding floods, earthquakes and named windstorms, the total $850 million limit of coverage per occurrence applies. Deductibles are 5% of insured values up to a maximum of $25 million for California earthquakes, floods and wind-related claims, and 2% of insured values for New Madrid fault earthquakes, with a maximum per claim deductible of $25 million. Floods and certain other covered losses, including fires and other perils, have a minimum deductible of $1 million.

Professional and General Liability Reserves

At September 30, 2017 and December 31, 2016, the aggregate current and long-term professional and general liability reserves in our accompanying Condensed Consolidated Balance Sheets were approximately $827 million and $794 million, respectively. These reserves include the reserves recorded by our captive insurance subsidiaries and our self-insured retention reserves recorded based on modeled estimates for the portion of our professional and general liability risks, including incurred but not reported claims, for which we do not have insurance coverage. We estimated the reserves for losses and related expenses using expected loss-reporting patterns discounted to their present value under a risk-free rate approach using a Federal Reserve seven-year maturity rate of 2.16% at September 30, 2017 and 2.25% at December 31, 2016.

If the aggregate limit of any of our professional and general liability policies is exhausted, in whole or in part, it could deplete or reduce the limits available to pay any other material claims applicable to that policy period.

Included in other operating expenses, net, in the accompanying Condensed Consolidated Statements of Operations is malpractice expense of $225 million and $233 million for the nine months ended September 30, 2017 and 2016, respectively.

NOTE 10. CLAIMS AND LAWSUITS

We operate in a highly regulated and litigious industry. Healthcare companies are subject to numerous investigations by various governmental agencies. Further, private parties have the right to bring qui tam or “whistleblower” lawsuits against companies that allegedly submit false claims for payments to, or improperly retain overpayments from, the government and, in some states, private payers. We and our subsidiaries have received inquiries in recent years from government agencies, and we may receive similar inquiries in future periods. We are also subject to class action lawsuits, employment-related claims and other legal actions in the ordinary course of business. Some of these actions may involve large demands, as well as substantial defense costs. We cannot predict the outcome of current or future legal actions against us or the effect that judgments or settlements in such matters may have on us.

We are also subject to a non-prosecution agreement, as described in our Annual Report. If we fail to comply with this agreement, we could be subject to criminal prosecution, substantial penalties and exclusion from participation in federal healthcare programs, any of which could adversely impact our business, financial condition, results of operations or cash flows.

We record accruals for estimated losses relating to claims and lawsuits when available information indicates that a loss is probable and we can reasonably estimate the amount of the loss or a range of loss. Significant judgment is required in both the determination of the probability of a loss and the determination as to whether a loss is reasonably estimable. These determinations are updated at least quarterly and are adjusted to reflect the effects of negotiations, settlements, rulings, advice of legal counsel and technical experts, and other information and events pertaining to a particular matter. If a loss on a material matter is reasonably possible and estimable, we disclose an estimate of the loss or a range of loss. In cases where we have not disclosed an estimate, we have concluded that the loss is either not reasonably possible or the loss, or a range of loss, is not reasonably estimable, based on available information.

Securities Litigation

In February 2017, the U.S. District Court for the Northern District of Texas consolidated two previously disclosed lawsuits filed by purported shareholders of the Company’s common stock against the Company and several current and former executive officers into a single matter captioned In re Tenet Healthcare Corporation Securities Litigation. In April 2017, the

16

four court-appointed lead plaintiffs filed a consolidated amended class action complaint asserting violations of the federal securities laws. The plaintiffs are seeking class certification on behalf of all persons who acquired the Company’s common stock between February 28, 2012 and August 1, 2016. The complaint alleges that false or misleading statements or omissions concerning the Company’s financial performance and compliance policies, specifically with respect to the previously disclosed civil qui tam litigation and parallel criminal investigation of the Company and certain of its subsidiaries (together, the “Clinica de la Mama matters”), caused the price of the Company’s common stock to be artificially inflated. In addition, the plaintiffs claim that the defendants violated GAAP by failing to disclose an estimate of the possible loss or a range of loss related to the Clinica de la Mama matters. The Company’s motion to dismiss the consolidated complaint on behalf of all defendants is pending with the court. The Company intends to continue to vigorously defend against the allegations in the purported shareholder class action.

Shareholder Derivative Litigation

In January 2017, the Dallas County District Court consolidated two previously disclosed shareholder derivative lawsuits filed by purported shareholders of the Company’s common stock on behalf of the Company against current and former officers and directors into a single matter captioned In re Tenet Healthcare Corporation Shareholder Derivative Litigation. The plaintiffs filed a consolidated shareholder derivative petition in February 2017. A separate shareholder derivative lawsuit, captioned Horwitz, derivatively on behalf of Tenet Healthcare Corporation, was filed in January 2017 in the U.S. District Court for the Northern District of Texas. The consolidated shareholder derivative petition and the Horowitz complaint generally track the allegations in the securities class action complaint described above and claim that the plaintiffs did not make demand on the Board of Directors to bring the lawsuits because such a demand would have been futile. Both shareholder derivative matters were stayed in the second quarter of 2017 pending the final resolution of the motion to dismiss in the consolidated securities litigation. The Company intends to vigorously defend against the allegations in the purported shareholder derivative lawsuits.

Antitrust Class Action Lawsuit Filed by Registered Nurses in San Antonio

In Maderazo, et al. v. VHS San Antonio Partners, L.P. d/b/a Baptist Health Systems, et al., filed in June 2006 in the U.S. District Court for the Western District of Texas, a purported class of registered nurses employed by three unaffiliated San Antonio-area hospital systems allege those hospital systems, including Baptist Health System, and other unidentified San Antonio regional hospitals violated Section §1 of the federal Sherman Act by conspiring to depress nurses’ compensation and exchanging compensation-related information among themselves in a manner that reduced competition and suppressed the wages paid to such nurses. The suit seeks unspecified damages (subject to trebling under federal law), interest, costs and attorneys’ fees. The case was stayed from 2008 through mid-2015. At this time, we are awaiting the court’s ruling on class certification and will continue to vigorously defend ourselves against the plaintiffs’ allegations. It remains impossible at this time to predict the outcome of these proceedings with any certainty; however, we believe that the ultimate resolution of this matter will not have a material effect on our business, financial condition or results of operations.

Ordinary Course Matters

We are also subject to other claims and lawsuits arising in the ordinary course of business, including potential claims related to, among other things, the care and treatment provided at our hospitals and outpatient facilities, the application of various federal and state labor laws, tax audits and other matters. Although the results of these claims and lawsuits cannot be predicted with certainty, we believe that the ultimate resolution of these ordinary course claims and lawsuits will not have a material effect on our business or financial condition.

New claims or inquiries may be initiated against us from time to time. These matters could (1) require us to pay substantial damages or amounts in judgments or settlements, which, individually or in the aggregate, could exceed amounts, if any, that may be recovered under our insurance policies where coverage applies and is available, (2) cause us to incur substantial expenses, (3) require significant time and attention from our management, and (4) cause us to close or sell hospitals or otherwise modify the way we conduct business.

17

The table below presents reconciliations of the beginning and ending liability balances in connection with legal settlements and related costs recorded during the nine months ended September 30, 2017 and 2016: 

	Balances at Beginning of Period		Litigation and Investigation Costs		Cash Payments			Balances at End of Period
Nine Months Ended September 30, 2017
Continuing operations	$	12	$	12	$	(14	)	$	10
Discontinued operations	—		—		—			—
	$	12	$	12	$	(14	)	$	10
Nine Months Ended September 30, 2016
Continuing operations	$	299	$	291	$	(59	)	$	531
Discontinued operations	—		—		—			—
	$	299	$	291	$	(59	)	$	531

For the nine months ended September 30, 2017 and 2016, we recorded costs of $12 million and $291 million, respectively, in continuing operations in connection with significant legal proceedings and governmental investigations.

NOTE 11. REDEEMABLE NONCONTROLLING INTERESTS IN EQUITY OF CONSOLIDATED SUBSIDIARIES

As previously disclosed, as part of the formation of our USPI joint venture in 2015, we entered into a put/call agreement (the “Put/Call Agreement”) with respect to the equity interests in the joint venture held by our joint venture partners. In January 2016, Welsh, Carson, Anderson & Stowe (“Welsh Carson”), on behalf of our joint venture partners, delivered a put notice for the minimum number of shares they were required to put to us in 2016 according to the Put/Call Agreement. In April 2016, we paid approximately $127 million to purchase those shares, which increased our ownership interest in the USPI joint venture to approximately 56.3%. On May 1, 2017, we amended and restated the Put/Call Agreement to provide for, among other things, the acceleration of our acquisition of certain shares of our USPI joint venture. Under the terms of the amendment, we agreed to pay Welsh Carson, on or before July 3, 2017, approximately $711 million to buy 23.7% of our USPI joint venture, which amount will be subject to adjustment for actual 2017 financial results in accordance with the terms of the Put/Call Agreement. On July 3, 2017, we paid approximately $716 million for the purchase of these shares, which increased our ownership interest in the USPI joint venture to 80.0%, as well as the final adjustment to the 2016 purchase price.

The amended and restated Put/Call Agreement also provides that the remaining 15% ownership interest in our USPI joint venture held by our Welsh Carson joint venture partners will be subject to put and call options in equal shares in each of 2018 and 2019. In the event our Welsh Carson joint venture partners do not exercise these put options, we will have the option, but not the obligation, to buy 7.5% of our USPI joint venture from them in 2018 and another 7.5% in 2019. In connection with such puts or calls, we will have the ability to choose whether to settle the purchase price in cash or shares of our common stock.

The following table shows the changes in redeemable noncontrolling interests in equity of consolidated subsidiaries during the nine months ended September 30, 2017 and 2016:

	Nine Months Ended September 30,
	2017			2016
Balances at beginning of period	$	2,393		$	2,266
Net income	155			170
Distributions paid to noncontrolling interests	(85		)	(69		)
Purchase accounting adjustments	—			(47		)
Accretion of redeemable noncontrolling interests	32			—
Purchases and sales of businesses and noncontrolling interests, net	(679		)	(13		)
Balances at end of period	$	1,816		$	2,307

The following tables show the composition by segment of our redeemable noncontrolling interests balances at September 30, 2017 and December 31, 2016, as well as our net income attributable to redeemable noncontrolling interests for the nine months ended September 30, 2017 and 2016:

18

	September 30, 2017		December 31, 2016
Hospital Operations and other	$	529	$	520
Ambulatory Care	1,090		1,715
Conifer	197		158
Redeemable noncontrolling interests	$	1,816	$	2,393

	Nine Months Ended September 30,
	2017		2016
Hospital Operations and other	$	14	$	16
Ambulatory Care	103		116
Conifer	38		38
Net income attributable to redeemable noncontrolling interests	$	155	$	170

NOTE 12. INCOME TAXES

During the three months ended September 30, 2017, we recorded an income tax benefit of $60 million in continuing operations on pre-tax loss of $348 million compared to income tax expense of $10 million on pre-tax income of $89 million during the three months ended September 30, 2016. During the nine months ended September 30, 2017, we recorded an income tax benefit of $105 million in continuing operations on pre-tax loss of $325 million compared to income tax expense of $61 million on pre-tax income of $219 million during the nine months ended September 30, 2016. Our provision for income taxes during interim reporting periods has historically been calculated by applying an estimate of the annual effective tax rate for the full year to “ordinary” income or loss (pre-tax income or loss excluding unusual or infrequently occurring discrete items) for the reporting period. However, we utilized the discrete effective tax rate method to calculate the interim period tax provision for the three and nine month periods ended September 30, 2017. We determined that, because minor fluctuations in estimated “ordinary” income would result in significant changes in the estimated annual effective tax rate, the historical method would not provide a reliable estimate for the three and nine month periods ended September 30, 2017. Due to Aspen being classified as held for sale, we have reversed our indefinite reinvestment assertion with respect to this investment outside the United States as of September 30, 2017, which resulted in an income tax benefit of $30 million in the three months ended September 30, 2017. The reconciliation between the amount of recorded income tax expense (benefit) and the amount calculated at the statutory federal tax rate is shown in the following table:

	Three Months Ended September 30,						Nine Months Ended September 30,
	2017			2016			2017			2016
Tax expense (benefit) at statutory federal rate of 35%	$	(122	)	$	31		$	(114	)	$	77
State income taxes, net of federal income tax benefit	8			3			13			10
Tax benefit attributable to noncontrolling interests	(25		)	(28		)	(79		)	(75		)
Nondeductible goodwill	104			—			104			29
Nontaxable gains	—			(1		)	—			(18		)
Nondeductible litigation	—			4			—			37
Change in tax contingency reserves, including interest	(1		)	(1		)	(3		)	(4		)
Stock-based compensation	—			—			9			—
Change in indefinite reinvestment assertion	(30		)	—			(30		)	—
Change in valuation allowance	(5		)	—			(5		)	—
Other items	11			2			—			5
	$	(60	)	$	10		$	(105	)	$	61

During the nine months ended September 30, 2017, we increased our estimated liabilities for uncertain tax positions by $33 million, net of related deferred tax assets. The total amount of unrecognized tax benefits at September 30, 2017 was $68 million, of which $65 million, if recognized, would impact our effective tax rate and income tax expense (benefit) from continuing operations. 

Our practice is to recognize interest and penalties related to income tax matters in income tax expense in our consolidated statements of operations. Total accrued interest and penalties on unrecognized tax benefits at September 30, 2017 were $4 million, all of which related to continuing operations.

At September 30, 2017, approximately $2 million of unrecognized federal and state tax benefits, as well as reserves for interest and penalties, may decrease in the next 12 months as a result of the settlement of audits, the filing of amended tax returns or the expiration of statutes of limitations.

19

NOTE 13. LOSS PER COMMON SHARE

The following table is a reconciliation of the numerators and denominators of our basic and diluted loss per common share calculations for our continuing operations for three and nine months ended September 30, 2017 and 2016. Loss attributable to our common shareholders is expressed in millions and weighted average shares are expressed in thousands.

	Loss Attributable to Common Shareholders (Numerator)			Weighted Average Shares (Denominator)	Per-Share Amount
Three Months Ended September 30, 2017
Net loss attributable to Tenet Healthcare Corporation common shareholders for basic loss per share	$	(366	)	100,812	$	(3.63	)
Effect of dilutive stock options, restricted stock units and deferred compensation units	—			—	—
Net loss attributable to Tenet Healthcare Corporation common shareholders for diluted loss per share	$	(366	)	100,812	$	(3.63	)
Three Months Ended September 30, 2016
Net loss attributable to Tenet Healthcare Corporation common shareholders for basic loss per share	$	(9	)	99,523	$	(0.09	)
Effect of dilutive stock options, restricted stock units and deferred compensation units	—			—	—
Net loss attributable to Tenet Healthcare Corporation common shareholders for diluted loss per share	$	(9	)	99,523	$	(0.09	)
Nine Months Ended September 30, 2017
Net loss attributable to Tenet Healthcare Corporation common shareholders for basic loss per share	$	(474	)	100,475	$	(4.72	)
Effect of dilutive stock options, restricted stock units and deferred compensation units	—			—	—
Net loss attributable to Tenet Healthcare Corporation common shareholders for diluted loss per share	$	(474	)	100,475	$	(4.72	)
Nine Months Ended September 30, 2016
Net loss attributable to Tenet Healthcare Corporation common shareholders for basic loss per share	$	(108	)	99,210	$	(1.09	)
Effect of dilutive stock options, restricted stock units and deferred compensation units	—			—	—
Net loss attributable to Tenet Healthcare Corporation common shareholders for diluted loss per share	$	(108	)	99,210	$	(1.09	)

All potentially dilutive securities were excluded from the calculation of diluted loss per share for the three and nine months ended September 30, 2017 and 2016 because we did not report income from continuing operations available to common shareholders in those periods. In circumstances where we do not have income from continuing operations available to common shareholders, the effect of stock options and other potentially dilutive securities is anti-dilutive, that is, a loss from continuing operations attributable to common shareholders has the effect of making the diluted loss per share less than the basic loss per share. Had we generated income from continuing operations available to common shareholders in the three and nine months ended September 30, 2017 and 2016, the effect (in thousands) of employee stock options, restricted stock units and deferred compensation units on the diluted shares calculation would have been an increase in shares of 711 and 1,455 for the three months ended September 30, 2017 and 2016, respectively, and 747 and 1,470 for the nine months ended September 30, 2017 and 2016, respectively.

NOTE 14. FAIR VALUE MEASUREMENTS

Our financial assets and liabilities recorded at fair value on a recurring basis primarily relate to investments in available-for-sale securities held by our captive insurance subsidiaries. The following tables present information about our assets and liabilities that are measured at fair value on a recurring basis. The following tables also indicate the fair value hierarchy of the valuation techniques we utilized to determine such fair values. In general, fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. We consider a security that trades at

20

least weekly to have an active market. Fair values determined by Level 2 inputs utilize data points that are observable, such as quoted prices, interest rates and yield curves. Fair values determined by Level 3 inputs are unobservable data points for the asset or liability, and include situations where there is little, if any, market activity for the asset or liability.

Investments	September 30, 2017		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Marketable debt securities — noncurrent	$	54	$	40	$	14	$	—
	$	54	$	40	$	14	$	—

Investments	December 31, 2016		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Marketable debt securities — noncurrent	$	49	$	23	$	26	$	—
	$	49	$	23	$	26	$	—

Our non-financial assets and liabilities not permitted or required to be measured at fair value on a recurring basis typically relate to long-lived assets held and used, long-lived assets held for sale and goodwill. We are required to provide additional disclosures about fair value measurements as part of our financial statements for each major category of assets and liabilities measured at fair value on a non-recurring basis. The following table presents this information and indicates the fair value hierarchy of the valuation techniques we utilized to determine such fair values. In general, fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities, which generally are not applicable to non-financial assets and liabilities. Fair values determined by Level 2 inputs utilize data points that are observable, such as definitive sales agreements, appraisals or established market values of comparable assets. Fair values determined by Level 3 inputs are unobservable data points for the asset or liability and include situations where there is little, if any, market activity for the asset or liability, such as internal estimates of future cash flows.

	September 30, 2017		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Long-lived assets held for sale	$	399	$	—	$	399	$	—
Other than temporarily impaired equity method investments	112		—		112		—
	$	511	$	—	$	511	$	—

	December 31, 2016		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Long-lived assets held and used	$	163	$	—	$	163	$	—
Other than temporarily impaired equity method investments	27		—		27		—
	$	190	$	—	$	190	$	—

As described in Note 4, in the nine months ended September 30, 2017, we recorded $294 million of impairment charges to write-down assets held for sale to their estimated fair value, less estimated costs to sell, for our Aspen and Philadelphia-area facilities, and a $29 million impairment charge related to certain of our equity method investments.

The fair value of our long-term debt (except for borrowings under the Credit Agreement) is based on quoted market prices (Level 1). The inputs used to establish the fair value of the borrowings outstanding under the Credit Agreement are considered to be Level 2 inputs, which include inputs other than quoted prices included in Level 1 that are observable, either directly or indirectly. At September 30, 2017 and December 31, 2016, the estimated fair value of our long-term debt was approximately 100.6% and 93.9%, respectively, of the carrying value of the debt.

21

NOTE 15. ACQUISITIONS

Preliminary purchase price allocations (representing the fair value of the consideration conveyed) for all acquisitions made during the nine months ended September 30, 2017 and 2016 are as follows:

	Nine Months Ended September 30,
	2017			2016
Current assets	$	4		$	42
Property and equipment	5			33
Other intangible assets	5			7
Goodwill	65			316
Other long-term assets	1			6
Current liabilities	(4		)	(25		)
Long-term liabilities	(1		)	(14		)
Redeemable noncontrolling interests	(18		)	(114		)
Noncontrolling interests	(13		)	(122		)
Cash paid, net of cash acquired	(41		)	(96		)
Gains on consolidations	$	3		$	33

The goodwill generated from these transactions, the majority of which will be deductible for income tax purposes, can be attributed to the benefits that we expect to realize from operating efficiencies and growth strategies. The goodwill total of $65 million from acquisitions completed during the nine months ended September 30, 2017 was recorded in our Ambulatory Care segment. Approximately $5 million in transaction costs related to prospective and closed acquisitions were expensed during both of the nine month periods ended September 30, 2017 and 2016, and are included in impairment and restructuring charges, and acquisition-related costs in the accompanying Condensed Consolidated Statement of Operations.

We are required to allocate the purchase prices of acquired businesses to assets acquired or liabilities assumed and, if applicable, noncontrolling interests based on their fair values. The excess of the purchase price allocation over those fair values is recorded as goodwill. We are in process of finalizing the purchase price allocations, including valuations of the acquired property and equipment, other intangible assets and noncontrolling interests for some of our 2016 acquisitions; therefore, those purchase price allocations are subject to adjustment once the valuations are completed.

During the nine months ended September 30, 2017 and 2016, we recognized gains totaling $3 million and $33 million, respectively, associated with stepping up our ownership interests in previously held equity investments, which we began consolidating after we acquired controlling interests.

NOTE 16. SEGMENT INFORMATION

Our business consists of our Hospital Operations and other segment, our Ambulatory Care segment and our Conifer segment. The factors for determining the reportable segments include the manner in which management evaluates operating performance combined with the nature of the individual business activities.

Our Hospital Operations and other segment is comprised of our acute care hospitals, ancillary outpatient facilities, urgent care centers, microhospitals and physician practices. We also own various related healthcare businesses.

Our Ambulatory Care segment is comprised of the operations of our USPI joint venture and our nine Aspen facilities in the United Kingdom. At September 30, 2017, our USPI joint venture had interests in 244ambulatory surgery centers, 34urgent care centers, 22imaging centers and 20surgical hospitals in 27states. At September 30, 2017, we owned 80.0% of our USPI joint venture.

Our Conifer segment provides healthcare business process services in the areas of hospital and physician revenue cycle management and value-based care solutions to healthcare systems, as well as individual hospitals, physician practices, self-insured organizations, health plans and other entities. At September 30, 2017, Conifer provided services to more than 800 Tenet and non-Tenet hospitals and other clients nationwide. In 2012, we entered into agreements documenting the terms and conditions of various services Conifer provides to Tenet hospitals, as well as certain administrative services our Hospital Operations and other segment provides to Conifer. The pricing terms for the services provided by each party to the other under these contracts were based on estimated third-party pricing terms in effect at the time the agreements were signed. At September 30, 2017, we owned 76.2% of Conifer Health Solutions, LLC, which is the principal subsidiary of Conifer Holdings, Inc.

22

The following tables include amounts for each of our reportable segments and the reconciling items necessary to agree to amounts reported in the accompanying Condensed Consolidated Balance Sheets and Condensed Consolidated Statements of Operations:

	September 30, 2017		December 31, 2016
Assets:
Hospital Operations and other	$	16,249	$	17,871
Ambulatory Care	5,847		5,722
Conifer	1,112		1,108
Total	$	23,208	$	24,701

	Three Months Ended September 30,						Nine Months Ended September 30,
	2017			2016			2017			2016
Capital expenditures:
Hospital Operations and other	$	122		$	182		$	441		$	557
Ambulatory Care	16			14			37			42
Conifer	6			5			14			15
Total	$	144		$	201		$	492		$	614
Net operating revenues:
Hospital Operations and other total prior to inter-segment eliminations(1)	$	3,866		$	4,162		$	12,066		$	12,761
Ambulatory Care	468			448			1,395			1,319
Conifer
Tenet	149			159			463			488
Other customers	252			239			740			681
Total Conifer	401			398			1,203			1,169
Inter-segment eliminations	(149		)	(159		)	(463		)	(488		)
Total	$	4,586		$	4,849		$	14,201		$	14,761
Equity in earnings of unconsolidated affiliates:
Hospital Operations and other	$	4		$	3		$	4		$	6
Ambulatory Care	34			28			91			79
Total	$	38		$	31		$	95		$	85
Adjusted EBITDA:
Hospital Operations and other(2)	$	269		$	346		$	924		$	1,191
Ambulatory Care	159			157			476			432
Conifer	79			79			204			205
Total	$	507		$	582		$	1,604		$	1,828
Depreciation and amortization:
Hospital Operations and other	$	185		$	170		$	560		$	525
Ambulatory Care	22			22			66			69
Conifer	12			13			36			38
Total	$	219		$	205		$	662		$	632

23

	Three Months Ended September 30,						Nine Months Ended September 30,
	2017			2016			2017			2016
Adjusted EBITDA	$	507		$	582		$	1,604		$	1,828
Loss from divested and closed businesses (i.e., the Company’s health plan businesses)	(6		)	(6		)	(41		)	(8		)
Depreciation and amortization	(219		)	(205		)	(662		)	(632		)
Impairment and restructuring charges, and acquisition-related costs	(329		)	(31		)	(403		)	(81		)
Litigation and investigation costs	(6		)	(4		)	(12		)	(291		)
Interest expense	(257		)	(243		)	(775		)	(730		)
Loss from early extinguishment of debt	(138		)	—			(164		)	—
Other non-operating expense, net	(4		)	(7		)	(14		)	(18		)
Gains on sales, consolidation and deconsolidation of facilities	104			3			142			151
Net income (loss) from continuing operations before income taxes	$	(348	)	$	89		$	(325	)	$	219

(1) Hospital Operations and other revenues includes health plan revenues of $10 million and $100 million for the three and nine months ended September 30, 2017, respectively, and $122 million and $385 million for the three and nine months ended September 30, 2016, respectively.

(2) Hospital Operations and other Adjusted EBITDA excludes health plan EBITDA of $(6) million and $(41) million for the three and nine months ended September 30, 2017, respectively, and $(6) million and $(8) million for the three and nine months ended September 30, 2016, respectively.

NOTE 17. RECENT ACCOUNTING STANDARDS

In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers (Topic 606)”

(“ASU 2014-09”). In August 2015, the FASB amended the guidance to defer the effective date of this standard by one year. ASU 2014-09 affects any entity that either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets unless those contracts are within the scope of other standards. The core principle of the guidance in ASU 2014-09 is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. We have substantially completed our evaluation of the requirements of the new standard to insure that we have processes, systems and internal controls in place to collect the necessary information to implement the standard, which will be effective for us beginning in 2018. It is our current intention to use a modified retrospective method of application to adopt ASU 2014-09. For our Hospital Operations and other and Ambulatory Care segments, we will use a portfolio approach to apply the new model to classes of payers with similar characteristics and will analyze cash collection trends over an appropriate collection look-back period of 18 to 36 months depending on the payer. Adoption of ASU 2014-09 will result in changes to our presentation for and disclosure of revenue related to uninsured or underinsured patients. Currently, a significant portion of our provision for doubtful accounts relates to self-pay patients, as well as co-pays and deductibles owed to us by patients with insurance, in our Hospital Operations and other segment. Under ASU 2014-09, the estimated uncollectable amounts due from these patients will generally be considered a direct reduction to net operating revenues and, correspondingly, will result in a material reduction in the amounts presented separately as provision for doubtful accounts. We have also substantially completed our process of assessing the impact of the new standard on various reimbursement programs that represent variable consideration.  These include supplemental state Medicaid programs, disproportionate share payments and settlements with third party payers. The payment mechanisms for these types of programs often vary by state. During July 2017, industry guidance surrounding these programs was issued by the American Institute of Certified Public Accountants’ Financial Reporting Executive Committee. Our implementation team reviewed the guidance and concluded it was substantially consistent with our existing accounting processes. For our Conifer segment, we expect the adoption of ASU 2014-09 will result in changes to our presentation and disclosure of customer contract assets and liabilities and variable consideration. While the adoption of ASU 2014-09 will have a material effect on the presentation of net operating revenues in our consolidated statements of operations and on certain of our disclosures, we do not expect it to materially impact our financial position, results of operations or cash flows. We believe that the cumulative effect of the change in accounting principle effective January 1, 2018, if any, will be immaterial.

In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842)” (“ASU 2016-02”), which affects any entity that enters into a lease (as that term is defined in ASU 2016-02), with some specified scope exceptions. The main difference between the guidance in ASU 2016-02 and current GAAP is the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under current GAAP. Recognition of these assets and liabilities will have a material impact to our consolidated balance sheets upon adoption. Under ASU 2016-02, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach, which includes a number of optional practical expedients. We are currently evaluating the potential impact of this guidance, which will be effective for us beginning in 2019, including performing an assessment of the quantity of and contractual provisions in various

24

leasing arrangements to guide our implementation plan related to processes, systems and internal controls and the conclusion on the use of the optional practical expedients.

In January 2017, the FASB issued ASU 2017-04, “Intangibles—Goodwill and Other (Topic 350)” (“ASU 2017-04”), which affects public business and other entities that have goodwill reported in their financial statements and have not elected the private company alternative for the subsequent measurement of goodwill. The amendments in ASU 2017-04 modify the concept of impairment from the condition that exists when the carrying amount of goodwill exceeds its implied fair value to the condition that exists when the carrying amount of a reporting unit exceeds its fair value. An entity no longer will determine goodwill impairment by calculating the implied fair value of goodwill by assigning the fair value of a reporting unit to all of its assets and liabilities as if that reporting unit had been acquired in a business combination. Because these amendments eliminate Step 2 from the goodwill impairment test, they should reduce the cost and complexity of evaluating goodwill for impairment. It is our intention to early adopt ASU 2017-04 for our annual goodwill impairment tests for the year ending December 31, 2017. As of September 30, 2017, we do not expect the adoption of this guidance to materially impact our financial position, results of operations or cash flows.

25

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

INTRODUCTION TO MANAGEMENT’S DISCUSSION AND ANALYSIS

The purpose of this section, Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”), is to provide a narrative explanation of our financial statements that enables investors to better understand our business, to enhance our overall financial disclosures, to provide the context within which our financial information may be analyzed, and to provide information about the quality of, and potential variability of, our financial condition, results of operations and cash flows. Our Hospital Operations and other segment is comprised of our acute care hospitals, ancillary outpatient facilities, urgent care centers, microhospitals and physician practices. Our Ambulatory Care segment is comprised of the operations of our USPI Holding Company, Inc. (“USPI joint venture” or “USPI”), in which we own a majority interest, and European Surgical Partners Limited (“Aspen”) facilities. At September 30, 2017, our USPI joint venture had interests in 244ambulatory surgery centers, 34urgent care centers, 22imaging centers and 20surgical hospitals in 27 states, and Aspen operated nine private hospitals and clinics in the United Kingdom. Our Conifer segment provides healthcare business process services in the areas of hospital and physician revenue cycle management and value-based care solutions to healthcare systems, as well as individual hospitals, physician practices, self-insured organizations, health plans and other entities, through our Conifer Holdings, Inc. (“Conifer”) subsidiary. MD&A, which should be read in conjunction with the accompanying Condensed Consolidated Financial Statements, includes the following sections:

• Management Overview

• Forward-Looking Statements

• Hospital Operations and Other Segment Sources of Revenue

• Results of Operations

• Liquidity and Capital Resources

• Off-Balance Sheet Arrangements

• Critical Accounting Estimates

Unless otherwise indicated, all financial and statistical information included in MD&A relates to our continuing operations, with dollar amounts expressed in millions (except per share, per admission, per adjusted admission, per patient day, per adjusted patient day, per visit and per case amounts). Continuing operations information includes the results of (i) our same72hospitals operated throughout the ninemonths endedSeptember 30, 2017 and 2016, (ii) five Georgia hospitals, which we divested effective April 1, 2016, (iii) The Hospitals of Providence (“THOP”) Transmountain Campus, a new teaching hospital we opened in January 2017 in El Paso, and (iv) three Houston-area hospitals, which we divested effective August 1, 2017. Continuing operations information excludes the results of our hospitals and other businesses that have been classified as discontinued operations for accounting purposes.

MANAGEMENT OVERVIEW

RECENT DEVELOPMENTS

Adoption of Shareholder Rights Plan To Protect Net Operating Loss Carryforwards—Effective August 31, 2017, our Board of Directors approved a short-term rights plan intended to protect shareholder interests, including our net operating loss carryforwards, while certain leadership and governance changes are executed. The rights plan is scheduled to expire following the conclusion of our 2018 annual meeting of shareholders.

Definitive Agreement To Sell Two Acute Care Hospitals and Related Operations in Philadelphia—On September 1, 2017, we announced a definitive agreement for the sale of our hospitals, physician practices and related assets in Philadelphia, Pennsylvania and the surrounding area. As a result of this anticipated transaction, we recorded impairment charges of $235 million in the three months ended September 30, 2017. This sale, which is subject to customary closing conditions, including regulatory approvals, is expected to be completed in the first quarter of 2018. For additional details, see Note 3 to our accompanying Condensed Consolidated Financial Statements.

Definitive Agreement To Sell MacNeal Hospital and Related Operations—On October 11, 2017, we announced a definitive agreement for the sale of MacNeal Hospital, which is located in a suburb of Chicago, as well as other operations affiliated with the hospital. This sale, which is subject to customary closing conditions, including regulatory approvals, is expected to be completed in the first quarter of 2018. For additional details, see Note 3 to our accompanying Condensed Consolidated Financial Statements.

26

TRENDS AND STRATEGIES

The healthcare industry, in general, and the acute care hospital business, in particular, are experiencing significant regulatory uncertainty based, in large part, on legislative and administrative efforts to significantly modify or repeal and potentially replace the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (“Affordable Care Act” or “ACA”). Although it is difficult to predict the full impact of this regulatory uncertainty on our future revenues and operations, we believe that our strategies will help us to address the following trends shaping the demand for healthcare services: (i) consumers, employers and insurers are actively seeking lower-cost solutions and better value as they focus more on healthcare spending; (ii) patient volumes are shifting from inpatient to outpatient settings due to technological advancements and demand for care that is more convenient, affordable and accessible; (iii) the industry is migrating to value-based payment models with government and private payers shifting risk to providers; and (iv) consolidation continues across the entire healthcare sector through traditional acquisition and divestiture activities.

Driving Growth in Our Hospital Systems—We are committed to better positioning our hospital systems and competing more effectively in the evolving healthcare environment. We are focused on improving operational effectiveness, increasing capital efficiency and margins, enhancing patient satisfaction, growing our higher-acuity inpatient service lines, expanding patient access points, and exiting businesses and markets that we believe are no longer strategic to our long-term growth. We recently announced an enterprise-wide cost reduction initiative – comprised primarily of workforce reductions and the renegotiation of contracts with suppliers and vendors – which is intended to lower annual operating expenses by $150 million. We anticipate achieving the full annualized run-rate savings by the end of 2018. Approximately 75% of the savings are expected to be achieved through actions within our Hospital Operations and other segment, including eliminating a regional management layer and streamlining corporate overhead and centralized support functions. In conjunction with this initiative, we expect to incur restructuring charges of approximately $40 million in the fourth quarter of 2017, substantially all of which relate to employee severance payments.

Expansion of Our Ambulatory Care Segment—We remain focused on opportunities to expand our Ambulatory Care segment through organic growth, building new outpatient centers, corporate development activities and strategic partnerships. We believe USPI’s surgery centers and surgical hospitals offer many advantages to patients and physicians, including greater affordability, predictability, flexibility and convenience. Moreover, due in part to advancements in medical technology, and due to the lower cost structure and greater efficiencies that are attainable at a specialized outpatient site, we believe the volume and complexity of surgical cases performed in an outpatient setting will continue to steadily increase. In addition, we have continued to grow our imaging and urgent care businesses through USPI to reflect our broader strategies to (1) offer more services to patients, (2) broaden the capabilities we offer to healthcare systems and physicians, and (3) expand into faster-growing, less capital intensive, higher-margin businesses. Historically, our outpatient services have generated significantly higher margins for us than inpatient services.

Driving Conifer’s Growth—We are focused on driving growth at Conifer by continuing to market and expand its revenue cycle management and value-based care services businesses and diversifying its customer base. Conifer serves more than 800 Tenet and non-Tenet hospital and other clients nationwide. In addition to providing revenue cycle management services to both healthcare systems and physicians, Conifer provides support to both providers and self-insured employers seeking assistance with clinical integration, financial risk management and population health management.

Improving Profitability—We are focused on improving profitability by growing patient volumes and effective cost management. We believe our patient volumes have been constrained by increased competition, utilization pressure by managed care organizations, new delivery models that are designed to lower the utilization of acute care hospital services, the effects of higher patient co-pays and deductibles, and depressed economic conditions and demographic trends in certain of our markets. However, we also believe that targeted capital spending on growth opportunities for our hospitals, emphasis on higher-demand clinical service lines (including outpatient services), focus on expanding our ambulatory care business and contracting strategies that create shared value with payers should help us grow our patient volumes.

Reducing Our Leverage—As of September 30, 2017, all of our long-term debt has a fixed rate of interest, and the maturity dates of our notes are staggered from 2019 through 2031. Although we believe that our capital structure minimizes the near-term impact of increased interest rates, and the staggered maturities of our debt reduce any near-term liquidity needs, it is nonetheless our long-term objective to lower our ratio of debt-to-Adjusted EBITDA, primarily through more efficient capital allocation and Adjusted EBITDA growth, which should lower our refinancing risk and increase the potential for us to continue to use lower rate secured debt to refinance portions of our higher rate unsecured debt.

Our ability to execute on our strategies and manage the aforementioned trends is subject to a number of risks and uncertainties that may cause actual results to be materially different from expectations. For information about risks and

27

uncertainties that could affect our results of operations, see the Forward-Looking Statements and Risk Factors sections in Part I of our Annual Report on Form 10-K for the year ended December 31, 2016 (“Annual Report”).

RESULTS OF OPERATIONS—OVERVIEW

The following tables show certain selected operating statistics for our continuing operations, which includes the results of (i) our same72hospitals operated throughout the nine months ended September 30, 2017 and 2016, (ii) five Georgia hospitals, which we divested effective April 1, 2016, (iii) our new THOP Transmountain Campus teaching hospital, which we opened in January 2017 in El Paso, and (iv) three Houston-area hospitals, which we divested effective August 1, 2017. We believe this information is useful to investors because it reflects our current portfolio of operations and the recent trends we are experiencing with respect to volumes, revenues and expenses.

	Continuing Operations Three Months Ended September 30,
Selected Operating Statistics	2017		2016		Increase (Decrease)
Hospital Operations and other – acute care hospitals and related outpatient facilities
Number of hospitals (at end of period)	73		75		(2	)	(1)
Total admissions	185,389		194,342		(4.6	)%
Adjusted patient admissions(2)	332,035		345,207		(3.8	)%
Paying admissions (excludes charity and uninsured)	174,803		183,042		(4.5	)%
Charity and uninsured admissions	10,586		11,300		(6.3	)%
Emergency department visits	685,096		707,713		(3.2	)%
Total surgeries	118,260		127,346		(7.1	)%
Patient days — total	853,059		894,323		(4.6	)%
Adjusted patient days(2)	1,502,831		1,567,894		(4.1	)%
Average length of stay (days)	4.60		4.60		—	%
Average licensed beds	19,783		20,367		(2.9	)%
Utilization of licensed beds(3)	46.9	%	47.7	%	(0.8	)%	(1)
Total visits	1,867,471		2,009,019		(7.0	)%
Paying visits (excludes charity and uninsured)	1,741,815		1,862,046		(6.5	)%
Charity and uninsured visits	125,656		146,973		(14.5	)%
Ambulatory Care
Total consolidated facilities (at end of period)	220		212		8		(1)
Total cases	454,484		445,493		2.0	%

(1)	The change is the difference between the 2017 and 2016 amounts shown.
(2)	Adjusted patient admissions/days represents actual patient admissions/days adjusted to include outpatient services provided by facilities in our Hospital Operations and other segment by multiplying actual patient admissions/days by the sum of gross inpatient revenues and outpatient revenues and dividing the results by gross inpatient revenues.
(3)	Utilization of licensed beds represents patient days divided by number of days in the period divided by average licensed beds.

Total admissions decreased by 8,953, or 4.6%, in the three months ended September 30, 2017 compared to the three months ended September 30, 2016, and total surgeries decreased by 9,086, or 7.1%, in the three months ended September 30, 2017 compared to the 2016 period. Our emergency department visits decreased3.2% in the three months ended September 30, 2017 compared to the same period in the prior year. Our volumes from continuing operations in the three months ended September 30, 2017 compared to the three months ended September 30, 2016 were negatively affected by the sale of our Houston-area facilities effective August 1, 2017 and the impact of Hurricane Irma on our facilities in Florida and South Carolina. Our Ambulatory Care total cases increased2.0% due to the increase in consolidated facilities. 

28

	Continuing Operations Three Months Ended September 30,
Revenues	2017			2016			Increase (Decrease)
Net operating revenues before provision for doubtful accounts
Hospital Operations and other prior to inter-segment eliminations	$	4,212		$	4,520		(6.8	)%
Ambulatory Care	477			457			4.4	%
Conifer	401			398			0.8	%
Inter-segment eliminations	(149		)	(159		)	(6.3	)%
Total	$	4,941		$	5,216		(5.3	)%
Selected Hospital Operations and other – acute care hospitals and related outpatient facilities revenue data
Net inpatient revenues	$	2,434		$	2,644		(7.9	)%
Net outpatient revenues	1,426			1,417			0.6	%
Net patient revenues	$	3,860		$	4,061		(4.9	)%
Self-pay net inpatient revenues	$	112		$	106		5.7	%
Self-pay net outpatient revenues	149			145			2.8	%
Total self-pay revenues	$	261		$	251		4.0	%

Net operating revenues before provision for doubtful accounts decreased by $275 million, or 5.3%, in the three months ended September 30, 2017 compared to the same period in 2016, primarily due to lower inpatient and outpatient volumes, as well as the sale of our Houston-area facilities effective August 1, 2017, as described above. The 2016 period also included $55 million of net revenues from the California provider fee program compared to no revenues under the program in the 2017 period because CMS has not yet approved the 2017 program. For our Hospital Operations and other segment, the impact of lower volumes on net operating revenues was partially mitigated by improved managed care pricing.

	Continuing Operations Three Months Ended September 30,
Provision for Doubtful Accounts	2017			2016			Increase (Decrease)
Provision for doubtful accounts
Hospital Operations and other	$	346		$	358		(3.4	)%
Ambulatory Care	9			9			—	%
Total	$	355		$	367		(3.3	)%
Provision for doubtful accounts as a percentage of net operating revenues before provision for doubtful accounts
Hospital Operations and other	8.2		%	7.9		%	0.3	%	(1)
Ambulatory Care	1.9		%	2.0		%	(0.1	)%	(1)
Total	7.2		%	7.0		%	0.2	%	(1)

(1) The change is the difference between the 2017 and 2016 amounts shown.

Provision for doubtful accounts as a percentage of net operating revenues before provision for doubtful accounts was 7.2% and 7.0% for the three months ended September 30, 2017 and 2016, respectively. This increase was primarily due to increases in uninsured revenues. Our accounts receivable days outstanding (“AR Days”) from continuing operations (which calculation includes the accounts receivable of our Philadelphia-area, Chicago-area and Aspen facilities that have been classified in assets held for sale on our Condensed Consolidated Balance Sheet at September 30, 2017, excludes our divested Houston-area facilities and health plan revenues, and excludes our California provider fee revenue from the 2016 period because the 2017 program has not yet been approved) were 55.6 days at September 30, 2017 and 56.5 days at December 31, 2016, compared to our target of less than 55 days.

29

	Continuing Operations Three Months Ended September 30,
Selected Operating Expenses	2017		2016		Increase (Decrease)
Hospital Operations and other
Salaries, wages and benefits	$	1,879	$	1,924	(2.3	)%
Supplies	644		678		(5.0	)%
Other operating expenses	936		1,066		(12.2	)%
Total	$	3,459	$	3,668	(5.7	)%
Ambulatory Care
Salaries, wages and benefits	$	155	$	144	7.6	%
Supplies	95		89		6.7	%
Other operating expenses	93		86		8.1	%
Total	$	343	$	319	7.5	%
Conifer
Salaries, wages and benefits	$	230	$	240	(4.2	)%
Supplies	1		—		100.0	%
Other operating expenses	91		79		15.2	%
Total	$	322	$	319	0.9	%
Total
Salaries, wages and benefits	$	2,264	$	2,308	(1.9	)%
Supplies	740		767		(3.5	)%
Other operating expenses	1,120		1,231		(9.0	)%
Total	$	4,124	$	4,306	(4.2	)%
Rent/lease expense(1)
Hospital Operations and other	$	61	$	59	3.4	%
Ambulatory Care	20		18		11.1	%
Conifer	4		5		(20.0	)%
Total	$	85	$	82	3.7	%

(1)  Included in other operating expenses.

	Continuing Operations Three Months Ended September 30,
Selected Operating Expenses per Adjusted Patient Admission	2017		2016		Increase (Decrease)
Hospital Operations and other
Salaries, wages and benefits per adjusted patient admission(1)	$	5,651	$	5,551	1.8	%
Supplies per adjusted patient admission(1)	1,938		1,958		(1.0	)%
Other operating expenses per adjusted patient admission(1)	2,778		2,681		3.6	%
Total per adjusted patient admission	$	10,367	$	10,190	1.7	%

(1)
Calculation excludes the expenses from our health plan businesses. Adjusted patient admissions represents actual patient admissions adjusted to include outpatient services provided by facilities in our Hospital Operations and other segment by multiplying actual patient admissions by the sum of gross inpatient revenues and outpatient revenues and dividing the results by gross inpatient revenues.

Salaries, wages and benefits per adjusted patient admission increased1.8% in the three months ended September 30, 2017 compared to the same period in 2016. This change is primarily due to annual merit increases for certain of our employees, increased health benefits costs and the effect of lower volumes on operating leverage due to certain fixed staffing costs, partially offset by decreased accruals for annual incentive compensation.

Supplies expense per adjusted patient admission decreased1.0% in the three months ended September 30, 2017 compared to the three months ended September 30, 2016. The change in supplies expense was primarily attributable to lower surgical volumes and the benefit of the group-purchasing strategies and supplies-management services we utilize to reduce costs.

30

Other operating expenses per adjusted patient admission increased by 3.6% in the three months ended September 30, 2017 compared to the prior-year period. This increase is due to higher contracted services and medical fees per adjusted patient admission, as well as the effect of lower volumes on operating leverage due to certain fixed costs. These increases in expenses per adjusted patient admission were partially offset by decreased malpractice expense and decreased costs associated with funding indigent care services, which decrease was substantially offset by reduced net patient revenues. Malpractice expense for our Hospital Operations and other segment was $11 millionlower in the 2017 period compared to the 2016 period. In the 2017 period, we recognized a favorable adjustment of approximately $1 million from a two basis point increase in the interest rate used to estimate the discounted present value of projected future malpractice liabilities. In the 2016 period, we recognized a favorable adjustment of approximately $3 million from a 13 basis point increase in the interest rate used to estimate the discounted present value of projected future malpractice liabilities.

LIQUIDITY AND CAPITAL RESOURCES OVERVIEW

Cash and cash equivalents were $429 million at September 30, 2017 compared to $475 million at June 30, 2017.

Significant cash flow items in the three months ended September 30, 2017 included:

• Net cash provided by operating activities before interest, taxes, discontinued operations and restructuring charges, acquisition-related costs, and litigation costs and settlements of $494 million;

• Payments for restructuring charges, acquisition-related costs, and litigation costs and settlements of $26 million;

• Capital expenditures of $144 million;

• Proceeds from the sale of facilities and other assets of $752 million;

• Interest payments of $149 million;

• Income tax payments of $10 million;

• $2.950 billion of proceeds from the issuance of our 4.625% senior secured notes due 2024, our 5.125% senior secured notes due 2025, and our 7.000% senior unsecured notes due 2025;

• $3.071 billion of payments to redeem our 6.250% senior secured notes due 2018, our 5.000% senior unsecured notes due 2019 and our 8.000% senior unsecured notes due 2020;

• $33 million of payments for debt issuance costs;

• $717 million of purchases of noncontrolling interests, primarily to increase our ownership interest in our USPI joint venture to 80.0%; and

• $55 million of distributions paid to noncontrolling interests.

Net cash provided by operating activities was $709 million in the nine months ended September 30, 2017 compared to $851 million in the nine months ended September 30, 2016. Key factors contributing to the change between the 2017 and 2016 periods include the following:

• Decreased income from continuing operations before income taxes of $224 million, excluding other non-operating expense, net, gain (loss) from early extinguishment of debt, interest expense, gains on sales, consolidation and deconsolidation of facilities, litigation and investigation costs, impairment and restructuring charges, and acquisition-related costs, depreciation and amortization, and income (loss) from divested operations and closed businesses (i.e., our health plan businesses) in the nine months ended September 30, 2017 compared to the nine months ended September 30, 2016;

• A $44 milliondecrease in payments on reserves for restructuring charges, acquisition-related costs, and litigation costs and settlements;

31

• Reduced cash flows from our health plan businesses of $101 million due to cash outflows in the 2017 period resulting from the sales and wind-down of these businesses in 2017, compared to slightly positive cash flows in the 2016 period; and

• The timing of other working capital items.

FORWARD-LOOKING STATEMENTS

This report includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. All statements, other than statements of historical or present facts, that address activities, events, outcomes, business strategies and other matters that we plan, expect, intend, assume, believe, budget, predict, forecast, project, estimate or anticipate (and other similar expressions) will, should or may occur in the future are forward-looking statements. These forward-looking statements represent management’s current expectations, based on currently available information, as to the outcome and timing of future events. They involve known and unknown risks, uncertainties and other factors — many of which we are unable to predict or control — that may cause our actual results, performance or achievements, or healthcare industry results, to be materially different from those expressed or implied by forward-looking statements. Such factors include, but are not limited to, the risks described in the Forward-Looking Statements and Risk Factors sections in Part I of our Annual Report.

When considering forward-looking statements, a reader should keep in mind the risk factors and other cautionary statements in our Annual Report and in this report. Should one or more of the risks and uncertainties described in our Annual Report or this report occur, or should underlying assumptions prove incorrect, our actual results and plans could differ materially from those expressed in any forward-looking statement. We specifically disclaim any obligation to update any information contained in a forward-looking statement or any forward-looking statement in its entirety and, therefore, disclaim any resulting liability for potentially related damages.

All forward-looking statements attributable to us are expressly qualified in their entirety by this cautionary statement.

HOSPITAL OPERATIONS AND OTHER SEGMENT SOURCES OF REVENUE

We earn revenues for patient services from a variety of sources, primarily managed care payers and the federal Medicare program, as well as state Medicaid programs, indemnity-based health insurance companies and self-pay patients (that is, patients who do not have health insurance and are not covered by some other form of third-party arrangement).

The following table shows the sources of net patient revenues before provision for doubtful accounts for our acute care hospitals and related outpatient facilities, expressed as percentages of net patient revenues before provision for doubtful accounts from all sources:

	Three Months Ended September 30,						Nine Months Ended September 30,
Net Patient Revenues from:	2017		2016		Increase (Decrease) (1)		2017		2016		Increase (Decrease) (1)
Medicare	20.0	%	19.9	%	0.1	%	20.4	%	20.5	%	(0.1	)%
Medicaid	6.5	%	8.4	%	(1.9	)%	6.7	%	8.2	%	(1.5	)%
Managed care	62.5	%	64.0	%	(1.5	)%	62.4	%	61.5	%	0.9	%
Indemnity, self-pay and other	11.0	%	7.7	%	3.3	%	10.5	%	9.8	%	0.7	%

(1) The increase (decrease) is the difference between the 2017 and 2016 percentages shown.

32

Our payer mix on an admissions basis for our acute care hospitals and related outpatient facilities, expressed as a percentage of total admissions from all sources, is shown below:

	Three Months Ended September 30,						Nine Months Ended September 30,
Admissions from:	2017		2016		Increase (Decrease) (1)		2017		2016		Increase (Decrease) (1)
Medicare	25.1	%	25.0	%	0.1	%	26.0	%	26.1	%	(0.1	)%
Medicaid	6.7	%	7.2	%	(0.5	)%	6.5	%	7.1	%	(0.6	)%
Managed care	60.2	%	60.2	%	—	%	59.7	%	59.2	%	0.5	%
Indemnity, self-pay and other	8.0	%	7.6	%	0.4	%	7.8	%	7.6	%	0.2	%

(1) The increase (decrease) is the difference between the 2017 and 2016 percentages shown.

GOVERNMENT PROGRAMS

The Centers for Medicare and Medicaid Services (“CMS”), an agency of the U.S. Department of Health and Human Services (“HHS”), is the single largest payer of healthcare services in the United States. Approximately 57 million individuals rely on healthcare benefits through Medicare, and approximately 74 million individuals are enrolled in Medicaid and the Children’s Health Insurance Program (“CHIP”). These three programs are authorized by federal law and directed by CMS. Medicare is a federally funded health insurance program primarily for individuals 65 years of age and older, certain younger people with disabilities, and people with end-stage renal disease, and is provided without regard to income or assets. Medicaid is administered by the states and is jointly funded by the federal government and state governments. Medicaid is the nation’s main public health insurance program for people with low incomes and is the largest source of health coverage in the United States. The CHIP, which is also administered by the states and jointly funded, provides health coverage to children in families with incomes too high to qualify for Medicaid, but too low to afford private coverage. Unlike Medicaid, the CHIP is limited in duration and requires the enactment of reauthorizing legislation every five years. The most recent funding authorization expired on September 30, 2017. Legislation has been introduced that would extend CHIP funding through 2022, however, we cannot predict what action the federal government may take with regard to the continuation of the CHIP.

Medicare

Medicare offers its beneficiaries different ways to obtain their medical benefits. One option, the Original Medicare Plan (which includes “Part A” and “Part B”), is a fee-for-service payment system. The other option, called Medicare Advantage (sometimes called “Part C” or “MA Plans”), includes health maintenance organizations (“HMOs”), preferred provider organizations (“PPOs”), private fee-for-service Medicare special needs plans and Medicare medical savings account plans. The major components of our net patient revenues from continuing operations of our Hospital Operations and other segment for services provided to patients enrolled in the Original Medicare Plan for the three and nine months ended September 30, 2017 and 2016 are set forth in the following table:

	Three Months Ended September 30,				Nine Months Ended September 30,
Revenue Descriptions	2017		2016		2017		2016
Medicare severity-adjusted diagnosis-related group — operating	$	388	$	402	$	1,248	$	1,291
Medicare severity-adjusted diagnosis-related group — capital	37		38		115		119
Outliers	21		20		64		58
Outpatient	221		221		686		695
Disproportionate share	65		74		204		224
Direct Graduate and Indirect Medical Education(1)	63		62		194		187
Other(2)	5		15		17		42
Adjustments for prior-year cost reports and related valuation allowances	9		12		35		42
Total Medicare net patient revenues	$	809	$	844	$	2,563	$	2,658

(1)	Includes Indirect Medical Education revenues earned by our children’s hospitals under the Children’s Hospitals Graduate Medical Education Payment Program administered by the Health Resources and Services Administration of HHS.
(2)	The other revenue category includes inpatient psychiatric units, inpatient rehabilitation units, one long-term acute care hospital, other revenue adjustments, and adjustments related to the estimates for current-year cost reports and related valuation allowances.

A general description of the types of payments we receive for services provided to patients enrolled in the Original Medicare Plan is provided in our Annual Report. Recent regulatory and legislative updates to the terms of these payment systems and their estimated effect on our revenues can be found under “Regulatory and Legislative Changes” below.

33

Medicaid

Medicaid programs and the corresponding reimbursement methodologies are administered by the states and vary from state to state and from year to year. Estimated revenues under various state Medicaid programs, including state-funded managed care Medicaid programs, constituted approximately 17.6% and 18.7% of total net patient revenues before provision for doubtful accounts of our acute care hospitals and related outpatient facilities for the nine months ended September 30, 2017 and 2016, respectively. We also receive disproportionate share hospital (“DSH”) and other supplemental revenues under various state Medicaid programs. For the nine months ended September 30, 2017 and 2016, our total Medicaid revenues attributable to DSH and other supplemental revenues were approximately $462 million and $691 million, respectively. The 2017 period included $167 million related the Michigan provider fee program, $107 million related to Medicaid DSH programs in multiple states, $71 million related to the Texas 1115 waiver program, and $117 million from a number of other state and local programs. The 2016 period included $167 million from the 36-month California provider fee program, which ended on December 31, 2016, compared to no revenues under the 30-month program, which covers the period from January 1, 2017 through June 30, 2019, in the 2017 period because CMS has not yet approved the 30-month program. In addition, the results for the three months ended September 30, 2017 included unfavorable revenue adjustments of approximately $8 million and $2 million from the Texas 1115 waiver program and the Florida Medicaid program, respectively.

Several states in which we operate face budgetary challenges that have resulted, and likely will continue to result, in reduced Medicaid funding levels to hospitals and other providers. Because most states must operate with balanced budgets, and the Medicaid program is generally a significant portion of a state’s budget, states can be expected to adopt or consider adopting future legislation designed to reduce or not increase their Medicaid expenditures. In addition, some states delay issuing Medicaid payments to providers to manage state expenditures. As an alternative means of funding provider payments, many of the states in which we operate have adopted provider fee programs or received waivers under Section 1115 of the Social Security Act. Under a Medicaid waiver, the federal government waives certain Medicaid requirements, thereby giving states flexibility in the operation of their Medicaid program to allow states to test new approaches and demonstration projects to improve care. Generally the Section 1115 waivers are for a period of five years with an option to extend the waiver for three additional years. Continuing pressure on state budgets and other factors could result in future reductions to Medicaid payments, payment delays or additional taxes on hospitals.

Because we cannot predict what actions the federal government or the states may take under existing legislation and future legislation to address budget gaps, deficits, Medicaid expansion, provider fee programs or Medicaid Section 1115 waivers, we are unable to assess the effect that any such legislation might have on our business, but the impact on our future financial position, results of operations or cash flows could be material.

Medicaid-related patient revenues from continuing operations recognized by our Hospital Operations and other segment from Medicaid-related programs in the states in which our facilities are located, as well as from Medicaid programs in neighboring states, for the nine months ended September 30, 2017 and 2016 are set forth in the following table:

	Nine Months Ended September 30,
	2017					2016
Hospital Location	Medicaid			Managed Medicaid		Medicaid			Managed Medicaid
Alabama	$	78		$	—	$	60		$	—
Arizona	(5		)	155		(4		)	163
California	125			324		293			317
Florida	51			130		55			128
Georgia	—			—		11			8
Illinois	55			56		35			56
Massachusetts	25			40		30			43
Michigan	284			266		273			239
Missouri	1			1		—			1
North Carolina	—			—		(2		)	—
Pennsylvania	60			178		63			174
South Carolina	9			28		13			29
Tennessee	3			24		3			24
Texas	137			171		180			189
	$	823		$	1,373	$	1,010		$	1,371

34

Regulatory and Legislative Changes

Material updates to the information set forth in our Annual Report about the Medicare and Medicaid payment systems are provided below.

Final Payment and Policy Changes to the Medicare Inpatient Prospective Payment Systems

Under Medicare law, CMS is required to annually update certain rules governing the inpatient prospective payment systems (“IPPS”). The updates generally become effective October 1, the beginning of the federal fiscal year (“FFY”). On August 2, 2017, CMS issued Changes to the Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and Fiscal Year 2018 Rates, and, on September 29, 2017, CMS issued a correction notice to the rule issued on August 2, 2017. The August 2, 2017 final rule and the September 29, 2017 correction notice are collectively referred to hereinafter as the “Final IPPS Rule.” The Final IPPS Rule includes the following payment and policy changes:

• A market basket increase of 2.7% for Medicare severity-adjusted diagnosis-related group (“MS-DRG”) operating payments for hospitals reporting specified quality measure data and that are meaningful users of electronic health record (“EHR”) technology (hospitals that do not report specified quality measure data and/or are not meaningful users of EHR technology will receive a reduced market basket increase); CMS also made certain adjustments to the 2.7% market basket increase that resulted in a net operating payment update of 1.21% (before budget neutrality adjustments), including:

• Market basket index and multifactor productivity reductions required by the ACA of 0.75% and 0.6%, respectively;

• A 0.4588% increase required under the 21st Century Cures Act; and

• A reduction of 0.6% to reverse the one-time increase of 0.6% made in FFY 2017 to address the effects of the 0.2% reduction in effect for FFYs 2014 through 2016 related to the two-midnight rule.

• Updates to the three factors used to determine the amount and distribution of Medicare uncompensated care disproportionate share (“UC-DSH”) payments, including a transition from using low-income days to estimated uncompensated care costs for the distribution of the UC-DSH pool;

• A 1.60% net increase in the capital federal MS-DRG rate; and

• An increase in the cost outlier threshold from $23,573 to $26,537.

According to CMS, the combined impact of the payment and policy changes in the Final IPPS Rule for operating costs will yield an average 1.4% increase in Medicare operating MS-DRG fee-for-service (“FFS”) payments for hospitals in large urban areas (populations over one million) in FFY 2018. We estimate that all of the payment and policy changes affecting operating MS-DRG payments, notably those affecting Medicare UC-DSH payments, will result in an estimated 0.1% increase in our annual Medicare FFS IPPS payments, which yields an estimated increase of approximately $2 million. The payment increase resulting from the 1.21% net market basket increase is offset by a reduction to our UC-DSH payments primarily due to the aforementioned transition to using uncompensated care costs for the distribution of the UC-DSH pool. Because of the uncertainty associated with various factors that may influence our future IPPS payments by individual hospital, including legislative action, admission volumes, length of stay and case mix, we cannot provide any assurances regarding our estimate of the impact of the final payment and policy changes.

Final Payment and Policy Changes to the Medicare Outpatient Prospective Payment and Ambulatory Surgery Center Payment Systems

On November 1, 2017, CMS released final policy changes, quality provisions and payment rates for the Medicare Hospital Outpatient Prospective Payment System (“OPPS”) and Ambulatory Surgical Center (“ASC”) Payment System for calendar year 2018 (“Final OPPS/ASC Rule”). The Final OPPS/ASC rule includes the following payment and policy changes:

• An increase of approximately 4.85% in the OPPS conversion factor (i.e., the base rate that is adjusted for geographic wage differences and multiplied by the Ambulatory Payment Classification (“APC”) relative weight to determine individual APC payments) comprised of (i) an increase of 1.35% based on a market basket increase of 2.7% reduced by market basket index and multifactor productivity reductions required by the ACA of 0.75% and 0.6%, respectively, (ii) wage index budget neutrality, pass-through and outlier spending adjustments, and (iii) an

35

increase of 3.19% resulting from a budget-neutral redistribution of approximately $1.6 billion related to payments for separately payable drugs purchased under the 340B program from average sale price (“ASP”) plus 6% to ASP minus 22.5%; the 340B program allows certain hospitals (i.e., only nonprofit organizations with specific federal designations and/or funding) to purchase separately payable drugs at discounted rates from drug manufacturers;

• The removal of total knee arthroplasty (“TKA”) from the CMS list of procedures that can be performed only on an inpatient basis (the “Inpatient Only List”), which permits TKAs to be performed in a hospital outpatient department; CMS did not add TKA to the ASC list of covered surgical procedures; and

• A 1.2% update to the ASC payment rates.

CMS projects that the combined impact of the payment and policy changes in the Final OPPS/ASC Rule will yield an average 1.4% increase in Medicare FFS OPPS payments for all hospitals, an average 1.3% increase in Medicare FFS OPPS payments for hospitals in large urban areas (populations over one million), and an average 4.5% increase in Medicare FFS OPPS payments for proprietary hospitals. Based on CMS’ estimates, the projected annual impact of the payment and policy changes in the Final OPPS/ASC Rule on our hospitals is an increase to Medicare FFS hospital outpatient revenues of approximately $32 million, which represents an increase of approximately 4.5%. Because of the uncertainty associated with various factors that may influence our future OPPS payments, including legislative or legal actions, volumes and case mix, we cannot provide any assurances regarding our estimate of the impact of the final payment and policy changes.

PRIVATE INSURANCE

Managed Care

We currently have thousands of managed care contracts with various HMOs and PPOs. HMOs generally maintain a full-service healthcare delivery network comprised of physician, hospital, pharmacy and ancillary service providers that HMO members must access through an assigned “primary care” physician. The member’s care is then managed by his or her primary care physician and other network providers in accordance with the HMO’s quality assurance and utilization review guidelines so that appropriate healthcare can be efficiently delivered in the most cost-effective manner. HMOs typically provide reduced benefits or reimbursement (or none at all) to their members who use non-contracted healthcare providers for non-emergency care.

PPOs generally offer limited benefits to members who use non-contracted healthcare providers. PPO members who use contracted healthcare providers receive a preferred benefit, typically in the form of lower co-pays, co-insurance or deductibles. As employers and employees have demanded more choice, managed care plans have developed hybrid products that combine elements of both HMO and PPO plans, including high-deductible healthcare plans that may have limited benefits, but cost the employee less in premiums.

The amount of our managed care net patient revenues from our Hospital Operations and other segment during the nine months ended September 30, 2017 and 2016 was $7.867 billion and $8.031 billion, respectively. Approximately 63% of our managed care net patient revenues for the nine months ended September 30, 2017 was derived from our top ten managed care payers. National payers generated approximately 45% of our total net managed care revenues. The remainder comes from regional or local payers. At September 30, 2017 and December 31, 2016, approximately 62% and 63%, respectively, of our net accounts receivable for our Hospital Operations and other segment were due from managed care payers.

In April 2017, we successfully concluded negotiations with a national payer to return to its provider network after ceasing our participation on October 1, 2016. As a result of this new agreement, our hospitals and other healthcare facilities, as well as our employed physicians, were all added to the payer’s national provider network on June 1, 2017. Prior to expiration of the contract on October 1, 2016, the contract represented approximately 2.9% of our net operating revenues before provision for doubtful accounts for the period subsequent to the sale of our Georgia hospitals on March 31, 2016 to the contract expiration on September 30, 2016.

Revenues under managed care plans are based primarily on payment terms involving predetermined rates per diagnosis, per-diem rates, discounted fee-for-service rates and other similar contractual arrangements. These revenues are also subject to review and possible audit by the payers, which can take several years before they are completely resolved. The payers are billed for patient services on an individual patient basis. An individual patient’s bill is subject to adjustment on a patient-by-patient basis in the ordinary course of business by the payers following their review and adjudication of each particular bill. We estimate the discounts for contractual allowances at the individual hospital level utilizing billing data on an individual patient basis. At the end of each month, on an individual hospital basis, we estimate our expected reimbursement for patients of

36

managed care plans based on the applicable contract terms. We believe it is reasonably likely for there to be an approximately 3% increase or decrease in the estimated contractual allowances related to managed care plans. Based on reserves at September 30, 2017, a 3% increase or decrease in the estimated contractual allowance would impact the estimated reserves by approximately $15 million. Some of the factors that can contribute to changes in the contractual allowance estimates include: (1) changes in reimbursement levels for procedures, supplies and drugs when threshold levels are triggered; (2) changes in reimbursement levels when stop-loss or outlier limits are reached; (3) changes in the admission status of a patient due to physician orders subsequent to initial diagnosis or testing; (4) final coding of in-house and discharged-not-final-billed patients that change reimbursement levels; (5) secondary benefits determined after primary insurance payments; and (6) reclassification of patients among insurance plans with different coverage and payment levels. Contractual allowance estimates are periodically reviewed for accuracy by taking into consideration known contract terms, as well as payment history. Although we do not separately accumulate and disclose the aggregate amount of adjustments to the estimated reimbursement for every patient bill, we believe our estimation and review process enables us to identify instances on a timely basis where such estimates need to be revised. We do not believe there were any adjustments to estimates of patient bills that were material to our operating income. In addition, on a corporate-wide basis, we do not record any general provision for adjustments to estimated contractual allowances for managed care plans.

We expect managed care governmental admissions to continue to increase as a percentage of total managed care admissions over the near term. However, the managed Medicare and Medicaid insurance plans typically generate lower yields than commercial managed care plans, which have been experiencing an improved pricing trend. Although we have benefited from solid year-over-year aggregate managed care pricing improvements for several years, we have seen these improvements moderate in recent years, and we believe the moderation could continue in future years. In the nine months ended September 30, 2017, our commercial managed care net inpatient revenue per admission from our acute care hospitals was approximately 88% higher than our aggregate yield on a per admission basis from government payers, including managed Medicare and Medicaid insurance plans.

Indemnity

An indemnity-based agreement generally requires the insurer to reimburse an insured patient for healthcare expenses after those expenses have been incurred by the patient, subject to policy conditions and exclusions. Unlike an HMO member, a patient with indemnity insurance is free to control his or her utilization of healthcare and selection of healthcare providers.

SELF-PAY PATIENTS

Self-pay patients are patients who do not qualify for government programs, such as Medicare and Medicaid, do not have some form of private insurance and, therefore, are responsible for their own medical bills. A significant number of our self-pay patients are admitted through our hospitals’ emergency departments and often require high-acuity treatment that is more costly to provide and, therefore, results in higher billings, which are the least collectible of all accounts.

Self-pay accounts pose significant collectability problems. At September 30, 2017 and December 31, 2016, approximately 6% and 5%, respectively, of our net accounts receivable for our Hospital Operations and other segment were due from self-pay patients. Further, a significant portion of our provision for doubtful accounts relates to self-pay patients, as well as co-pays and deductibles owed to us by patients with insurance. We provide revenue cycle management services through our Conifer subsidiary, which is subject to various laws, rules and regulations regarding consumer finance, debt collection and credit reporting activities. For additional information, see Item 1, Business — Regulations Affecting Conifer’s Operations, in Part I of our Annual Report.

Conifer has performed systematic analyses to focus our attention on the drivers of bad debt expense for each hospital. While emergency department use is the primary contributor to our provision for doubtful accounts in the aggregate, this is not the case at all hospitals. As a result, we have increased our focus on targeted initiatives that concentrate on non-emergency department patients as well. These initiatives are intended to promote process efficiencies in collecting self‑pay accounts, as well as co-pay and deductible amounts owed to us by patients with insurance, that we deem highly collectible. We leverage a statistical-based collections model that aligns our operational capacity to maximize our collections performance. We are dedicated to modifying and refining our processes as needed, enhancing our technology and improving staff training throughout the revenue cycle process in an effort to increase collections and reduce accounts receivable.

Over the longer term, several other initiatives we have previously announced should also help address this challenge. For example, our Compact with Uninsured Patients (“Compact”) is designed to offer managed care-style discounts to certain uninsured patients, which enables us to offer lower rates to those patients who historically had been charged standard gross charges. A significant portion of those charges had previously been written down in our provision for doubtful accounts. Under

37

the Compact, the discount offered to uninsured patients is recognized as a contractual allowance, which reduces net operating revenues at the time the self-pay accounts are recorded. The uninsured patient accounts, net of contractual allowances recorded, are further reduced to their net realizable value through provision for doubtful accounts based on historical collection trends for self-pay accounts and other factors that affect the estimation process.

We also provide charity care to patients who are unable to pay for the healthcare services they receive. Most patients who qualify for charity care are charged a per-diem amount for services received, subject to a cap. Except for the per-diem amounts, our policy is not to pursue collection of amounts determined to qualify as charity care; therefore, we do not report these amounts in net operating revenues. Most states include an estimate of the cost of charity care in the determination of a hospital’s eligibility for Medicaid DSH payments. These payments are intended to mitigate our cost of uncompensated care, as well as reduced Medicaid funding levels. Generally, our method of measuring the estimated costs uses adjusted self-pay/charity patient days multiplied by selected operating expenses (which include salaries, wages and benefits, supplies and other operating expenses) per adjusted patient day. The adjusted self‑pay/charity patient days represents actual self-pay/charity patient days adjusted to include self-pay/charity outpatient services by multiplying actual self-pay/charity patient days by the sum of gross self-pay/charity inpatient revenues and gross self-pay/charity outpatient revenues and dividing the results by gross self-pay/charity inpatient revenues. The following table shows our estimated costs (based on selected operating expenses, which exclude the costs of our health plan businesses) of caring for self-pay patients and charity care patients, as well as revenues attributable to Medicaid DSH and other supplemental revenues we recognized, in the three and nine months ended September 30, 2017 and 2016:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2017		2016		2017		2016
Estimated costs for:
Self-pay patients	$	164	$	158	$	484	$	453
Charity care patients	29		36		92		104
Total	$	193	$	194	$	576	$	557
Medicaid DSH and other supplemental revenues	$	140	$	249	$	462	$	691

The expansion of health insurance coverage in prior periods has resulted in an increase in the number of patients using our facilities who have either health insurance exchange or government healthcare insurance program coverage. However, we continue to have to provide uninsured discounts and charity care due to the failure of states to expand Medicaid coverage and for persons living in the country illegally who are not permitted to enroll in a health insurance exchange or government healthcare insurance program. Furthermore, on October 12, 2017, the Trump administration announced that it would immediately end cost-sharing reduction (“CSR”) payments to insurers under the ACA, which compensate insurers for subsidizing out-of-pocket costs for low-income enrollees. Without the CSR payments, some insurers may seek approval to increase premiums for plans offered on ACA exchanges or withdraw from offering plans on some or all of the exchanges. Legislation has been introduced in Congress that would restore the CSR payments. In addition, a group of state attorneys general have filed a lawsuit seeking court action to block the Trump administration order ending the payments. We cannot predict what actions insurers might take as a result of the order, the impact of those actions on our operations, or the outcome of legislative efforts or litigation seeking to restore the payments. We also do not know what adverse impact the continued uncertainty may have on 2018 marketplace enrollment and coverage.

38

RESULTS OF OPERATIONS

The following two tables summarize our consolidated net operating revenues, operating expenses and operating income from continuing operations, both in dollar amounts and as percentages of net operating revenues, for the three and nine months ended September 30, 2017 and 2016: 

	Three Months Ended September 30,						Nine Months Ended September 30,
	2017			2016			2017			2016
Net operating revenues:
General hospitals	$	3,873		$	4,065		$	12,052		$	12,429
Other operations	1,068			1,151			3,258			3,427
Net operating revenues before provision for doubtful accounts	4,941			5,216			15,310			15,856
Less provision for doubtful accounts	355			367			1,109			1,095
Net operating revenues	4,586			4,849			14,201			14,761
Equity in earnings of unconsolidated affiliates	38			31			95			85
Operating expenses:
Salaries, wages and benefits	2,264			2,308			6,990			7,012
Supplies	740			767			2,285			2,351
Other operating expenses, net	1,120			1,231			3,466			3,686
Electronic health record incentives	(1		)	(2		)	(8		)	(23		)
Depreciation and amortization	219			205			662			632
Impairment and restructuring charges, and acquisition-related costs	329			31			403			81
Litigation and investigation costs	6			4			12			291
Gains on sales, consolidation and deconsolidation of facilities	(104		)	(3		)	(142		)	(151		)
Operating income	$	51		$	339		$	628		$	967

	Three Months Ended September 30,				Nine Months Ended September 30,
	2017		2016		2017		2016
Net operating revenues	100.0	%	100.0	%	100.0	%	100.0	%
Equity in earnings of unconsolidated affiliates	0.8	%	0.6	%	0.7	%	0.6	%
Operating expenses:
Salaries, wages and benefits	49.4	%	47.6	%	49.3	%	47.5	%
Supplies	16.1	%	15.8	%	16.1	%	15.9	%
Other operating expenses, net	24.4	%	25.4	%	24.4	%	25.0	%
Electronic health record incentives	—	%	—	%	(0.1	)%	(0.2	)%
Depreciation and amortization	4.8	%	4.2	%	4.7	%	4.3	%
Impairment and restructuring charges, and acquisition-related costs	7.2	%	0.6	%	2.8	%	0.5	%
Litigation and investigation costs	0.1	%	0.1	%	0.1	%	2.0	%
Gains on sales, consolidation and deconsolidation of facilities	(2.3	)%	(0.1	)%	(1.0	)%	(1.0	)%
Operating income	1.1	%	7.0	%	4.4	%	6.6	%

Net operating revenues of our general hospitals include inpatient and outpatient revenues for services provided by facilities in our Hospital Operations and other segment, as well as nonpatient revenues (e.g., rental income, management fee revenue, and income from services such as cafeterias, gift shops and parking) and other miscellaneous revenue. Net operating revenues of other operations primarily consist of revenues from (1) physician practices, (2) a long-term acute care hospital, which we divested effective August 1, 2017, (3) our Ambulatory Care segment, (4) services provided by our Conifer subsidiary to third parties and (5) our health plans. Revenues from our general hospitals represented approximately 78% of our total net operating revenues before provision for doubtful accounts for both of the three month periods ended September 30, 2017 and 2016, and 79% and 78% for the nine month periods ended September 30, 2017 and 2016, respectively.

Net operating revenues from our other operations were $1.068 billion and $1.151 billion in the three months ended September 30, 2017 and 2016, respectively, and $3.258 billion and $3.427 billion in the nine months ended September 30, 2017 and 2016, respectively. The decrease in net operating revenues from other operations during 2017 primarily relates to our health plans, partially offset by increases in revenues from our Conifer subsidiary and our USPI joint venture. Equity earnings of unconsolidated affiliates were $38 million and $31 million for the three months ended September 30, 2017 and 2016, respectively, and $95 million and $85 million for the nine months ended September 30, 2017 and 2016, respectively.

The following table shows selected operating expenses of our three reportable business segments. Information for our Hospital Operations and other segment is presented on a same-hospital basis, which includes the results of our same

39

72 hospitals operated throughout the nine months ended September 30, 2017 and 2016. The results of five Georgia hospitals, which we divested effective April 1, 2016, our new THOP Transmountain Campus teaching hospital, which we opened in January 2017 in El Paso, and three Houston-area hospitals, which we divested effective August 1, 2017, are excluded from our same-hospital information.

	Three Months Ended September 30,						Nine Months Ended September 30,
Selected Operating Expenses	2017		2016		Increase (Decrease)		2017		2016		Increase (Decrease)
Hospital Operations and other — Same-Hospital
Salaries, wages and benefits	$	1,846	$	1,856	(0.5	)%	$	5,617	$	5,579	0.7	%
Supplies	633		657		(3.7	)%	1,946		2,003		(2.8	)%
Other operating expenses	898		1,004		(10.6	)%	2,771		2,961		(6.4	)%
Total	$	3,377	$	3,517	(4.0	)%	$	10,334	$	10,543	(2.0	)%
Ambulatory Care
Salaries, wages and benefits	$	155	$	144	7.6	%	$	458	$	437	4.8	%
Supplies	95		89		6.7	%	285		266		7.1	%
Other operating expenses	93		86		8.1	%	267		263		1.5	%
Total	$	343	$	319	7.5	%	$	1,010	$	966	4.6	%
Conifer
Salaries, wages and benefits	$	230	$	240	(4.2	)%	$	730	$	717	1.8	%
Supplies	1		—		100.0	%	3		—		100.0	%
Other operating expenses	91		79		15.2	%	266		247		7.7	%
Total	$	322	$	319	0.9	%	$	999	$	964	3.6	%
Total
Salaries, wages and benefits	$	2,231	$	2,240	(0.4	)%	$	6,805	$	6,733	1.1	%
Supplies	729		746		(2.3	)%	2,234		2,269		(1.5	)%
Other operating expenses	1,082		1,169		(7.4	)%	3,304		3,471		(4.8	)%
Total	$	4,042	$	4,155	(2.7	)%	$	12,343	$	12,473	(1.0	)%
Rent/lease expense (1)
Hospital Operations and other	$	57	$	55	3.6	%	$	170	$	167	1.8	%
Ambulatory Care	20		18		11.1	%	57		55		3.6	%
Conifer	4		5		(20.0	)%	14		14		—	%
Total	$	81	$	78	3.8	%	$	241	$	236	2.1	%

(1)  Included in other operating expenses.

RESULTS OF OPERATIONS BY SEGMENT

Our operations are reported in three segments:

• Hospital Operations and other, which is comprised of our acute care hospitals, ancillary outpatient facilities, urgent care centers, microhospitals and physician practices;

• Ambulatory Care, which is comprised of our USPI joint venture’s ambulatory surgery centers, urgent care centers, imaging centers and surgical hospitals, as well as Aspen’s hospitals and clinics; and

• Conifer, which provides healthcare business process services in the areas of hospital and physician revenue cycle management and value-based care solutions to healthcare systems, as well as individual hospitals, physician practices, self-insured organizations, health plans and other entities.

HospitalOperations andOtherSegment

The following tables show operating statistics of our continuing operations acute care hospitals and related outpatient facilities on a same-hospital basis, unless otherwise indicated, which includes the results of our same 72 hospitals operated throughout the nine months ended September 30, 2017 and 2016. The results of five Georgia hospitals, which we divested effective April 1, 2016, our new THOP Transmountain Campus teaching hospital, which we opened in January 2017 in El Paso, and three Houston-area hospitals, which we divested effective August 1, 2017, are excluded from our same-hospital information.

40

	Same-Hospital Continuing Operations							Same-Hospital Continuing Operations
	Three Months Ended September 30,							Nine Months Ended September 30,
Admissions, Patient Days and Surgeries	2017		2016		Increase (Decrease)			2017		2016		Increase (Decrease)
Number of hospitals (at end of period)	72		72		—		(1)	72		72		—		(1)
Total admissions	181,970		186,765		(2.6	)%		553,651		569,112		(2.7	)%
Adjusted patient admissions(2)	320,821		327,960		(2.2	)%		970,418		990,517		(2.0	)%
Paying admissions (excludes charity and uninsured)	171,791		176,376		(2.6	)%		524,588		540,172		(2.9	)%
Charity and uninsured admissions	10,179		10,389		(2.0	)%		29,063		28,940		0.4	%
Admissions through emergency department	118,361		116,234		1.8	%		357,078		359,694		(0.7	)%
Paying admissions as a percentage of total admissions	94.4	%	94.4	%	—	%	(1)	94.8	%	94.9	%	(0.1	)%	(1)
Charity and uninsured admissions as a percentage of total admissions	5.6	%	5.6	%	—	%	(1)	5.2	%	5.1	%	0.1	%	(1)
Emergency department admissions as a percentage of total admissions	65.0	%	62.2	%	2.8	%	(1)	64.5	%	63.2	%	1.3	%	(1)
Surgeries — inpatient	50,074		52,556		(4.7	)%		149,801		156,638		(4.4	)%
Surgeries — outpatient	66,482		70,206		(5.3	)%		202,796		215,632		(6.0	)%
Total surgeries	116,556		122,762		(5.1	)%		352,597		372,270		(5.3	)%
Patient days — total	838,215		863,100		(2.9	)%		2,570,717		2,657,969		(3.3	)%
Adjusted patient days(2)	1,466,266		1,508,217		(2.8	)%		4,478,793		4,598,669		(2.6	)%
Average length of stay (days)	4.61		4.62		(0.2	)%		4.64		4.67		(0.6	)%
Licensed beds (at end of period)	19,327		19,292		0.2	%		19,327		19,292		0.2	%
Average licensed beds	19,328		19,319		—	%		19,297		19,326		(0.2	)%
Utilization of licensed beds(3)	47.1	%	48.6	%	(1.5	)%	(1)	48.8	%	50.4	%	(1.6	)%	(1)

(1)	The change is the difference between 2017 and 2016 amounts shown.
(2)	Adjusted patient admissions/days represents actual patient admissions/days adjusted to include outpatient services provided by facilities in our Hospital Operations and other segment by multiplying actual patient admissions/days by the sum of gross inpatient revenues and outpatient revenues and dividing the results by gross inpatient revenues.
(3)	Utilization of licensed beds represents patient days divided by number of days in the period divided by average licensed beds.

	Same-Hospital Continuing Operations							Same-Hospital Continuing Operations
	Three Months Ended September 30,							Nine Months Ended September 30,
Outpatient Visits	2017		2016		Increase (Decrease)			2017		2016		Increase (Decrease)
Total visits	1,813,595		1,917,200		(5.4	)%		5,629,973		5,843,476		(3.7	)%
Paying visits (excludes charity and uninsured)	1,696,468		1,784,379		(4.9	)%		5,281,403		5,447,091		(3.0	)%
Charity and uninsured visits	117,127		132,821		(11.8	)%		348,570		396,385		(12.1	)%
Emergency department visits	646,331		662,625		(2.5	)%		1,987,743		2,038,946		(2.5	)%
Surgery visits	66,482		70,206		(5.3	)%		202,796		215,632		(6.0	)%
Paying visits as a percentage of total visits	93.5	%	93.1	%	0.4	%	(1)	93.8	%	93.2	%	0.6	%	(1)
Charity and uninsured visits as a percentage of total visits	6.5	%	6.9	%	(0.4	)%	(1)	6.2	%	6.8	%	(0.6	)%	(1)

(1) The change is the difference between 2017 and 2016 amounts shown.

41

	Same-Hospital Continuing Operations						Same-Hospital Continuing Operations
	Three Months Ended September 30,						Nine Months Ended September 30,
Revenues	2017		2016		Increase (Decrease)		2017		2016		Increase (Decrease)
Total segment net operating revenues	$	3,641	$	3,849	(5.4	)%	$	11,195	$	11,642	(3.8	)%
Selected acute care hospitals and related outpatient facilities revenue data
Net inpatient revenues	$	2,391	$	2,533	(5.6	)%	$	7,342	$	7,571	(3.0	)%
Net outpatient revenues	1,386		1,334		3.9	%	4,195		4,081		2.8	%
Net patient revenues	$	3,777	$	3,867	(2.3	)%	$	11,537	$	11,652	(1.0	)%
Self-pay net inpatient revenues	$	107	$	89	20.2	%	$	297	$	254	16.9	%
Self-pay net outpatient revenues	142		127		11.8	%	418		368		13.6	%
Total self-pay revenues	$	249	$	216	15.3	%	$	715	$	622	15.0	%

	Same-Hospital Continuing Operations						Same-Hospital Continuing Operations
	Three Months Ended September 30,						Nine Months Ended September 30,
Revenues on a Per Admission, Per Patient Day and Per Visit Basis	2017		2016		Increase (Decrease)		2017		2016		Increase (Decrease)
Net inpatient revenue per admission	$	13,140	$	13,562	(3.1	)%	$	13,261	$	13,303	(0.3	)%
Net inpatient revenue per patient day	$	2,852	$	2,935	(2.8	)%	$	2,856	$	2,848	0.3	%
Net outpatient revenue per visit	$	764	$	696	9.8	%	$	745	$	698	6.7	%
Net patient revenue per adjusted patient admission(1)	$	11,773	$	11,791	(0.2	)%	$	11,889	$	11,764	1.1	%
Net patient revenue per adjusted patient day(1)	$	2,576	$	2,564	0.5	%	$	2,576	$	2,534	1.7	%

(1) Adjusted patient admissions/days represents actual patient admissions/days adjusted to include outpatient services provided by facilities in our Hospital Operations and other segment by multiplying actual patient admissions/days by the sum of gross inpatient revenues and outpatient revenues and dividing the results by gross inpatient revenues.

	Same-Hospital Continuing Operations									Same-Hospital Continuing Operations
	Three Months Ended September 30,									Nine Months Ended September 30,
Total Segment Provision for Doubtful Accounts	2017			2016			Increase (Decrease)			2017			2016			Increase (Decrease)
Provision for doubtful accounts	$	334		$	308		8.4	%		$	986		$	906		8.8	%
Provision for doubtful accounts as a percentage of net operating revenues before provision for doubtful accounts	8.4		%	7.4		%	1.0	%	(1)	8.1		%	7.2		%	0.9	%	(1)

(1) The change is the difference between 2017 and 2016 amounts shown.

42

	Same-Hospital Continuing Operations							Same-Hospital Continuing Operations
	Three Months Ended September 30,							Nine Months Ended September 30,
Total Segment Selected Operating Expenses	2017		2016		Increase (Decrease)			2017		2016		Increase (Decrease)
Salaries, wages and benefits as a percentage of net operating revenues	50.7	%	48.2	%	2.5	%	(1)	50.2	%	47.9	%	2.3	%	(1	)
Supplies as a percentage of net operating revenues	17.4	%	17.1	%	0.3	%	(1)	17.4	%	17.2	%	0.2	%	(1	)
Other operating expenses as a percentage of net operating revenues	24.7	%	26.1	%	(1.4	)%	(1)	24.8	%	25.4	%	(0.6	)%	(1	)

(1) The change is the difference between 2017 and 2016 amounts shown.

Revenues

Same-hospital net operating revenues decreased$208 million, or 5.4%, during the three months ended September 30, 2017 compared to the three months ended September 30, 2016, primarily due to lower inpatient and outpatient volumes, as well as California provider fee revenues. Our 2017 same-hospital inpatient and outpatient volumes were negatively affected compared to the 2016 period by the impact of Hurricane Irma on our facilities in Florida and South Carolina. Also, the 2016 period included $55 million of net revenues from the California provider fee program compared to no revenues under the program in the 2017 period because CMS has not yet approved the 2017 program. In addition, the results for the three months ended September 30, 2017 included unfavorable revenue adjustments of approximately $8 million and $2 million from the Texas 1115 waiver program and the Florida Medicaid program, respectively. Same-hospital net inpatient revenues decreased$142 million, or 5.6%, and same-hospital admissions decreased2.6% in the three months ended September 30, 2017 compared to the same period in 2016. Same-hospital net inpatient revenue per admission decreased3.1% despite the improved terms of our managed care contracts in the three months ended September 30, 2017 compared to the three months ended September 30, 2016, primarily due to the impact of the delay in approval of the California provider fee program. Same-hospital net outpatient revenues increased$52 million, or 3.9%, while same-hospital outpatient visits decreased5.4% in the three months ended September 30, 2017 compared to the same period in 2016 due in part to the sale of home health and hospice assets. Growth in outpatient revenues was primarily driven by improved terms of our managed care contracts. Same-hospital net outpatient revenue per visit increased9.8% in the three months ended September 30, 2017 compared to the three months ended September 30, 2016, primarily due to the improved terms of our managed care contracts and the sale of home health and hospice assets, which generate lower revenues per visit.

Same-hospital net operating revenues decreased$447 million, or 3.8%, during the nine months ended September 30, 2017 compared to the nine months ended September 30, 2016, primarily due to lower inpatient and outpatient volumes, as well as California provider fee revenues. Our 2017 same-hospital inpatient and outpatient volumes were negatively affected compared to the 2016 period by the impact of Hurricane Irma on our facilities in Florida and South Carolina, a leap-year day in the 2016 period and our out-of-network status with a national payer for over half of the 2017 period. Also, the 2016 period included $167 million of net revenues from the California provider fee program compared to no revenues under the program in the 2017 period because CMS has not yet approved the 2017 program. Same-hospital net inpatient revenues decreased$229 million, or 3.0%, and same-hospital admissions decreased2.7% in the nine months ended September 30, 2017 compared to the same period in 2016. Same-hospital net inpatient revenue per admission decreased0.3% despite the improved terms of our managed care contracts in the nine months ended September 30, 2017 compared to the nine months ended September 30, 2016, primarily due to the impact of the delay in approval of the California provider fee program. Same-hospital net outpatient revenues increased$114 million, or 2.8%, while same-hospital outpatient visits decreased3.7% in the nine months ended September 30, 2017 compared to the same period in 2016 due in part to the sale of home health and hospice assets. Growth in outpatient revenues was primarily driven by improved terms of our managed care contracts. Same-hospital net outpatient revenue per visit increased6.7% in the nine months ended September 30, 2017 compared to the nine months ended September 30,2016, primarily due to the improved terms of our managed care contracts and the sale of home health and hospice assets, which generate lower revenues per visit.

43

Provision for Doubtful Accounts

Same-hospital provision for doubtful accounts as a percentage of net operating revenues before provision for doubtful accounts was 8.4% and 7.4% for the three months ended September 30, 2017 and 2016, respectively, and 8.1% and 7.2% for the nine months ended September 30, 2017 and 2016, respectively. The increases in the 2017 periods compared to the 2016 periods were primarily driven by increases in uninsured revenues of $33 million and $93 million in the three month and nine month periods, respectively.

The following table shows the consolidated net accounts receivable and allowance for doubtful accounts by payer at September 30, 2017 and December 31, 2016:

	September 30, 2017								December 31, 2016
	Accounts Receivable Before Allowance for Doubtful Accounts			Allowance for Doubtful Accounts		Net			Accounts Receivable Before Allowance for Doubtful Accounts			Allowance for Doubtful Accounts		Net
Medicare	$	264		$	—	$	264		$	294		$	—	$	294
Medicaid	96			—		96			125			—		125
Net cost report settlements payable and valuation allowances	(2		)	—		(2		)	(14		)	—		(14		)
Managed care	1,687			178		1,509			1,911			190		1,721
Self-pay uninsured	416			363		53			479			412		67
Self-pay balance after insurance	265			165		100			226			147		79
Estimated future recoveries	130			—		130			141			—		141
Other payers	451			185		266			537			239		298
Total Hospital Operations and other	3,307			891		2,416			3,699			988		2,711
Ambulatory Care	192			43		149			227			43		184
Total discontinued operations	2			—		2			2			—		2
	$	3,501		$	934	$	2,567		$	3,928		$	1,031	$	2,897

A significant portion of our provision for doubtful accounts relates to self-pay patients, as well as co-pays and deductibles owed to us by patients with insurance. Collection of accounts receivable has been a key area of focus, particularly over the past several years. At September 30, 2017, our Hospital Operations and other segment collection rate on self-pay accounts was approximately 25.2%. Our self-pay collection rate includes payments made by patients, including co-pays and deductibles paid by patients with insurance. Based on our accounts receivable from self-pay patients and co-pays and deductibles owed to us by patients with insurance at September 30, 2017, a 10% decrease or increase in our self-pay collection rate, or approximately 3%, which we believe could be a reasonably likely change, would result in an unfavorable or favorable adjustment to provision for doubtful accounts of approximately $10 million.

Payment pressure from managed care payers also affects our provision for doubtful accounts. We typically experience ongoing managed care payment delays and disputes; however, we continue to work with these payers to obtain adequate and timely reimbursement for our services. Our estimated Hospital Operations and other segment collection rate from managed care payers was approximately 97.3% at September 30, 2017.

We manage our provision for doubtful accounts using hospital-specific goals and benchmarks such as (1) total cash collections, (2) point-of-service cash collections, (3) AR Days and (4) accounts receivable by aging category. The following tables present the approximate aging by payer of our net accounts receivable from the continuing operations of our Hospital Operations and other segment of $2.418 billion and $2.725 billion at September 30, 2017 and December 31, 2016, respectively, excluding cost report settlements payable and valuation allowances of $2 million and $14 million, respectively, at September 30, 2017 and December 31, 2016:

	September 30, 2017
	Medicare		Medicaid		Managed Care		Indemnity, Self-Pay and Other		Total
0-60 days	89	%	60	%	62	%	23	%	57	%
61-120 days	6	%	18	%	14	%	18	%	14	%
121-180 days	2	%	8	%	8	%	12	%	8	%
Over 180 days	3	%	14	%	16	%	47	%	21	%
Total	100	%	100	%	100	%	100	%	100	%

44

	December 31, 2016
	Medicare		Medicaid		Managed Care		Indemnity, Self-Pay and Other		Total
0-60 days	92	%	75	%	61	%	24	%	60	%
61-120 days	5	%	15	%	15	%	14	%	13	%
121-180 days	2	%	4	%	8	%	10	%	6	%
Over 180 days	1	%	6	%	16	%	52	%	21	%
Total	100	%	100	%	100	%	100	%	100	%

Conifer continues to implement revenue cycle initiatives to improve our cash flow. These initiatives are focused on standardizing and improving patient access processes, including pre-registration, registration, verification of eligibility and benefits, liability identification and collection at point-of-service, and financial counseling. These initiatives are intended to reduce denials, improve service levels to patients and increase the quality of accounts that end up in accounts receivable. Although we continue to focus on improving our methodology for evaluating the collectability of our accounts receivable, we may incur future charges if there are unfavorable changes in the trends affecting the net realizable value of our accounts receivable.

At September 30, 2017, we had a cumulative total of patient account assignments to Conifer of approximately $2.537 billion related to our continuing operations. These accounts have already been written off and are not included in our receivables or in the allowance for doubtful accounts; however, an estimate of future recoveries from all the accounts assigned to Conifer is determined based on our historical experience and recorded in accounts receivable. 

Patient advocates from Conifer’s Medicaid Eligibility Program (“MEP”) screen patients in the hospital to determine whether those patients meet eligibility requirements for financial assistance programs. They also expedite the process of applying for these government programs. Receivables from patients who are potentially eligible for Medicaid are classified as Medicaid pending, under the MEP, with appropriate contractual allowances recorded. Based on recent trends, approximately 95% of all accounts in the MEP are ultimately approved for benefits under a government program, such as Medicaid. The following table shows the approximate amount of accounts receivable in the MEP still awaiting determination of eligibility under a government program at September 30, 2017 and December 31, 2016 by aging category for the hospitals currently in the program:

	September 30,		December 31,
	2017		2016
0-60 days	$	63	$	84
61-120 days	13		13
121-180 days	2		4
Over 180 days	3		4
Total	$	81	$	105

Salaries, Wages and Benefits

Same-hospital salaries, wages and benefits as a percentage of net operating revenues increased250 basis points to 50.7% in the three months ended September 30, 2017 compared to the same period in 2016. Same-hospital net operating revenues decreased5.4% during the three months ended September 30, 2017 compared to the three months ended September 30,2016, and same-hospital salaries, wages and benefits decreased0.5% in the three months ended September 30, 2017 compared to the 2016 period. The change in same-hospital salaries, wages and benefits as a percentage of net operating revenues was primarily due to annual merit increases for certain of our employees, increased health benefits costs and the effect of lower net operating revenues and volumes on operating leverage due to certain fixed staffing costs, partially offset by decreased accruals for annual incentive compensation. Salaries, wages and benefits expense for the three months ended September 30, 2017 and 2016 included stock-based compensation expense of $10 million and $15 million, respectively.

Same-hospital salaries, wages and benefits as a percentage of net operating revenues increased230 basis points to 50.2% in the nine months ended September 30, 2017 compared to the same period in 2016. Same-hospital net operating revenues decreased3.8% during the nine months ended September 30, 2017 compared to the nine months ended September 30,2016, and same-hospital salaries, wages and benefits increased0.7% in the nine months ended September 30, 2017 compared to the 2016 period. The change in same-hospital salaries, wages and benefits as a percentage of net operating revenues was primarily due to annual merit increases for certain of our employees, increased health benefits costs and the effect of lower net operating revenues and volumes on operating leverage due to certain fixed staffing costs, partially offset by decreased accruals for annual incentive compensation and the impact of recent favorable workers’ compensation

45

claims experience. Salaries, wages and benefits expense for the nine months ended September 30, 2017 and 2016 included stock-based compensation expense of $32 million and $44 million, respectively.

At September 30, 2017, approximately 24% of the employees in our Hospital Operations and other segment were represented by labor unions. There were no unionized employees in our Ambulatory Care segment, and less than 1% of Conifer’s employees belong to a union. Unionized employees – primarily registered nurses and service, technical and maintenance workers – are located at 34 of our hospitals, the majority of which are in California, Florida and Michigan. We currently have eight expired contracts covering approximately 7% of our unionized employees and are or will be negotiating renewals under extension agreements. We are also negotiating (or will soon negotiate) first contracts at three hospitals and one physician practice where employees recently selected union representation; these contracts cover approximately 6% of our unionized employees. At this time, we are unable to predict the outcome of the negotiations, but increases in salaries, wages and benefits could result from these agreements. Furthermore, there is a possibility that strikes could occur during the negotiation process, which could increase our labor costs and have an adverse effect on our patient admissions and net operating revenues. Organizing activities by labor unions could increase our level of union representation in future periods.

Supplies

Same-hospital supplies expense as a percentage of net operating revenues increased30 basis points to 17.4% for the three months ended September 30, 2017 compared to the three months ended September 30, 2016. Same-hospital supplies expense as a percentage of net operating revenues increased20 basis points to 17.4% for the nine months ended September 30, 2017 compared to the nine months ended September 30, 2016. The change in supplies expense as a percentage of net operating revenues was primarily attributable to increased costs from our higher acuity supply-intensive surgical services and lower California provider fee revenues, partially offset by the benefit of the group-purchasing strategies and supplies-management services we utilize to reduce costs.

We strive to control supplies expense through product standardization, contract compliance, improved utilization, bulk purchases and operational improvements. The items of current cost reduction focus continue to be cardiac stents and pacemakers, orthopedics and implants, and high-cost pharmaceuticals.

Other Operating Expenses, Net

Same-hospital other operating expenses as a percentage of net operating revenues decreased140 basis points to 24.7% in the three months ended September 30, 2017 compared to 26.1% in the same period in 2016. Same-hospital other operating expenses decreased by $106 million, or 10.6%, and net operating revenues decreased by $208 million, or 5.4%, for the three months ended September 30, 2017 compared to the three months ended September 30, 2016. The changes in other operating expenses included:

• decreasedexpenses associated with our health plan businesses of $110 million due to the sale and wind-down of these businesses in 2017;

• decreased costs associated with funding indigent care services of $7 million, which costs were substantially offset by additional net patient revenues; and

• decreasedmalpractice expense of $10 million; partially offset by

• increased costs of contracted services of $9 million; and

• the effect of lower volumes on operating leverage due to certain fixed costs.

Same-hospital malpractice expense in the 2017 period included a favorable adjustment of approximately $1 million from the two basis point increase in the interest rate used to estimate the discounted present value of projected future malpractice liabilities. In the 2016 period, we recognized a favorable adjustment of approximately $3 million from the 13 basis point increase in the interest rate used to estimate the discounted present value of projected future malpractice liabilities.

Same-hospital other operating expenses as a percentage of net operating revenues decreased60 basis points to 24.8% in the nine months ended September 30, 2017 compared to 25.4% in the same period in 2016. Same-hospital other operating expenses decreased by $190 million, or 6.4%, and net operating revenues decreased by $447 million, or 3.8%, for the nine months ended September 30, 2017 compared to the nine months ended September 30, 2016. The changes in other operating expenses included:

46

• decreasedexpenses associated with our health plan businesses of $249 million due to the sale and wind-down of these businesses in 2017; and

• gains on the sales of assets of $20 million primarily related to the sale of home health and hospice assets; partially offset by

• increasedmedical fees of $18 million;

• increased costs of contracted services of $41 million;

• increased costs associated with funding indigent care services of $9 million, which costs were substantially offset by additional net patient revenues; and

• the effect of lower volumes on operating leverage due to certain fixed costs.

Same-hospital malpractice expense in the 2017 period included an unfavorable adjustment of approximately $1 million from the 9 basis point decrease in the interest rate used to estimate the discounted present value of projected future malpractice liabilities. In the 2016 period, we recognized an unfavorable adjustment of approximately $15 million from the 67 basis point decrease in the interest rate used to estimate the discounted present value of projected future malpractice liabilities.

Ambulatory Care Segment

Our Ambulatory Care segment is comprised of our USPI joint venture’s ambulatory surgery centers, urgent care centers, imaging centers and surgical hospitals, as well as Aspen’s hospitals and clinics. Our USPI joint venture operates its surgical facilities in partnership with local physicians and, in many of these facilities, a healthcare system partner. We hold an ownership interest in each facility, with each being operated through a separate legal entity in most cases. The joint venture operates facilities on a day-to-day basis through management services contracts. Our sources of earnings from each facility consist of:

• management services revenues, computed as a percentage of each facility’s net revenues (often net of bad debt expense); and

• our share of each facility’s net income (loss), which is computed by multiplying the facility’s net income (loss) times the percentage of each facility’s equity interests owned by our USPI joint venture.

Our role as an owner and day-to-day manager provides us with significant influence over the operations of each facility. In many of the facilities our Ambulatory Care segment operates (109 of 329 facilities at September 30, 2017), this influence does not represent control of the facility, so we account for our investment in the facility under the equity method for an unconsolidated affiliate. Our USPI joint venture controls 220 of the facilities our Ambulatory Care segment operates, and we account for these investments as consolidated subsidiaries. Our net earnings from a facility are the same under either method, but the classification of those earnings differs. For consolidated subsidiaries, our financial statements reflect 100% of the revenues and expenses of the subsidiaries, after the elimination of intercompany amounts. The net profit attributable to owners other than our USPI joint venture is classified within “net income attributable to noncontrolling interests.”

For unconsolidated affiliates, our consolidated statements of operations reflect our earnings in two line items:

• equity in earnings of unconsolidated affiliates—our share of the net income of each facility, which is based on the facility’s net income and the percentage of the facility’s outstanding equity interests owned by us; and

• management and administrative services revenues, which is included in our net operating revenues—income we earn for managing the day-to-day operations of each facility, usually quantified as a percentage of each facility’s net revenues less bad debt expense.

Our Ambulatory Care segment operating income is driven by the performance of all facilities our USPI joint venture operates and by the joint venture’s ownership interests in those facilities, but our individual revenue and expense line items contain only consolidated businesses, which represent 67% of those facilities. This translates to trends in consolidated operating income that often do not correspond with changes in consolidated revenues and expenses.

47

Results of Operations

The following table summarizes certain consolidated statements of operations items for the periods indicated:

	Three Months Ended September 30,						Nine Months Ended September 30,
Ambulatory Care Results of Operations	2017		2016		Increase (Decrease)		2017		2016		Increase (Decrease)
Net operating revenues	$	468	$	448	4.5	%	$	1,395	$	1,319	5.8	%
Equity in earnings of unconsolidated affiliates	$	34	$	28	21.4	%	$	91	$	79	15.2	%
Salaries, wages and benefits	$	155	$	144	7.6	%	$	458	$	437	4.8	%
Supplies	$	95	$	89	6.7	%	$	285	$	266	7.1	%
Other operating expenses, net	$	93	$	86	8.1	%	$	267	$	263	1.5	%

Our Ambulatory Care net operating revenues increased by $20 million and $76 million, or 4.5% and 5.8%, for the three and nine months ended September 30, 2017, respectively, compared to the three and nine months ended September 30,2016, respectively. The growth in 2017 revenues was primarily driven by increases from acquisitions of $27 million and $78 million for the three and nine month periods, respectively. Our Ambulatory Care volumes and revenues in the three months ended September 30, 2017 were negatively affected by the impact of Hurricane Harvey and Hurricane Irma on our facilities in Texas, Florida and South Carolina.

Salaries, wages and benefits expense increased by $11 million and $21 million, or 7.6% and 4.8%, for the three and nine months ended September 30, 2017, respectively, compared to the three and nine months ended September 30, 2016, respectively. The 2017 increases were primarily driven by salaries, wages and benefits expense from acquisitions of $6 million and $19 million for the three and nine month periods, respectively.

Supplies expense increased by $6 million and $19 million, or 6.7% and 7.1%, for the three and nine months ended September 30, 2017, respectively, compared to the three and nine months ended September 30, 2016, respectively. The 2017 increases were primarily driven by supplies expense from acquisitions of $6 million and $18 million for the three and nine month periods, respectively.

Other operating expenses increased by $7 million and $4 million, or 8.1% and 1.5%, for the three and nine months ended September 30, 2017, respectively, compared to the three and nine months ended September 30, 2016, respectively. The change in other operating expenses for the three months ended September 30, 2017 was driven by other operating expenses from acquisitions of $4 million. For the nine months ended September 30, 2017, the increase was driven by acquisitions of $13 million, partially offset by decreases in same-facility other operating expenses of $8 million.

Facility Growth

The following table summarizes the changes in our same-facility revenue year-over-year on a pro forma systemwide basis, which includes both consolidated and unconsolidated (equity method) facilities. While we do not record the revenues of unconsolidated facilities, we believe this information is important in understanding the financial performance of our Ambulatory Care segment because these revenues are the basis for calculating our management services revenues and, together with the expenses of our unconsolidated facilities, are the basis for our equity in earnings of unconsolidated affiliates.

Ambulatory Care Facility Growth	Three Months Ended September 30, 2017		Nine Months Ended September 30, 2017
Net revenues	0.9	%	3.5	%
Cases	(2.4	)%	(0.8	)%
Net revenue per case	3.4	%	4.3	%

48

Joint Ventures with Healthcare System Partners

Our USPI joint venture’s business model is to jointly own its facilities with local physicians and not-for-profit healthcare systems. Accordingly, as of September 30, 2017, the majority of facilities in our Ambulatory Care segment are operated in this model.

Ambulatory Care Facilities	Nine Months Ended September 30, 2017
Facilities:
With a healthcare system partner	192
Without a healthcare system partner	137
Total facilities operated	329
Change from December 31, 2016
Acquisitions	7
De novo	1
Dispositions/Mergers	(2	)
Total increase in number of facilities operated	6

During the nine months ended September 30, 2017, we acquired controlling interests in a single-specialty gastroenterology surgery center in each of Texas and Arizona, a single-specialty ophthalmology surgery center in Florida, a single-specialty orthopedics surgery center in Colorado and an imaging center in California. We paid cash totaling approximately $28 million for these acquisitions. All five facilities are jointly owned with local physicians, and a healthcare system partner has an ownership interest in each of the Arizona, Colorado and Florida surgery centers. During the nine months ended September 30, 2017, we acquired non-controlling interests in a surgical hospital in Texas and a multi-specialty surgery center in California. We paid cash totaling approximately $49 million for these ownership interests. Both facilities are jointly owned with local physicians and a healthcare system partner.

ConiferSegment

Our Conifer segment generated net operating revenues of $401 million and $398 million during the three months ended September 30, 2017 and 2016, respectively, and $1.203 billion and $1.169 billion during the nine months ended September 30, 2017 and 2016, respectively, a portion of which was eliminated in consolidation as described in Note 16 to the Condensed Consolidated Financial Statements. The increases in revenues from third-party customers of $13 million and $59 million for the three and nine month periods ended September 30, 2017, respectively, which are not eliminated in consolidation, are primarily due to new clients.

Salaries, wages and benefits expense for Conifer decreased$10 million, or 4.2%, in the three months ended September 30, 2017 compared to the three months ended September 30, 2016 primarily due to lower incentive compensation expense. Salaries, wages and benefits expense for Conifer increased$13 million, or 1.8%, in the nine months ended September 30, 2017 compared to the nine months ended September 30, 2016 due to an increase in staffing as a result of the growth in Conifer’s business primarily attributable to new clients, partially offset by lower incentive compensation expense.

Other operating expenses for Conifer increased$12 million, or 15.2%, in the three months ended September 30, 2017 compared to the three months ended September 30, 2016, and increased$19 million, or 7.7%, in the nine months ended September 30, 2017 compared to the nine months ended September 30, 2016, in both cases primarily due to the growth in Conifer’s business primarily attributable to new clients. Conifer typically incurs start-up and other transition costs during the initial period of new client contracts. 

Consolidated 

Impairment and Restructuring Charges, and Acquisition-Related Costs

During the three months ended September 30, 2017, we recorded impairment and restructuring charges and acquisition-related costs of $329 million primarily related to our Hospital Operations and other segment, consisting of approximately $294 million of charges to write-down assets held for sale to their estimated fair value, less estimated costs to sell, for our Aspen and Philadelphia-area facilities, $14 million of impairment of two equity method investments, $10 million of employee severance costs, $1 million of contract and lease termination fees, $1 million to write-down intangible assets, $6 million of other restructuring costs, and $3 million in acquisition-related transaction costs.

49

During the three months ended September 30, 2016, we recorded impairment and restructuring charges and acquisition-related costs of $31 million primarily related to our Hospital Operations and other segment, consisting of approximately $9 million of employee severance costs, $3 million of contract and lease termination fees, $7 million of other restructuring costs, and $12 million in acquisition-related costs, which include $2 million of transaction costs and $10 million of acquisition integration charges.

During the nine months ended September 30, 2017, we recorded impairment and restructuring charges and acquisition-related costs of $403 million primarily related to our Hospital Operations and other segment, consisting of approximately $294 million of charges to write-down assets held for sale to their estimated fair value, less estimated costs to sell, for our Aspen and Philadelphia-area facilities, $29 million of impairment of two equity method investments, $40 million of employee severance costs, $8 million of contract and lease termination fees, $3 million to write-down intangible assets, $13 million of other restructuring costs, and $16 million in acquisition-related costs, which include $5 million of transaction costs and $11 million of acquisition integration charges.

During the nine months ended September 30, 2016, we recorded impairment and restructuring charges and acquisition-related costs of $81 million primarily related to our Hospital Operations and other segment, consisting of approximately $26 million of employee severance costs, $4 million of contract and lease termination fees, $2 million to write-down intangible assets, $9 million of other restructuring costs, and $40 million in acquisition-related costs, which include $5 million of transaction costs and $35 million of acquisition integration charges.

Litigation and Investigation Costs

Litigation and investigation costs for the three months ended September 30, 2017 and 2016 were $6 million and $4 million, respectively.

Litigation and investigation costs for the nine months ended September 30, 2017 and 2016 were $12 million and $291 million, respectively. The costs in the 2016 period include reserves we recorded for a regulatory investigation that was settled in October 2016.

Gains on Sales, Consolidation and Deconsolidation of Facilities

During the three months ended September 30, 2017, we recorded gains on sales, consolidation and deconsolidation of facilities of approximately $104 million, primarily comprised of a $111 million gain from the sale of our hospitals, physician practices and related assets in Houston, Texas and the surrounding area. 

During the three months ended September 30, 2016, we recorded gains on sales, consolidation and deconsolidation of facilities of approximately $3 million, primarily comprised of gains related to the consolidation and deconsolidation of certain businesses of our USPI joint venture due to ownership changes.

During the nine months ended September 30, 2017, we recorded gains on sales, consolidation and deconsolidation of facilities of approximately $142 million, primarily comprised of a $111 million gain from the sale of our hospitals, physician practices and related assets in Houston, Texas and the surrounding area, $13 million from the sale of one of our health plans in Arizona, $10 million from the sale of our health plan in Texas and $3 million from the sale of our health plan in Michigan. 

During the nine months ended September 30, 2016, we recorded gains on sales, consolidation and deconsolidation of facilities of approximately $151 million, primarily comprised of a $113 million gain from the sale of our Atlanta-area facilities and $33 million of gains related to the consolidation and deconsolidation of certain businesses of our USPI joint venture due to ownership changes.

Interest Expense

Interest expense for the three months ended September 30, 2017 was $257 million compared to $243 million for the same period in 2016. Interest expense for the nine months ended September 30, 2017 was $775 million compared to $730 million for the same period in 2016. These increases are attributable to additional senior notes issued since the 2016 period, partially offset by the impact of the redemption of other senior notes since the 2016 period.

50

Income Tax Expense

During the three months ended September 30, 2017, we recorded an income tax benefit of $60 million in continuing operations on pre-tax loss of $348 million compared to income tax expense of $10 million on pre-tax income of $89 million during the three months ended September 30, 2016. During the nine months ended September 30, 2017, we recorded an income tax benefit of $105 million in continuing operations on pre-tax loss of $325 million compared to income tax expense of $61 million on pre-tax income of $219 million during the nine months ended September 30, 2016. Our provision for income taxes during interim reporting periods has historically been calculated by applying an estimate of the annual effective tax rate for the full year to “ordinary” income or loss (pre-tax income or loss excluding unusual or infrequently occurring discrete items) for the reporting period. However, we utilized the discrete effective tax rate method to calculate the interim period tax provision for the three and nine month periods ended September 30, 2017. We determined that, because minor fluctuations in estimated “ordinary” income would result in significant changes in the estimated annual effective tax rate, the historical method would not provide a reliable estimate for the three and nine month periods ended September 30, 2017. Due to Aspen being classified as held for sale, we have reversed our indefinite reinvestment assertion with respect to this investment outside the United States as of September 30, 2017, which resulted in an income tax benefit of $30 million in the three months ended September 30, 2017. The reconciliation between the amount of recorded income tax expense (benefit) and the amount calculated at the statutory federal tax rate is shown in the following table:

	Three Months Ended September 30,						Nine Months Ended September 30,
	2017			2016			2017			2016
Tax expense (benefit) at statutory federal rate of 35%	$	(122	)	$	31		$	(114	)	$	77
State income taxes, net of federal income tax benefit	8			3			13			10
Tax benefit attributable to noncontrolling interests	(25		)	(28		)	(79		)	(75		)
Nondeductible goodwill	104			—			104			29
Nontaxable gains	—			(1		)	—			(18		)
Nondeductible litigation	—			4			—			37
Change in tax contingency reserves, including interest	(1		)	(1		)	(3		)	(4		)
Stock-based compensation	—			—			9			—
Change in indefinite reinvestment assertion	(30		)	—			(30		)	—
Change in valuation allowance	(5		)	—			(5		)	—
Other items	11			2			—			5
	$	(60	)	$	10		$	(105	)	$	61

The Committee on Ways and Means of the U.S. House of Representatives recently introduced tax reform legislation that would make significant changes to income taxation of individuals, corporations and estates. The proposed corporate income tax changes include a reduction in the corporate tax rate, a limitation on the deductibility of net interest expense, and a provision to allow for current expensing of certain capital expenditures. If enacted, we would be required to record the impact of the corporate tax rate change on our deferred tax assets and liabilities in the reporting period in which the legislation is signed into law. At this time, we are unable to predict whether any of these proposed corporate tax changes will be enacted, however; if enacted, certain provisions could have a material adverse impact on our financial condition and results of operations.

Net Income Attributable to Noncontrolling Interests

Net income attributable to noncontrolling interests was $78 million for the three months ended September 30, 2017 compared to $88 million for the three months ended September 30, 2016. Net income attributable to noncontrolling interests for the three months ended September 30, 2017 was comprised of $2 million related to our Hospital Operations and other segment, $61 million related to our Ambulatory Care segment and $15 million related to our Conifer segment. Of the portion related to our Ambulatory Care segment, $6 million was related to the minority interests in our USPI joint venture.

Net income attributable to noncontrolling interests was $254 million for the nine months ended September 30, 2017 compared to $266 million for the nine months ended September 30, 2016. Net income attributable to noncontrolling interests for the nine months ended September 30, 2017 was comprised of $23 million related to our Hospital Operations and other segment, $193 million related to our Ambulatory Care segment and $38 million related to our Conifer segment. Of the portion related to our Ambulatory Care segment, $27 million was related to the minority interests in our USPI joint venture.

51

ADDITIONAL SUPPLEMENTAL NON-GAAP DISCLOSURES

The financial information provided throughout this report, including our Condensed Consolidated Financial Statements and the notes thereto, has been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). However, we use certain non-GAAP financial measures defined below in communications with investors, analysts, rating agencies, banks and others to assist such parties in understanding the impact of various items on our financial statements, some of which are recurring or involve cash payments. We use this information in our analysis of the performance of our business, excluding items we do not consider relevant to the performance of our continuing operations. In addition, from time to time we use these measures to define certain performance targets under our compensation programs.

“Adjusted EBITDA” is a non-GAAP measure defined by the Company as net income available (loss attributable) to Tenet Healthcare Corporation common shareholders before (1) the cumulative effect of changes in accounting principle, (2) net loss (income) attributable to noncontrolling interests, (3) income (loss) from discontinued operations, (4) income tax benefit (expense), (5) other non-operating income (expense), net, (6) gain (loss) from early extinguishment of debt, (7) interest expense, (8) litigation and investigation (costs) benefit, net of insurance recoveries, (9) net gains (losses) on sales, consolidation and deconsolidation of facilities, (10) impairment and restructuring charges and acquisition-related costs, (11) depreciation and amortization, and (12) income (loss) from divested operations and closed businesses (i.e., our health plan businesses). Litigation and investigation costs do not include ordinary course of business malpractice and other litigation and related expense.

The Company believes the foregoing non-GAAP measure is useful to investors and analysts because it presents additional information on the Company’s financial performance. Investors, analysts, Company management and the Company’s Board of Directors utilize this non-GAAP measure, in addition to GAAP measures, to track the Company’s financial and operating performance and compare the Company’s performance to peer companies, which utilize similar non-GAAP measures in their presentations. The Human Resources Committee of the Company’s Board of Directors also uses certain non-GAAP measures to evaluate management’s performance for the purpose of determining incentive compensation. The Company believes that Adjusted EBITDA is a useful measure, in part, because certain investors and analysts use both historical and projected Adjusted EBITDA, in addition to GAAP and other non-GAAP measures, as factors in determining the estimated fair value of shares of the Company’s common stock. Company management also regularly reviews the Adjusted EBITDA performance for each operating segment. The Company does not use Adjusted EBITDA to measure liquidity, but instead to measure operating performance. The non-GAAP Adjusted EBITDA measure the Company utilizes may not be comparable to similarly titled measures reported by other companies. Because this measure excludes many items that are included in our financial statements, it does not provide a complete measure of our operating performance. Accordingly, investors are encouraged to use GAAP measures when evaluating the Company’s financial performance.

52

The table below shows the reconciliation of Adjusted EBITDA to net income available (loss attributable) to Tenet Healthcare Corporation common shareholders (the most comparable GAAP term) for the three and nine months ended September 30, 2017 and 2016:

	Three Months Ended						Nine Months Ended
	September 30,						September 30,
	2017			2016			2017			2016
Net loss attributable to Tenet Healthcare Corporation common shareholders	$	(367	)	$	(8	)	$	(475	)	$	(113	)
Less: Net income attributable to noncontrolling interests	(78		)	(88		)	(254		)	(266		)
Net income (loss) from discontinued operations, net of tax	(1		)	1			(1		)	(5		)
Net income (loss) from continuing operations	(288		)	79			(220		)	158
Income tax benefit (expense)	60			(10		)	105			(61		)
Loss from early extinguishment of debt	(138		)	—			(164		)	—
Other non-operating expense, net	(4		)	(7		)	(14		)	(18		)
Interest expense	(257		)	(243		)	(775		)	(730		)
Operating income	51			339			628			967
Litigation and investigation costs	(6		)	(4		)	(12		)	(291		)
Gains on sales, consolidation and deconsolidation of facilities	104			3			142			151
Impairment and restructuring charges, and acquisition-related costs	(329		)	(31		)	(403		)	(81		)
Depreciation and amortization	(219		)	(205		)	(662		)	(632		)
Loss from divested and closed businesses (i.e., the Company’s health plan businesses)	(6		)	(6		)	(41		)	(8		)
Adjusted EBITDA	$	507		$	582		$	1,604		$	1,828
Net operating revenues	$	4,586		$	4,849		$	14,201		$	14,761
Less: Net operating revenues from health plans	10			122			100			385
Adjusted net operating revenues	$	4,576		$	4,727		$	14,101		$	14,376
Net loss attributable to Tenet Healthcare Corporation common shareholders as a % of net operating revenues	(8.0		)%	(0.2		)%	(3.3		)%	(0.8		)%
Adjusted EBITDA as % of adjusted net operating revenues (Adjusted EBITDA margin)	11.1		%	12.3		%	11.4		%	12.7		%

LIQUIDITY AND CAPITAL RESOURCES

CASH REQUIREMENTS

There have been no material changes to our obligations to make future cash payments under contracts and under contingent commitments, such as standby letters of credit and minimum revenue guarantees, as disclosed in our Annual Report, except for the refinancing of long-term debt, as discussed in Note 5 to our accompanying Condensed Consolidated Financial Statements, and the renegotiation of the Put/Call Agreement, as discussed in Note 11 to our accompanying Condensed Consolidated Financial Statements.

As part of our long-term objective to manage our capital structure, we may from time to time seek to retire, purchase, redeem or refinance some of our outstanding debt or equity securities subject to prevailing market conditions, our liquidity requirements, contractual restrictions and other factors. These actions are part of our strategy to manage our leverage and capital structure over time, which is dependent on our total amount of debt, our cash and our operating results. We continue to seek further initiatives to increase the efficiency of our balance sheet by generating incremental cash, including by means of the sale of underutilized or inefficient assets.

At September 30, 2017, using the last 12 months of Adjusted EBITDA, our ratio of total long-term debt, net of cash and cash equivalent balances, to Adjusted EBITDA was 6.4x. This ratio has been negatively impacted in 2017 by our inability to recognize any California provider fee program revenues this year because CMS has not yet approved the 2017 program. In general, we anticipate this ratio will fluctuate from quarter to quarter based on earnings performance and other factors, including the use of our revolving credit facility as a source of liquidity and acquisitions that involve the assumption of long-term debt. We intend to manage this ratio by following our business plan, managing our cost structure, possible asset divestitures and through other changes in our capital structure, including, if appropriate, the issuance of equity or convertible

53

securities. Our ability to achieve our leverage and capital structure objectives is subject to numerous risks and uncertainties, many of which are described in the Forward-Looking Statements and Risk Factors sections in Part I of our Annual Report.

Our capital expenditures primarily relate to the expansion and renovation of existing facilities (including amounts to comply with applicable laws and regulations), equipment and information systems additions and replacements, introduction of new medical technologies, design and construction of new buildings, and various other capital improvements, as well as commitments to make capital expenditures in connection with the acquisitions of businesses. Capital expenditures were $492 million and $614 million in the nine months ended September 30, 2017 and 2016, respectively. We anticipate that our capital expenditures for continuing operations for the year ending December 31, 2017 will total approximately $675 million to $725 million, including $179 million that was accrued as a liability at December 31, 2016.

Interest payments, net of capitalized interest, were $617 million and $596 million in the nine months ended September 30, 2017 and 2016, respectively.

Income tax payments, net of tax refunds, were approximately $54 million and $33 million in the nine months ended September 30, 2017 and 2016, respectively.

SOURCES AND USES OF CASH

Our liquidity for the nine months ended September 30, 2017 was primarily derived from net cash provided by operating activities, cash on hand and borrowings under our revolving credit facility. We had approximately $429 million of cash and cash equivalents on hand at September 30, 2017 to fund our operations and capital expenditures, and our borrowing availability under our credit facility was $998 million based on our borrowing base calculation at September 30, 2017.

Our primary source of operating cash is the collection of accounts receivable. As such, our operating cash flow is impacted by levels of cash collections and levels of bad debt due to shifts in payer mix and other factors.

Net cash provided by operating activities was $709 million in the nine months ended September 30, 2017 compared to $851 million in the nine months ended September 30, 2016. Key factors contributing to the change between the 2017 and 2016 periods include the following:

• Decreased income from continuing operations before income taxes of $224 million, excluding other non-operating expense, net, gain (loss) from early extinguishment of debt, interest expense, gains on sales, consolidation and deconsolidation of facilities, litigation and investigation costs, impairment and restructuring charges, and acquisition-related costs, depreciation and amortization, and income (loss) from divested operations and closed businesses (i.e., our health plan businesses) in the nine months ended September 30, 2017 compared to the nine months ended September 30, 2016;

• A $44 milliondecrease in payments on reserves for restructuring charges, acquisition-related costs, and litigation costs and settlements;

• Reduced cash flows from our health plan businesses of $101 million due to cash outflows in the 2017 period resulting from the sales and wind-down of these businesses in 2017, compared to slightly positive cash flows in the 2016 period; and

• The timing of other working capital items.

Net cash provided by investing activities was $227 million for the nine months ended September 30, 2017 compared to net cash used in investing activities of $150 million for the nine months ended September 30, 2016. The primary reason for the increase was due to proceeds from sales of facilities and other assets of $826 million in the 2017 period when we completed the sale of our hospitals, physician practices and related assets in Houston, Texas and the surrounding area compared to $573 million in the 2016 period when we completed the sale of five Georgia facilities. Capital expenditures were $492 million and $614 million in the nine months ended September 30, 2017 and 2016, respectively.

Net cash used in financing activities was $1.223 billion and $408 million for the nine months ended September 30, 2017 and 2016, respectively. The 2017 amount included $722 million related to purchases of noncontrolling interests, primarily our purchase of an additional 23.7% of our USPI joint venture, which increased our ownership interest in the USPI joint venture to 80.0%, compared to $180 million in the 2016 period, when we paid $127 million to increase our ownership interest in the USPI joint venture from 50.1% to approximately 56.3%. The 2017 amount also included our

54

redemption of $250 million aggregate principal amount of our 8.000% senior unsecured notes due 2020 using cash on hand, and our purchase of the land and improvements associated with our Palm Beach Gardens Medical Center, which we previously leased under a capital lease, by retiring the lease obligation for approximately $44 million.

We record our investments that are available-for-sale at fair market value. As shown in Note 14 to our Condensed Consolidated Financial Statements, the majority of our investments are valued based on quoted market prices or other observable inputs. We have no investments that we expect will be negatively affected by the current economic conditions such that they will materially impact our financial condition, results of operations or cash flows.

DEBT INSTRUMENTS, GUARANTEES AND RELATED COVENANTS

Senior Secured and Senior Unsecured Note Refinancing Transactions—On June 14, 2017, we sold $830 million aggregate principal amount of our 4.625% senior secured first lien notes, which will mature on July 15, 2024 (the “2024 Secured First Lien Notes”). We will pay interest on the 2024 Secured First Lien Notes semi-annually in arrears on January 15 and July 15 of each year, commencing on January 15, 2018. The proceeds from the sale of the 2024 Secured First Lien Notes were used, after payment of fees and expenses, together with cash on hand, to deposit with the trustee an amount sufficient to fund the redemption of all $900 million in aggregate principal amount of ourfloating rate senior secured notes due 2020 (the “2020 Floating Rate Notes”) on July 14, 2017, thereby fully discharging the 2020 Floating Rate Notes as of June 14, 2017. In connection with the redemption, we recorded a loss from early extinguishment of debt of approximately $26 million in the three months ended June 30, 2017, primarily related to the difference between the redemption price and the par value of the notes, as well as the write-off of associated unamortized note discounts and issuance costs.

Also on June 14, 2017, THC Escrow Corporation III (“Escrow Corp.”), a Delaware corporation established for the purpose of issuing the securities referred to in this paragraph, issued $1.040 billion in aggregate principal amount of 4.625% senior secured first lien notes due 2024 (the “Escrow Secured First Lien Notes”), $1.410 billion in aggregate principal amount of 5.125% senior secured second lien notes due 2025 (the “Escrow Secured Second Lien Notes”) and $500 million in aggregate principal amount of 7.000% senior unsecured notes due 2025 (the “Escrow Unsecured Notes”).

On July 14, 2017, we (i) assumed Escrow Corp.’s obligations with respect to the Escrow Secured Second Lien Notes and (ii) effected a mandatory exchange of all outstanding Escrow Secured First Lien Notes for a like principal amount of our newly issued 2024 Secured First Lien Notes. The proceeds from the sale of the Escrow Secured Second Lien Notes and Escrow Secured First Lien Notes were released from escrow on July 14, 2017 and were used, after payment of fees and expenses, to finance our redemption on July 14, 2017 of $1.041 billion aggregate principal amount of our outstanding 6.250% senior secured notes due 2018 and $1.100 billion aggregate principal amount of our outstanding 5.000% senior unsecured notes due 2019.

On August 1, 2017, we assumed Escrow Corp.’s obligations with respect to the Escrow Unsecured Notes. The proceeds from the sale of the Escrow Unsecured Notes were released from escrow on August 1, 2017 and were used, after payment of fees and expenses, to finance our redemption on August 1, 2017 of $500 million aggregate principal amount of our 8.000% senior unsecured notes due 2020.

On September 11, 2017, we redeemed the remaining $250 million aggregate principal amount of our 8.000% senior unsecured notes due 2020 using cash on hand.

As a result of the redemption activities in the three months ended September 30, 2017 discussed above, we recorded a loss from early extinguishment of debt of approximately $138 million in the period, primarily related to the difference between the redemption price and the par value of the notes, as well as the write-off of associated unamortized note discounts and issuance costs.

Credit Agreement.We have a senior secured revolving credit facility (as amended, the “Credit Agreement”) that provides, subject to borrowing availability, for revolving loans in an aggregate principal amount of up to $1 billion, with a $300 million subfacility for standby letters of credit. Obligations under the Credit Agreement, which has a scheduled maturity date of December 4, 2020, are guaranteed by substantially all of our domestic wholly owned hospital subsidiaries and are secured by a first-priority lien on the accounts receivable owned by us and the subsidiary guarantors. At September 30, 2017, we were in compliance with all covenants and conditions in our Credit Agreement. At September 30, 2017, we had no cash borrowings outstanding under the Credit Agreement, and we had approximately $2 million of standby letters of credit outstanding. Based on our eligible receivables, approximately $998 million was available for borrowing under the Credit Agreement at September 30, 2017.  

55

Letter of Credit Facility.We have a letter of credit facility (as amended, the “LC Facility”) that provides for the issuance of standby and documentary letters of credit, from time to time, in an aggregate principal amount of up to $180 million (subject to increase to up to $200 million). Obligations under the LC Facility are guaranteed and secured by a first-priority pledge of the capital stock and other ownership interests of certain of our wholly owned domestic hospital subsidiaries on an equal ranking basis with our senior secured first lien notes. At September 30, 2017, we were in compliance with all covenants and conditions in our LC Facility. At September 30, 2017, we had approximately $105 million of standby letters of credit outstanding under the LC Facility.

For additional information regarding our long-term debt and capital lease obligations, see Notes 5 and 18 to our accompanying Condensed Consolidated Financial Statements and Note 6 to the Consolidated Financial Statements included in our Annual Report.

LIQUIDITY

From time to time, we expect to engage in additional capital markets, bank credit and other financing activities depending on our needs and financing alternatives available at that time. We believe our existing debt agreements provide flexibility for future secured or unsecured borrowings.

Our cash on hand fluctuates day-to-day throughout the year based on the timing and levels of routine cash receipts and disbursements, including our book overdrafts, and required cash disbursements, such as interest and income tax payments. These fluctuations result in material intra-quarter net operating and investing uses of cash that have caused, and in the future could cause, us to use our Credit Agreement as a source of liquidity. We believe that existing cash and cash equivalents on hand, availability under our Credit Agreement, anticipated future cash provided by operating activities, and our investments in marketable securities of our captive insurance companies classified as noncurrent investments on our balance sheet should be adequate to meet our current cash needs. These sources of liquidity, in combination with any potential future debt incurrence, should also be adequate to finance planned capital expenditures, payments on the current portion of our long-term debt, payments to joint venture partners, including those related to put and call arrangements, and other presently known operating needs.

Long-term liquidity for debt service and other purposes will be dependent on the amount of cash provided by operating activities and, subject to favorable market and other conditions, the successful completion of future borrowings and potential refinancings. However, our cash requirements could be materially affected by the use of cash in acquisitions of businesses, repurchases of securities, the exercise of put rights or other exit options by our joint venture partners, and contractual commitments to fund capital expenditures in, or intercompany borrowings to, businesses we own. In addition, liquidity could be adversely affected by a deterioration in our results of operations, including our ability to generate cash from operations, as well as by the various risks and uncertainties discussed in this section and other sections of this report, including any costs associated with legal proceedings and government investigations.

We do not rely on commercial paper or other short-term financing arrangements nor do we enter into repurchase agreements or other short-term financing arrangements not otherwise reported in our period-end balance sheets. In addition, we do not have significant exposure to floating interest rates given that all of our current long-term indebtedness has fixed rates of interest.

OFF-BALANCE SHEET ARRANGEMENTS

We have no off-balance sheet arrangements that may have a current or future material effect on our financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources, except for $146 million of standby letters of credit outstanding and guarantees at September 30, 2017.

CRITICAL ACCOUNTING ESTIMATES

In preparing our Condensed Consolidated Financial Statements in conformity with GAAP, we must use estimates and assumptions that affect the amounts reported in our Condensed Consolidated Financial Statements and accompanying notes. We regularly evaluate the accounting policies and estimates we use. In general, we base the estimates on historical experience and on assumptions that we believe to be reasonable, given the particular circumstances in which we operate. Actual results may vary from those estimates.

We consider our critical accounting estimates to be those that (1) involve significant judgments and uncertainties, (2) require estimates that are more difficult for management to determine, and (3) may produce materially different outcomes under different conditions or when using different assumptions.

56

Our critical accounting estimates have not changed from the description provided in our Annual Report.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

The table below presents information about certain of our market-sensitive financial instruments at September 30, 2017. The fair values were determined based on quoted market prices for the same or similar instruments. The average effective interest rates presented are based on the rate in effect at the reporting date. The effects of unamortized premiums, discounts and issue costs are excluded from the table.

	Maturity Date, Years Ending December 31,
	2017			2018			2019			2020			2021			Thereafter			Total			Fair Value
	(Dollars in Millions)
Fixed rate long-term debt	$	87		$	93		$	572		$	2,644		$	1,928		$	9,798		$	15,122		$	15,211
Average effective interest rates	5.8		%	5.3		%	5.9		%	6.2		%	4.7		%	7.0		%	6.5		%

At September 30, 2017, we had long-term, market-sensitive investments held by our captive insurance subsidiaries. Our market risk associated with our investments in debt securities classified as non-current assets is substantially mitigated by the long-term nature and type of the investments in the portfolio.

We have no affiliation with partnerships, trusts or other entities (sometimes referred to as “special-purpose” or “variable-interest” entities) whose purpose is to facilitate off-balance sheet financial transactions or similar arrangements by us. As a result, we have no exposure to the financing, liquidity, market or credit risks associated with such entities.

We do not hold or issue derivative instruments for trading purposes and are not a party to any instruments with leverage or prepayment features.

ITEM 4. CONTROLS AND PROCEDURES

We carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as defined by Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as of the end of the period covered by this report. The evaluation was performed under the supervision and with the participation of management, including our chief executive officer and chief financial officer. Based upon that evaluation, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures are effective to ensure that material information is recorded, processed, summarized and reported by management on a timely basis in order to comply with our disclosure obligations under the Exchange Act and the SEC rules thereunder.

There were no changes in our internal control over financial reporting during the quarter ended September 30, 2017 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

57

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

Because we provide healthcare services in a highly regulated industry, we have been and expect to continue to be party to various lawsuits, claims and regulatory investigations from time to time. For information regarding material pending legal proceedings in which we are involved, see Note 10 to our Condensed Consolidated Financial Statements, which is incorporated by reference.

ITEM 1A. RISK FACTORS

There have been no material changes to the risk factors discussed in our Annual Report on Form 10-K for the year ended December 31, 2016, except that the following is added as a new paragraph to the end of the Risk Factor entitled “The utilization of our tax losses could be substantially limited if we experience an ownership change as defined in the Internal Revenue Code.”

In August 2017, the Company’s Board of Directors adopted a rights agreement as a measure intended to deter the above-referenced ownership changes in order to preserve the Company’s NOL carryforwards. The rights agreement may not prevent an ownership change, however. In addition, while the rights agreement is in effect, it could discourage or prevent a merger, tender offer, proxy contest or accumulations of substantial blocks of shares for which some shareholders might receive a premium above market value. It could also adversely affect the liquidity of the market for the Company’s common stock.

58

ITEM 6. EXHIBITS

Unless otherwise indicated, the following exhibits are filed with this report: 

(3	)	Articles of Incorporation and Bylaws
		(a)	Certificate of Designation of Series R Preferred Stock, par value $0.15 per share, dated August 31, 2017 (Incorporated by reference to Exhibit 3.1 to Registrant’s Current Report on Form 8-K filed September 1, 2017)
(4	)	Instruments Defining the Rights of Security Holders, Including Indentures
		(a)	Supplemental Indenture, dated as of July 14, 2017, among the Registrant, certain of its subsidiaries and The Bank of New York Mellon Trust Company, N.A. relating to 5.125% Senior Secured Second Lien Notes Due 2025 (Incorporated by reference to Exhibit 4.4 to Registrant’s Current Report on Form 8-K filed July 17, 2017)
		(b)	Supplemental Indenture, dated as of August 1, 2017, among the Registrant and The Bank of New York Mellon Trust Company, N.A. relating to 7.000% Senior Notes Due 2025 (Incorporated by reference to Exhibit 4.5 to Registrant’s Current Report on Form 8-K filed August 2, 2017)
		(c)	Rights Agreement, dated as of August 31, 2017, between the Registrant and Computershare Trust Company, N.A., as Rights Agent (Incorporated by reference to Exhibit 4.1 to Registrant’s Current Report on Form 8-K filed September 1, 2017)
(10)		Material Contracts
		(a)	Exchange and Registration Rights Agreement, dated as of July 14, 2017, among the Registrant, certain of its subsidiaries and Barclays Capital Inc. as representative of the other initial purchasers of the Notes named therein (Incorporated by reference to Exhibit 10.1 to Registrant’s Current Report on Form 8-K filed July 17, 2017)
		(b)	Exchange and Registration Rights Agreement, dated as of August 1, 2017, among the Registrant and Barclays Capital Inc. as representative of the other initial purchasers of the Notes named therein (Incorporated by reference to Exhibit 10.1 to Registrant’s Current Report on Form 8-K filed August 2, 2017)
		(c)	Terms and Conditions of Non-Qualified Stock Option Performance Awards Granted to Ronald A. Rittenmeyer under the Tenet Healthcare 2008 Stock Incentive Plan*
		(d)	Separation Agreement and Release between the Registrant and Trevor Fetter (Incorporated by reference to Exhibit 10.1 to Registrant’s Current Report on Form 8-K filed October 23, 2017)*
(31)		Rule 13a-14(a)/15d-14(a) Certifications
		(a)	Certification of Ronald A. Rittenmeyer, Executive Chairman and Chief Executive Officer
		(b)	Certification of Daniel J. Cancelmi, Chief Financial Officer
(32)		Section 1350 Certification of Ronald A. Rittenmeyer, Executive Chairman and Chief Executive Officer, and Daniel J. Cancelmi, Chief Financial Officer
(101 INS)		XBRL Instance Document
(101 SCH)		XBRL Taxonomy Extension Schema Document
(101 CAL)		XBRL Taxonomy Extension Calculation Linkbase Document
(101 DEF)		XBRL Taxonomy Extension Definition Linkbase Document
(101 LAB)		XBRL Taxonomy Extension Label Linkbase Document
(101 PRE)		XBRL Taxonomy Extension Presentation Linkbase Document
* Management contract or compensatory plan or arrangement.

59

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

		TENET HEALTHCARE CORPORATION (Registrant)
Date: November 6, 2017	By:	/s/ R. SCOTT RAMSEY
		R. Scott Ramsey
		Vice President and Controller
		(Principal Accounting Officer)

60

EX-10.(C)

Exhibit 10(c)

TENET HEALTHCARE 2008 STOCK INCENTIVE PLAN
TERMS AND CONDITIONS OF

NON-QUALIFIED STOCK OPTION PERFORMANCE AWARDS

The Human Resources Committee (the “Committee”) of the Board of Directors of Tenet Healthcare Corporation (the “Company”) is authorized under the Company’s 2008 Stock Incentive Plan, as such may be amended from time to time (the “Plan”), to make awards of non-qualified stock options and to determine the terms of such stock options.

On September 29, 2017 (the “Grant Date”), the Committee granted you, Ronald A. Rittenmeyer(“You”), an award of non-qualified stock options (the “Stock Options”). The Stock Options were granted by the Committee subject to the terms and conditions set forth below in this certificate (the “Certificate”). The Stock Options are also subject to the terms and conditions of the Plan, which are incorporated herein by this reference. Each capitalized term not otherwise defined herein will have the meaning given to such term in the Plan.

1. Grant. The Committee has granted You Stock Options representing the right to purchase 408,526 Shares, with a $16.43 exercise price per Share (the “Exercise Price”), in consideration for services to be performed by You for the Company or a Subsidiary of the Company. The Stock Options are not intended to qualify as “incentive stock options” as defined in Section 422 of the Code.

2. Performance Criterion.

(a) Performance Period. Your Stock Options are subject to a four-year performance period that begins on the Grant Date and ends on the fourth anniversary of the Grant Date (the “Performance Period”).

(b) Performance Measures. Your Stock Options will become exercisable (subject to becoming vested pursuant to Section 3 or 4 below) only if the average of the per Share closing prices, as reported on the New York Stock Exchange and calculated over any period of thirty (30) sequential trading days during the Performance Period, equals or exceeds $20.53 (the “Performance Criterion”).

3. Vesting and Exercisability. The Stock Options will vest on the first anniversary of the Grant Date (the “Vesting Date”), however Your vested Stock Options may only be exercised following the satisfaction of the Performance Criterion (such date, the “Exercisability Date”). The Committee shall determine the date on which the Performance Criterion is satisfied.

The Stock Options will expire on the fifth anniversary of the Grant Date (the “Expiration Date”). Your vested Stock Options will become exercisable to the extent provided in, and in accordance with, the terms of this Certificate. Except as provided in Section 4, below, You may exercise Your Stock Options at any time following the Exercisability Date and prior to the Expiration Date.

4. Certain Termination Events. Yourunvested Stock Options will vest as provided in this Section 4 in the event of Your:

(i) death,

(ii) disability (as defined under section 409A(a)(2)(C)(ii) of the Internal Revenue Code), or

(iii) a termination of Your employment without Cause

(each a “Termination Event”), in each case prior to the Vesting Date. In the event of such a Termination Event, 100% of Your Stock Options will vest on the date of the Termination Event, but will become exercisable only if the Performance Criterion is achieved prior to the end of the Performance Period.

In the event of Your death, disability, or in the event of a termination of Your employment without Cause, Your vested and exercisable Stock Options will remain outstanding until the Expiration Date. In the event of Your termination for Cause, all of Your Stock Options (whether then vested or unvested) shall be immediately forfeited and cancelled. In the event of Your resignation for any reason, all of Your unvested Stock Options shall be immediately forfeited and cancelled.

5. Change in Control. In the event of a Change in Control, and conditioned on the occurrence of a Change in Control, 100% of the Stock Options will become vested and exercisable and the Performance Criterion will be deemed satisfied on the date that is two (2) business days prior to the Change in Control.

6. Exercise. Subject to the terms of the Plan, You may exercise Your Stock Options and pay the exercise price for Your Shares:

(a) in cash or cash equivalents;

(b) by having the Company withhold Shares otherwise issuable on exercise;

(c) by exercising Your Options to buy Shares and selling enough of the shares to cover the Exercise Price, estimated income taxes, and any applicable fees; or

(c) by exercising Your Stock Options and then immediately selling the Shares.

Upon the exercise of Your Stock Options, You will recognize ordinary income. The Company is required to withhold payroll taxes due with respect to that ordinary income. Pursuant to the Plan, at its option the Committee either may (1) have the Company withhold Shares having a Fair Market Value equal to the amount of the tax withholding or (2) require You to pay to the Company the amount of the tax withholding.

7. Restrictive Covenants.

(a) Acknowledgements. You and the Company agree that (i) on and following Your execution of this Certificate, the Company and its Affiliates provided You with access to and knowledge of a substantial amount of confidential and proprietary information of the Company and its Affiliates, which was and is of vital importance to the success of the business of the Company and its Affiliates, (ii) in exchange for agreeing to the restrictive covenants contained within this Section 7, You were granted Stock Options pursuant to this Certificate and provided with additional confidential and propriety information as described in sub-clause (i) above and (iii) You are receiving consideration for which You would not otherwise be entitled in the absence of agreeing to and complying with the restrictive covenants contained within this Section 7. You further acknowledge and agree that the enforcement of the restrictive covenants contained within this Section 7 is necessary to ensure the protection and continuity of the business and goodwill of the Company and that such restrictions are reasonable as to geography, duration and scope.

(b) Non-Competition. During Your employment with the Company and/or service on the Company’s Board of Directors and for six (6) months following Your termination of employment with the Company (such date, the “Separation Date”), You may not, directly or indirectly, carry on or conduct, in competition with the Company and its Affiliates, any business in the nature in which the Company or its Affiliates are then engaged in any geographical area in which the Company or its Affiliates engage in business at the time of Your Separation Date, or in which any of them, prior to Your Separation Date, evidenced in writing, at any time during the six (6) month period prior to such Separation Date, an intention to engage in such business. This prohibition extends to Your conducting or engaging in any such business either as an individual on Your own account or as a partner or joint venture or as an executive, agent, consultant or salesman for any other person or entity, or as an officer or director of a corporation or as a shareholder in a corporation of which You will then own ten percent (10%) or more of any class of stock. The provisions of this Section 7(a) will not apply following Your Separation Date if Your Separation Date occurs within six (6) months prior to or twenty-four (24) months following a Change in Control.

(c) Confidential Information. During Your employment with the Company and/or service on the Company’s Board of Directors and at all times following the Separation Date, You may not, directly or indirectly, reveal, divulge or make known to any person or entity, or use for Your personal benefit (including without limitation for the purpose of soliciting business, whether or not competitive with any business of the Company or any of its Affiliates), any information acquired during Your employment with or service to the Company or its Affiliates with regard to the financial, business or other affairs of the Company or any of its Affiliates (including without limitation any list or record of persons or entities with which the Company or any of its Affiliates has any dealings), other than (i) information already in the public domain, (ii) information of a type not considered confidential by persons engaged in the same business or a business similar to that conducted by the Company or its Affiliates, or (iii) information that You are required to disclose under the following circumstances: (A) at the express direction of any authorized governmental entity; (B) pursuant to a subpoena or other court process; (C) as otherwise required by law or the rules, regulations or orders of any applicable regulatory body; or (D) as otherwise necessary, in the opinion of Your counsel, to be disclosed by You in connection with any legal action or proceeding involving You and the Company or any Affiliate in Your capacity as an employee, officer, director, or stockholder of the Company or any Affiliate. You will, at any time required by the Company (either during your employment with or service to the Company and its Affiliates or following Your Separation Date), promptly deliver to the Company all memoranda, notes, reports, lists and other documents (and all copies thereof) relating to the business of the Company or any of its Affiliates which You may then possess or have under Your control.

(d) Agreement Not To Solicit Employees. During Your employment with the Company and/or service on the Company’s Board of Directors and for six (6) months following the Separation Date You directly or indirectly solicit or induce, or in any manner attempt to solicit or induce, any person employed by, or any agent of, the Company or any of its Affiliates to terminate such employee’s employment or agency, as the case may be, with the Company or any Affiliate.

(e) Nondisparagement. During Your employment with the Company and/or service on the Company’s Board of Directors and at all times following the Separation Date, You may not, directly or indirectly, disparage the

2

Company or its Affiliates and their respective boards of directors or other governing body, executives, employees and products or services. The Company will direct its directors and executive officers to not disparage You during the period of your employment with or service to the Company and its Affiliates or thereafter. For purposes of this Section 7(e), disparagement does not include (i) compliance with legal process or subpoenas to the extent only truthful statements are rendered in such compliance attempt, (ii) statements in response to an inquiry from a court or regulatory body, or (iii) statements or comments in rebuttal of medial stories or alleged media stories.

You agree that the Company would suffer irreparable harm if You were to breach, or threaten to breach, the restrictive covenants contained within this Section 7 and that the Company would, by reason of such breach, or threatened breach, be entitled to injunctive relief in a court of appropriate jurisdiction, without the need to post a bond. The violation of any portion of this Section 7 by You will entitle the Company to complete relief from such violation including, but not limited to, injunctive relief and damages, the forfeiture of Stock Options and a return of all proceeds received from the exercise and/or sale of Stock Options granted herein. The violation of Section 7(e) by the Company will entitle You to complete relief from such violation including, but not limited to, injunctive relief and damages.

8. Rights as Shareholder. You will not have any rights of a shareholder prior to the exercise of Your Stock Options and the delivery of the Shares, at which time You will have all of the rights of a shareholder with respect to the Shares received upon the exercise of those Stock Options, including the right to vote the Shares and receive all dividends and other distributions, if any, paid or made with respect thereto.

9. Clawback. Any Shares issued upon the exercise of the Stock Options or other amounts paid or provided to You pursuant to this Certificate (including any gains realized on Shares upon the exercise of the Stock Options) shall be subject to recovery by the Company in the circumstances and manner provided in any Incentive Compensation Clawback Policy that may be adopted or implemented by the Company and in effect from time to time on or after the date hereof, and You shall effectuate any such recovery at such time and in such manner as the Company may specify. For purposes of this Certificate, the term "Incentive Compensation Clawback Policy" means and includes any policy of the type contemplated by Section 10D of the Securities Exchange Act, any rules or regulations of the Securities and Exchange Commission adopted pursuant thereto, or any related rules or listing standards of any national securities exchange or national securities association applicable to the Company. Until the Company shall adopt such an Incentive Compensation Clawback Policy, the following clawback provision shall apply to the Stock Options:

In the event that, within three years of the end of the Performance Period, the Company restates its financial results with respect to the Company’s performance during the Performance Period due to material non-compliance with any financial reporting requirement under the securities laws as generally applied and the Board of Directors determines Your fraud or misconduct caused or partially caused the need for the restatement, then the Board of Directors shall require You to immediately return to the Company the Stock Options or any Shares issued upon the exercise of the Stock Options (including any gains realized on Shares upon the exercise of the Stock Options) or the pre-tax income derived from any disposition of the Shares previously received upon the exercise of the Stock Options (plus a reasonable rate of interest if deemed appropriate by the Board of Directors) that would not have been granted and/or vested based upon the restated financial results.

10. Transferability. The Stock Options generally may not be transferred, assigned or made subject to any encumbrance, pledge or charge. Limited exceptions to this rule apply in the case of death, divorce or gift as provided in Section 12.3 of the Plan.

11. Effect on Other Employee Benefit Plans. The value of the Stock Options evidenced by this Certificate will not be included as compensation, earnings, salaries, or other similar terms used when calculating Your benefits under any employee benefit plan sponsored by the Company or a Subsidiary, except as such plan otherwise expressly provides.

12. No Employment Rights. Nothing in this Certificate will confer upon You any right to continue in the employ or service of the Company or any Subsidiary or affect the right of the Company or a Subsidiary to terminate Your employment at any time with or without Cause.

13. Amendment. By written notice to You, the Committee reserves the right to amend the Plan or the provisions of this Certificate provided that no such amendment will impair in any material respect Your rights under this Certificate without Your consent except as required to comply with applicable securities laws or Section 409A of the Code.

14. Severability. If any term or provision of this Certificate is declared by any court or government authority to be unlawful or invalid, such unlawfulness or invalidity will not invalidate any term or provision of this Certificate not declared to be unlawful or invalid. Any term or provision of this Certificate so declared to be unlawful or invalid will, if possible, be construed in a manner that will give effect to such term or provision to the fullest extent possible while remaining lawful and valid.

3

15. Construction. A copy of the Plan has been made available to You and additional copies of the Plan are available upon request to the Company's Corporate Secretary at the Company's principal executive office during normal business hours. To the extent that any term or provision of this Certificate violates or is inconsistent with an express term or provision of the Plan, the Plan term or provision will govern and any inconsistent term or provision in this Certificate will be of no force or effect.

16. Binding Effect and Benefit. This Certificate will be binding upon and, subject to the terms and conditions hereof, inure to the benefit of the Company, its successors and assigns, and You and Your successors and assigns.

17. Entire Understanding. This Certificate embodies the entire understanding and agreement of the Company and You in relation to the subject matter hereof, and no promise, condition, representation or warranty, expressed or implied, not herein stated, will bind the Company or You.

18. Governing Law. This Certificate will be governed by, and construed in accordance with, the laws of the State of Nevada, without reference to principles of conflict of law.

4

EX-31.(A)

Exhibit 31(a)

Rule 13a-14(a)/15d-14(a) Certification

I, Ronald A. Rittenmeyer, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Tenet Healthcare Corporation (the “Registrant”);

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;

4. The Registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the Registrant’s most recent fiscal quarter (the Registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting; and

5. The Registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting.

Date: November 6, 2017	/s/ RONALD A. RITTENMEYER
	Ronald A. Rittenmeyer
	Executive Chairman and Chief Executive Officer

EX-31.(B)

Exhibit 31(b)

Rule 13a-14(a)/15d-14(a) Certification

I, Daniel J. Cancelmi, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Tenet Healthcare Corporation (the “Registrant”);

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;

4. The Registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the Registrant’s most recent fiscal quarter (the Registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting; and

5. The Registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting.

Date: November 6, 2017	/s/ DANIEL J. CANCELMI
	Daniel J. Cancelmi
	Chief Financial Officer

EX-32

Exhibit 32

Certifications Pursuant to Section 1350 of Chapter 63
of Title 18 of the United States Code

We, the undersigned Ronald A. Rittenmeyer and Daniel J. Cancelmi, being, respectively, the Executive Chairman and Chief Executive Officer and the Chief Financial Officer of Tenet Healthcare Corporation (the “Registrant”), do each hereby certify that (i) the Registrant’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2017 (the “Form 10-Q”), to be filed with the Securities and Exchange Commission on the date hereof, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and (ii) the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Registrant and its subsidiaries.

Date: November 6, 2017	/s/ RONALD A. RITTENMEYER
	Ronald A. Rittenmeyer
	Executive Chairman and Chief Executive Officer
Date: November 6, 2017	/s/ DANIEL J. CANCELMI
	Daniel J. Cancelmi
	Chief Financial Officer

The foregoing certification is being furnished solely pursuant to 18 U.S.C. §1350; it is not being filed for purposes of Section 18 of the Securities Exchange Act, and is not to be incorporated by reference into any filing of the Registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

XML

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2017	Oct. 31, 2017
Document and Entity Information
Entity Registrant Name	TENET HEALTHCARE CORP
Entity Central Index Key	0000070318
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Document Type	10-Q
Document Period End Date	Sep. 30, 2017
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q3
Amendment Flag	false
Entity Current Reporting Status	Yes
Entity Common Stock, Shares Outstanding (in shares)		100,936,869

XML

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Sep. 30, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 429	$ 716
Accounts receivable, less allowance for doubtful accounts ($934 at September 30, 2017 and $1,031 at December 31, 2016)	2,567	2,897
Inventories of supplies, at cost	297	326
Income tax receivable	14	4
Assets held for sale	842	29
Other current assets	1,160	1,285
Total current assets	5,309	5,257
Investments and other assets	1,253	1,250
Deferred income taxes	783	871
Property and equipment, at cost, less accumulated depreciation and amortization ($4,750 at September 30, 2017 and $4,974 at December 31, 2016)	7,077	8,053
Goodwill	7,022	7,425
Other intangible assets, at cost, less accumulated amortization ($841 at September 30, 2017 and $772 at December 31, 2016)	1,764	1,845
Total assets	23,208	24,701
Current liabilities:
Current portion of long-term debt	140	191
Accounts payable	1,100	1,329
Accrued compensation and benefits	800	872
Professional and general liability reserves	210	181
Accrued interest payable	336	210
Liabilities held for sale	407	9
Other current liabilities	1,146	1,242
Total current liabilities	4,139	4,034
Long-term debt, net of current portion	14,741	15,064
Professional and general liability reserves	617	613
Defined benefit plan obligations	596	626
Deferred income taxes	0	279
Other long-term liabilities	604	610
Total liabilities	20,697	21,226
Commitments and contingencies
Redeemable noncontrolling interests in equity of consolidated subsidiaries	1,816	2,393
Shareholders’ equity:
Common stock, $0.05 par value; authorized 262,500,000 shares; 149,244,229 shares issued at September 30, 2017 and 148,106,249 shares issued at December 31, 2016	7	7
Additional paid-in capital	4,835	4,827
Accumulated other comprehensive loss	(238)	(258)
Accumulated deficit	(2,161)	(1,742)
Common stock in treasury, at cost, 48,413,280 shares at September 30, 2017 and 48,420,650 shares at December 31, 2016	(2,419)	(2,417)
Total shareholders’ equity	24	417
Noncontrolling interests	671	665
Total equity	695	1,082
Total liabilities and equity	$ 23,208	$ 24,701

XML

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Millions	Sep. 30, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Accounts receivable, allowance for doubtful accounts	$ 934	$ 1,031
Property and equipment, accumulated depreciation and amortization	4,750	4,974
Other intangible assets, accumulated amortization	$ 841	$ 772
Common stock, par value (in dollars per share)	$ 0.05	$ 0.05
Common stock, authorized shares (in shares)	262,500,000	262,500,000
Common stock, shares issued (in shares)	149,224,229	148,106,249
Common stock in treasury (in shares)	48,413,280	48,420,650

XML

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Net operating revenues:
Net operating revenues before provision for doubtful accounts	$ 4,941	$ 5,216	$ 15,310	$ 15,856
Less: Provision for doubtful accounts	355	367	1,109	1,095
Net operating revenues	4,586	4,849	14,201	14,761
Equity in earnings of unconsolidated affiliates	38	31	95	85
Operating expenses:
Salaries, wages and benefits	2,264	2,308	6,990	7,012
Supplies	740	767	2,285	2,351
Other operating expenses, net	1,120	1,231	3,466	3,686
Electronic health record incentives	(1)	(2)	(8)	(23)
Depreciation and amortization	219	205	662	632
Impairment and restructuring charges, and acquisition-related costs	329	31	403	81
Litigation and investigation costs	6	4	12	291
Gains on sales, consolidation and deconsolidation of facilities	(104)	(3)	(142)	(151)
Operating income	51	339	628	967
Interest expense	(257)	(243)	(775)	(730)
Other non-operating expense, net	(4)	(7)	(14)	(18)
Loss from early extinguishment of debt	(138)	0	(164)	0
Net income (loss) from continuing operations, before income taxes	(348)	89	(325)	219
Income tax benefit (expense)	60	(10)	105	(61)
Net income (loss) from continuing operations, before discontinued operations	(288)	79	(220)	158
Discontinued operations:
Income (loss) from operations	(1)	2	(1)	(5)
Income tax benefit (expense)	0	(1)	0	0
Net income (loss) from discontinued operations	(1)	1	(1)	(5)
Net income (loss)	(289)	80	(221)	153
Less: Net income attributable to noncontrolling interests	78	88	254	266
Net loss attributable to Tenet Healthcare Corporation common shareholders	(367)	(8)	(475)	(113)
Amounts attributable to Tenet Healthcare Corporation common shareholders
Net loss from continuing operations, net of tax	(366)	(9)	(474)	(108)
Net income (loss) from discontinued operations, net of tax	(1)	1	(1)	(5)
Net loss attributable to Tenet Healthcare Corporation common shareholders	$ (367)	$ (8)	$ (475)	$ (113)
Basic
Continuing operations (in dollars per share)	$ (3.63)	$ (0.09)	$ (4.72)	$ (1.09)
Discontinued operations (in dollars per share)	(0.01)	0.01	(0.01)	(0.05)
Total loss per share, Basic (in dollars per share)	(3.64)	(0.08)	(4.73)	(1.14)
Diluted
Continuing operations (in dollars per share)	(3.63)	(0.09)	(4.72)	(1.09)
Discontinued operations (in dollars per share)	(0.01)	0.01	(0.01)	(0.05)
Total loss per share, Diluted (in dollars per share)	$ (3.64)	$ (0.08)	$ (4.73)	$ (1.14)
Weighted average shares and dilutive securities outstanding (in thousands):
Basic (in shares)	100,812	99,523	100,475	99,210
Diluted (in shares)	100,812	99,523	100,475	99,210

XML

CONDENSED CONSOLIDATED STATEMENTS OF OTHER COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Statement of Comprehensive Income [Abstract]
Net income (loss)	$ (289)	$ 80	$ (221)	$ 153
Other comprehensive income (loss):
Amortization of net actuarial loss included in other non-operating expense, net	4	5	12	8
Unrealized gains on securities held as available-for-sale	2	2	5	3
Foreign currency translation adjustments	5	(3)	14	(44)
Other comprehensive income (loss) before income taxes	11	4	31	(33)
Income tax expense related to items of other comprehensive income (loss)	(7)	(1)	(11)	(3)
Total other comprehensive income (loss), net of tax	4	3	20	(36)
Comprehensive net income (loss)	(285)	83	(201)	117
Less: Comprehensive income attributable to noncontrolling interests	78	88	254	266
Comprehensive loss attributable to Tenet Healthcare Corporation common shareholders	$ (363)	$ (5)	$ (455)	$ (149)

XML

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Statement of Cash Flows [Abstract]
Net income (loss)	$ (221)	$ 153
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	662	632
Provision for doubtful accounts	1,109	1,095
Deferred income tax expense (benefit)	(145)	32
Stock-based compensation expense	44	51
Impairment and restructuring charges, and acquisition-related costs	403	81
Litigation and investigation costs	12	291
Gains on sales, consolidation and deconsolidation of facilities	(142)	(151)
Loss from early extinguishment of debt	164	0
Equity in earnings of unconsolidated affiliates, net of distributions received	(4)	2
Amortization of debt discount and debt issuance costs	33	33
Pre-tax loss from discontinued operations	1	5
Other items, net	(19)	(3)
Changes in cash from operating assets and liabilities:
Accounts receivable	(1,046)	(1,156)
Inventories and other current assets	97	(95)
Income taxes	(14)	(1)
Accounts payable, accrued expenses and other current liabilities	(141)	(35)
Other long-term liabilities	7	48
Payments for restructuring charges, acquisition-related costs, and litigation costs and settlements	(88)	(132)
Net cash provided by (used in) operating activities from discontinued operations, excluding income taxes	(3)	1
Net cash provided by operating activities	709	851
Cash flows from investing activities:
Purchases of property and equipment — continuing operations	(492)	(614)
Purchases of businesses or joint venture interests, net of cash acquired	(41)	(96)
Proceeds from sales of facilities and other assets	826	573
Proceeds from sales of marketable securities, long-term investments and other assets	20	36
Purchases of equity investments	(64)	(37)
Other long-term assets	(16)	(15)
Other items, net	(6)	3
Net cash provided by (used in) investing activities	227	(150)
Cash flows from financing activities:
Repayments of borrowings under credit facility	(850)	(1,195)
Proceeds from borrowings under credit facility	850	1,195
Repayments of other borrowings	(4,099)	(112)
Proceeds from other borrowings	3,788	4
Debt issuance costs	(62)	(1)
Distributions paid to noncontrolling interests	(178)	(151)
Proceeds from sales of noncontrolling interests	29	19
Purchases of noncontrolling interests	(722)	(180)
Proceeds from employee stock plan purchases	5	4
Other items, net	16	9
Net cash used in financing activities	(1,223)	(408)
Net increase (decrease) in cash and cash equivalents	(287)	293
Cash and cash equivalents at beginning of period	716	356
Cash and cash equivalents at end of period	429	649
Supplemental disclosures:
Interest paid, net of capitalized interest	(617)	(596)
Income tax payments, net	$ (54)	$ (33)

XML

BASIS OF PRESENTATION

9 Months Ended

Sep. 30, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

BASIS OF PRESENTATION

BASIS OF PRESENTATION

Description of Business and Basis of Presentation

Tenet Healthcare Corporation (together with our subsidiaries, referred to herein as “Tenet,” “we” or “us”) is a diversified healthcare services company. At September 30, 2017, we operated 77 hospitals, 20 surgical hospitals and over 460 outpatient centers in the United States, as well as nine facilities in the United Kingdom, through our subsidiaries, partnerships and joint ventures, including USPI Holding Company, Inc. (“USPI joint venture”). Our Conifer Holdings, Inc. (“Conifer”) subsidiary provides healthcare business process services in the areas of hospital and physician revenue cycle management and value-based care solutions to healthcare systems, as well as individual hospitals, physician practices, self-insured organizations, health plans and other entities.

This quarterly report supplements our Annual Report on Form 10-K for the year ended December 31, 2016 (“Annual Report”). As permitted by the Securities and Exchange Commission for interim reporting, we have omitted certain notes and disclosures that substantially duplicate those in our Annual Report. For further information, refer to the audited Consolidated Financial Statements and notes included in our Annual Report. Unless otherwise indicated, all financial and statistical data included in these notes to our Condensed Consolidated Financial Statements relate to our continuing operations, with dollar amounts expressed in millions (except per-share amounts).  In addition to the impact of the new accounting standards discussed below, certain prior-year amounts have also been reclassified to conform to the current-year presentation, primarily related to the detail of other intangible assets in Note 1 and the line items presented in the changes in shareholders’ equity table in Note 8.

Effective January 1, 2017, we adopted the Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) 2016-09, “Compensation—Stock Compensation (Topic 718) Improvements to Employee Share-Based Payment Accounting” (“ASU 2016-09”), which affects all entities that issue share-based payment awards to their employees. The guidance in ASU 2016-09 simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. Upon adoption of ASU 2016-09, we recorded previously unrecognized excess tax benefits of approximately $56 million as a deferred tax asset and a cumulative effect adjustment to retained earnings as of January 1, 2017. Prospectively, all excess tax benefits and deficiencies will be recognized as income tax benefit or expense in our consolidated statement of operations when awards vest.

Also effective January 1, 2017, we early adopted ASU 2017-07, “Compensation—Retirement Benefits (Topic 715) Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost” (“ASU 2017-07”), which the FASB issued in March 2017. The amendments in ASU 2017-07 apply to all employers that offer to their employees defined benefit pension plans, other postretirement benefit plans, or other types of benefits accounted for under Topic 715 of the FASB Accounting Standards Codification. The guidance in ASU 2017-07 requires that an employer report the service cost component in the same line item or items as other compensation costs arising from services rendered by the pertinent employees during the period. The other components of net benefit cost are required to be presented in the statement of operations separately from the service cost component and outside a subtotal of income from operations. The line item or items used in the statement of operations to present the other components of net benefit cost must be disclosed. The amendments in ASU 2017-07 must be applied retrospectively for the presentation of the service cost component and the other components of net periodic pension cost and net periodic postretirement benefit cost in the statement of operations. As a result of the adoption of ASU 2017-07, we reclassified approximately $20 million of net benefit cost from salaries, wages and benefits expense to other non-operating income (expense), net, in the accompanying Condensed Consolidated Statement of Operations for both of the nine month periods ended September 30, 2017 and 2016. Upon adoption of ASU 2017-07, we also reclassified approximately $8 million of net benefit cost from salaries, wages and benefits expense to other non-operating income (expense), net for the three months ended December 31, 2016, and we reclassified approximately $21 million of net benefit cost from salaries, wages and benefits expense to other non-operating income (expense), net for the year ended December 31, 2015.

Although the Condensed Consolidated Financial Statements and related notes within this document are unaudited, we believe all adjustments considered necessary for a fair presentation have been included and are of a normal recurring nature. In preparing our financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”), we are required to make estimates and assumptions that affect the amounts reported in our Condensed Consolidated Financial Statements and these accompanying notes. We regularly evaluate the accounting policies and estimates we use. In general, we base the estimates on historical experience and on assumptions that we believe to be reasonable given the particular circumstances in which we operate. Actual results may vary from those estimates. Financial and statistical information we report to other regulatory agencies may be prepared on a basis other than GAAP or using different assumptions or reporting periods and, therefore, may vary from amounts presented herein. Although we make every effort to ensure that the information we report to those agencies is accurate, complete and consistent with applicable reporting guidelines, we cannot be responsible for the accuracy of the information they make available to the public.

Operating results for the three and nine month periods ended September 30, 2017 are not necessarily indicative of the results that may be expected for the full year. Reasons for this include, but are not limited to: overall revenue and cost trends, particularly the timing and magnitude of price changes; fluctuations in contractual allowances and cost report settlements and valuation allowances; managed care contract negotiations, settlements or terminations and payer consolidations; changes in Medicare and Medicaid regulations; Medicaid and other supplemental funding levels set by the states in which we operate; the timing of approval by the Centers for Medicare and Medicaid Services of Medicaid provider fee revenue programs; trends in patient accounts receivable collectability and associated provisions for doubtful accounts; fluctuations in interest rates; levels of malpractice insurance expense and settlement trends; the timing of when we meet the criteria to recognize electronic health record incentives; impairment of long-lived assets and goodwill; restructuring charges; losses, costs and insurance recoveries related to natural disasters and other weather-related occurrences; litigation and investigation costs; gains (losses) on sales, consolidation and deconsolidation of facilities; income tax rates and deferred tax asset valuation allowance activity; changes in estimates of accruals for annual incentive compensation; the timing and amounts of stock option and restricted stock unit grants to employees and directors; gains or losses from early extinguishment of debt; and changes in occupancy levels and patient volumes. Factors that affect patient volumes and, thereby, the results of operations at our hospitals and related healthcare facilities include, but are not limited to: the business environment, economic conditions and demographics of local communities in which we operate; the number of uninsured and underinsured individuals in local communities treated at our hospitals; seasonal cycles of illness; climate and weather conditions; physician recruitment, retention and attrition; advances in technology and treatments that reduce length of stay; local healthcare competitors; managed care contract negotiations or terminations; the number of patients with high-deductible health insurance plans; any unfavorable publicity about us, or our joint venture partners, that impacts our relationships with physicians and patients; changes in healthcare regulations and the participation of individual states in federal programs; and the timing of elective procedures. These considerations apply to year-to-year comparisons as well.

Translation of Foreign Currencies

The accounts of European Surgical Partners Limited (“Aspen”) were measured in its local currency (the pound sterling) and then translated into U.S. dollars. All assets and liabilities were translated using the current rate of exchange at the balance sheet date. Results of operations were translated using the average rates prevailing throughout the period of operations. Translation gains or losses resulting from changes in exchange rates are accumulated in shareholders’ equity.

Net Operating Revenues Before Provision for Doubtful Accounts

We recognize net operating revenues before provision for doubtful accounts in the period in which our services are performed. Net operating revenues before provision for doubtful accounts primarily consist of net patient service revenues that are recorded based on established billing rates (i.e., gross charges), less estimated discounts for contractual and other allowances, principally for patients covered by Medicare, Medicaid, managed care and other health plans, as well as certain uninsured patients under our Compact with Uninsured Patients and other uninsured discount and charity programs.

The table below shows the sources of net operating revenues before provision for doubtful accounts from continuing operations:

	Three Months Ended September 30,						Nine Months Ended September 30,
	2017			2016			2017			2016
Hospital Operations and other:
Net patient revenues from acute care hospitals, related outpatient facilities and physician practices
Medicare	$	809		$	844		$	2,563		$	2,658
Medicaid	256			339			822			1,009
Managed care	2,524			2,729			7,867			8,031
Indemnity, self-pay and other	442			328			1,316			1,264
Net patient revenues(1)	4,031			4,240			12,568			12,962
Health plans	10			122			100			385
Revenue from other sources	171			158			480			482
Hospital Operations and other total prior to inter-segment eliminations	4,212			4,520			13,148			13,829
Ambulatory Care	477			457			1,422			1,346
Conifer	401			398			1,203			1,169
Inter-segment eliminations	(149		)	(159		)	(463		)	(488		)
Net operating revenues before provision for doubtful accounts	$	4,941		$	5,216		$	15,310		$	15,856

(1) Net patient revenues include revenues from physician practices of $171 million and $179 million for the three months ended September 30, 2017 and 2016, respectively, and $551 million and $558 million for the nine months ended September 30, 2017 and 2016, respectively.

Cash and Cash Equivalents

We treat highly liquid investments with original maturities of three months or less as cash equivalents. Cash and cash equivalents were approximately $429 million and $716 million at September 30, 2017 and December 31, 2016, respectively. At September 30, 2017 and December 31, 2016, our book overdrafts were approximately $240 million and $279 million, respectively, which were classified as accounts payable.

At September 30, 2017 and December 31, 2016, approximately $167 million and $147 million, respectively, of total cash and cash equivalents in the accompanying Condensed Consolidated Balance Sheets were intended for the operations of our captive insurance subsidiaries, and approximately $62 million and $85 million, respectively, of total cash and cash equivalents in the accompanying Condensed Consolidated Balance Sheets were intended for the operations of our health plan-related businesses.

Also at September 30, 2017 and December 31, 2016, we had $89 million and $179 million, respectively, of property and equipment purchases accrued for items received but not yet paid. Of these amounts, $57 million and $141 million, respectively, were included in accounts payable.

During the nine months ended September 30, 2017 and 2016, we entered into non-cancellable capital leases of approximately $82 million and $110 million, respectively, primarily for equipment.

Other Intangible Assets

The following tables provide information regarding other intangible assets, which are included in the accompanying Condensed Consolidated Balance Sheets at September 30, 2017 and December 31, 2016:

	Gross Carrying Amount		Accumulated Amortization			Net Book Value
At September 30, 2017:
Capitalized software costs	$	1,537	$	(721	)	$	816
Trade names	105		—			105
Contracts	855		(55		)	800
Other	108		(65		)	43
Total	$	2,605	$	(841	)	$	1,764

	Gross Carrying Amount		Accumulated Amortization			Net Book Value
At December 31, 2016:
Capitalized software costs	$	1,572	$	(681	)	$	891
Trade names	106		—			106
Contracts	845		(43		)	802
Other	94		(48		)	46
Total	$	2,617	$	(772	)	$	1,845

Estimated future amortization of intangibles with finite useful lives at September 30, 2017 is as follows:

			Three Months Ending		Years Ending								Later Years
			December 31,
	Total		2017		2018		2019		2020		2021
Amortization of intangible assets	$	1,097	$	47	$	152	$	135	$	104	$	92	$	567

We recognized amortization expense of $125 million and $111 million in the accompanying Condensed Consolidated Statements of Operations for the nine months ended September 30, 2017 and 2016, respectively.

Investments in Unconsolidated Affiliates

We control 220 of the facilities within our Ambulatory Care segment and, therefore, consolidate their results. We account for many of the facilities our Ambulatory Care segment operates (109 of 329 at September 30, 2017) and four of the hospitals our Hospital Operations and other segment operates, as well as 11 additional facilities in which our Hospital Operations and other segment holds ownership interests, under the equity method as investments in unconsolidated affiliates and report only our share of net income attributable to the investee as equity in earnings of unconsolidated affiliates in the accompanying Condensed Consolidated Statements of Operations. Summarized financial information for the equity method investees within our Ambulatory Care segment and the four equity method investee hospitals operated by our Hospital Operations and other segment are included in the following table. For investments acquired during the reported periods, amounts reflect 100% of the investee’s results beginning on the date of our acquisition of the investment.

	Three Months Ended September 30,				Nine Months Ended September 30,
	2017		2016		2017		2016
Net operating revenues	$	635	$	610	$	1,819	$	1,803
Net income	$	143	$	129	$	376	$	364
Net income attributable to the investees	$	93	$	83	$	242	$	241

XML

ACCOUNTS RECEIVABLE AND ALLOWANCE FOR DOUBTFUL ACCOUNTS

9 Months Ended

Sep. 30, 2017

Accounts Receivable Additional Disclosures [Abstract]

ACCOUNTS RECEIVABLE AND ALLOWANCE FOR DOUBTFUL ACCOUNTS

ACCOUNTS RECEIVABLE AND ALLOWANCE FOR DOUBTFUL ACCOUNTS

The principal components of accounts receivable are shown in the table below: 

	September 30, 2017			December 31, 2016
Continuing operations:
Patient accounts receivable	$	3,371		$	3,799
Allowance for doubtful accounts	(934		)	(1,031		)
Estimated future recoveries	130			141
Net cost reports and settlements payable and valuation allowances	(2		)	(14		)
	2,565			2,895
Discontinued operations	2			2
Accounts receivable, net	$	2,567		$	2,897

At September 30, 2017 and December 31, 2016, our allowance for doubtful accounts was 27.7% and 27.1%, respectively, of our patient accounts receivable. Accounts that are pursued for collection through Conifer’s business offices are maintained on our hospitals’ books and reflected in patient accounts receivable with an allowance for doubtful accounts established to reduce the carrying value of such receivables to their estimated net realizable value. Generally, we estimate this allowance based on the aging of our accounts receivable by hospital, our historical collection experience by hospital and for each type of payer, and other relevant factors.

We also provide charity care to patients who are unable to pay for the healthcare services they receive. Most patients who qualify for charity care are charged a per-diem amount for services received, subject to a cap. Except for the per-diem amounts, our policy is not to pursue collection of amounts determined to qualify as charity care; therefore, we do not report these amounts in net operating revenues. Most states include an estimate of the cost of charity care in the determination of a hospital’s eligibility for Medicaid disproportionate share hospital (“DSH”) payments. These payments are intended to mitigate our cost of uncompensated care, as well as reduced Medicaid funding levels. The table below shows our estimated costs (based on selected operating expenses, which include salaries, wages and benefits, supplies and other operating expenses and which exclude the costs of our health plan businesses) of caring for our self-pay patients and charity care patients, and revenues attributable to Medicaid DSH and other supplemental revenues we recognized in three and nine months ended September 30, 2017 and 2016:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2017		2016		2017		2016
Estimated costs for:
Self-pay patients	$	164	$	158	$	484	$	453
Charity care patients	29		36		92		104
Total	$	193	$	194	$	576	$	557
Medicaid DSH and other supplemental revenues	$	140	$	249	$	462	$	691

At September 30, 2017 and December 31, 2016, we had approximately $375 million and $537 million, respectively, of receivables recorded in other current assets and approximately $56 million and $139 million, respectively, of payables recorded in other current liabilities in the accompanying Condensed Consolidated Balance Sheets related to California’s provider fee program.

XML

ASSETS AND LIABILITIES HELD FOR SALE

9 Months Ended

Sep. 30, 2017

Discontinued Operation, Additional Disclosures [Abstract]

ASSETS AND LIABILITIES HELD FOR SALE

ASSETS AND LIABILITIES HELD FOR SALE

In the three months ended September 30, 2017, we entered into a definitive agreement for the sale of our hospitals, physician practices and related assets in Philadelphia, Pennsylvania and the surrounding area. In accordance with the guidance in the FASB’s Accounting Standards Codification (“ASC”) 360, “Property, Plant and Equipment,” we classified $222 million of our Philadelphia-area assets as “assets held for sale” in current assets and the related liabilities of $52 million as “liabilities held for sale” in current liabilities in the accompanying Condensed Consolidated Balance Sheet at September 30, 2017. These assets and liabilities, which are in our Hospital Operations and other segment, were recorded at the lower of their carrying amount or their fair value less estimated costs to sell. We recorded impairment charges of $235 million for the write-down of assets held for sale to their estimated fair value, less estimated costs to sell, as a result of this anticipated transaction.

Also in the three months ended September 30, 2017, MacNeal Hospital, which is located in a suburb of Chicago, as well as other operations affiliated with the hospital, met the criteria to be classified as held for sale. As a result, we classified these assets totaling $222 million as “assets held for sale” in current assets and the related liabilities of $33 million as “liabilities held for sale” in current liabilities in the accompanying Condensed Consolidated Balance Sheet at September 30, 2017. These assets and liabilities, which are in our Hospital Operations and other segment, were recorded at the lower of their carrying amount or their fair value less estimated costs to sell. There was no impairment recorded for the write-down of assets held for sale to their estimated fair value, less estimated costs to sell, as a result of the planned divestiture of these assets.

Additionally, our nine Aspen facilities in the United Kingdom met the criteria to be classified as held for sale in the three months ended September 30, 2017. We classified $398 million of our United Kingdom assets as “assets held for sale” in current assets and the related liabilities of $322 million as “liabilities held for sale” in current liabilities in the accompanying Condensed Consolidated Balance Sheet at September 30, 2017. These assets and liabilities, which are in our Ambulatory Care segment, were recorded at the lower of their carrying amount or their fair value less estimated costs to sell. We recorded impairment charges of $59 million for the write-down of assets held for sale to their estimated fair value, less estimated costs to sell.

Assets and liabilities classified as held for sale at September 30, 2017 were comprised of the following:

Accounts receivable	$	178
Other current assets	100
Investments and other long-term assets	20
Property and equipment	456
Other intangible assets	8
Goodwill	80
Current liabilities	(107		)
Long-term liabilities	(300		)
Net assets held for sale	$	435

In the three months ended June 30, 2017, we entered into a definitive agreement for the sale of our hospitals, physician practices and related assets in Houston, Texas and the surrounding area, and we classified these assets and liabilities as held for sale. Effective August 1, 2017, we completed the sale for net proceeds of approximately $750 million and recognized a gain on sale of approximately $111 million.

In the three months ended September 30, 2016, certain of our health plan assets and liabilities met the criteria to be classified as held for sale. In the nine months ended September 30, 2017, we completed the sales of certain of our health plan businesses in Michigan, Arizona and Texas at transaction prices of approximately $20 million, $13 million and $12 million, respectively, and recognized gains on the sales of approximately $3 million, $13 million and $10 million, respectively.

Our hospitals, physician practices and related assets in Georgia met the criteria to be classified as assets held for sale in the three months ended June 30, 2015. We completed the sale of our Georgia assets on March 31, 2016 at a transaction price of approximately $575 million and recognized a gain on sale of approximately $113 million. Because we did not sell the related accounts receivable with respect to the pre-closing period, net receivables of approximately $17 million are included in accounts receivable, less allowance for doubtful accounts, in the accompanying Condensed Consolidated Balance Sheet at September 30, 2017.

XML

IMPAIRMENT AND RESTRUCTURING CHARGES, AND ACQUISITION-RELATED COSTS

9 Months Ended

Sep. 30, 2017

Restructuring Costs and Asset Impairment Charges [Abstract]

IMPAIRMENT AND RESTRUCTURING CHARGES, AND ACQUISITION-RELATED COSTS

IMPAIRMENT AND RESTRUCTURING CHARGES, AND ACQUISITION-RELATED COSTS

During the nine months ended September 30, 2017, we recorded impairment and restructuring charges and acquisition-related costs of $403 million, consisting of approximately $294 million of charges to write-down assets held for sale to their estimated fair value, less estimated costs to sell, for our Aspen and Philadelphia-area facilities, $29 million of impairment of two equity method investments, $40 million of employee severance costs, $8 million of contract and lease termination fees, $3 million to write-down intangible assets, $13 million of other restructuring costs, and $16 million in acquisition-related costs, which include $5 million of transaction costs and $11 million of acquisition integration charges. Our impairment and restructuring charges and acquisition-related costs for the nine months ended September 30, 2017 were comprised of $319 million from our Hospital Operations and other segment, $70 million from our Ambulatory Care segment and $14 million from our Conifer segment.

During the nine months ended September 30, 2016, we recorded impairment and restructuring charges and acquisition-related costs of $81 million primarily related to our Hospital Operations and other segment, consisting of approximately $26 million of employee severance costs, $4 million of contract and lease termination fees, $2 million to write-down intangible assets, $9 million of other restructuring costs, and $40 million in acquisition-related costs, which include $5 million of transaction costs and $35 million of acquisition integration charges.

Our impairment tests presume stable, improving or, in some cases, declining operating results in our facilities, which are based on programs and initiatives being implemented that are designed to achieve the facility’s most recent projections. If these projections are not met, or if in the future negative trends occur that impact our future outlook, impairments of long-lived assets and goodwill may occur, and we may incur additional restructuring charges, which could be material.

At September 30, 2017, our continuing operations consisted of three reportable segments, Hospital Operations and other, Ambulatory Care and Conifer. Our Hospital Operations and other segment was structured as follows at September 30, 2017:

• Our Eastern region included all of our segment operations in Alabama, Florida, Illinois, Massachusetts, Michigan, Missouri, Pennsylvania, South Carolina and Tennessee;

• Our Texas region included all of our segment operations in New Mexico and Texas; and 

• Our Western region included all of our segment operations in Arizona and California.

These regions are reporting units used to perform our goodwill impairment analysis and are one level below our reportable business segments. We also perform a goodwill impairment analysis for our Ambulatory Care and Conifer reporting units.

We periodically incur costs to implement restructuring efforts for specific operations, which are recorded in our consolidated statements of operations as they are incurred. Our restructuring plans focus on various aspects of operations, including aligning our operations in the most strategic and cost-effective structure. Certain restructuring and acquisition-related costs are based on estimates. Changes in estimates are recognized as they occur.

XML

LONG-TERM DEBT AND LEASE OBLIGATIONS

9 Months Ended

Sep. 30, 2017

Long-term Debt and Capital Lease Obligations [Abstract]

LONG-TERM DEBT AND LEASE OBLIGATIONS

LONG-TERM DEBT AND LEASE OBLIGATIONS

The table below shows our long-term debt at September 30, 2017 and December 31, 2016:

	September 30, 2017			December 31, 2016
Senior unsecured notes:
5.000% due 2019	$	—		$	1,100
5.500% due 2019	500			500
6.750% due 2020	300			300
8.000% due 2020	—			750
8.125% due 2022	2,800			2,800
6.750% due 2023	1,900			1,900
7.000% due 2025	500			—
6.875% due 2031	430			430
Senior secured notes:
6.250% due 2018	—			1,041
4.750% due 2020	500			500
6.000% due 2020	1,800			1,800
Floating % due 2020	—			900
4.500% due 2021	850			850
4.375% due 2021	1,050			1,050
7.500% due 2022	750			750
4.625% due 2024	1,870			—
5.125% due 2025	1,410			—
Capital leases	377			735
Mortgage notes	85			84
Unamortized issue costs, note discounts and premiums	(241		)	(235		)
Total long-term debt	14,881			15,255
Less current portion	140			191
Long-term debt, net of current portion	$	14,741		$	15,064

Senior Secured and Senior Unsecured Notes

On June 14, 2017, we sold $830 million aggregate principal amount of our 4.625% senior secured first lien notes, which will mature on July 15, 2024 (the “2024 Secured First Lien Notes”). We will pay interest on the 2024 Secured First Lien Notes semi-annually in arrears on January 15 and July 15 of each year, commencing on January 15, 2018. The proceeds from the sale of the 2024 Secured First Lien Notes were used, after payment of fees and expenses, together with cash on hand, to deposit with the trustee an amount sufficient to fund the redemption of all $900 million in aggregate principal amount of ourfloating rate senior secured notes due 2020 (the “2020 Floating Rate Notes”) on July 14, 2017, thereby fully discharging the 2020 Floating Rate Notes as of June 14, 2017. In connection with the redemption, we recorded a loss from early extinguishment of debt of approximately $26 million in the three months ended June 30, 2017, primarily related to the difference between the redemption price and the par value of the notes, as well as the write-off of associated unamortized note discounts and issuance costs.

Also on June 14, 2017, THC Escrow Corporation III (“Escrow Corp.”), a Delaware corporation established for the purpose of issuing the securities referred to in this paragraph, issued $1.040 billion in aggregate principal amount of 4.625% senior secured first lien notes due 2024 (the “Escrow Secured First Lien Notes”), $1.410 billion in aggregate principal amount of 5.125% senior secured second lien notes due 2025 (the “Escrow Secured Second Lien Notes”) and $500 million in aggregate principal amount of 7.000% senior unsecured notes due 2025 (the “Escrow Unsecured Notes”).

On July 14, 2017, we (i) assumed Escrow Corp.’s obligations with respect to the Escrow Secured Second Lien Notes and (ii) effected a mandatory exchange of all outstanding Escrow Secured First Lien Notes for a like principal amount of our newly issued 2024 Secured First Lien Notes. The proceeds from the sale of the Escrow Secured Second Lien Notes and Escrow Secured First Lien Notes were released from escrow on July 14, 2017 and were used, after payment of fees and expenses, to finance our redemption on July 14, 2017 of $1.041 billion aggregate principal amount of our outstanding 6.250% senior secured notes due 2018 and $1.100 billion aggregate principal amount of our outstanding 5.000% senior unsecured notes due 2019.

On August 1, 2017, we assumed Escrow Corp.’s obligations with respect to the Escrow Unsecured Notes. The proceeds from the sale of the Escrow Unsecured Notes were released from escrow on August 1, 2017 and were used, after payment of fees and expenses, to finance our redemption on August 1, 2017 of $500 million aggregate principal amount of our 8.000% senior unsecured notes due 2020.

On September 11, 2017, we redeemed the remaining $250 million aggregate principal amount of our 8.000% senior unsecured notes due 2020 using cash on hand.

As a result of the redemption activities in the three months ended September 30, 2017 discussed above, we recorded a loss from early extinguishment of debt of approximately $138 million in the period, primarily related to the difference between the redemption price and the par value of the notes, as well as the write-off of associated unamortized note discounts and issuance costs.

Credit Agreement

We have a senior secured revolving credit facility (as amended, the “Credit Agreement”) that provides, subject to borrowing availability, for revolving loans in an aggregate principal amount of up to $1 billion, with a $300 million subfacility for standby letters of credit. Obligations under the Credit Agreement, which has a scheduled maturity date of December 4, 2020, are guaranteed by substantially all of our domestic wholly owned hospital subsidiaries and are secured by a first-priority lien on the accounts receivable owned by us and the subsidiary guarantors. Outstanding revolving loans accrue interest at a base rate plus a margin ranging from 0.25% to 0.75% per annum or the London Interbank Offered Rate (“LIBOR”) plus a margin ranging from 1.25% to 1.75% per annum, in each case based on available credit. An unused commitment fee payable on the undrawn portion of the revolving loans ranges from 0.25% to 0.375% per annum based on available credit. Our borrowing availability is based on a specified percentage of eligible accounts receivable, including self-pay accounts. At September 30, 2017, we had no cash borrowings outstanding under the Credit Agreement, and we had approximately $2 million of standby letters of credit outstanding. Based on our eligible receivables, approximately $998 million was available for borrowing under the Credit Agreement at September 30, 2017.

Letter of Credit Facility

We have a letter of credit facility (as amended, the “LC Facility”) that provides for the issuance of standby and documentary letters of credit, from time to time, in an aggregate principal amount of up to $180 million (subject to increase to up to $200 million). Obligations under the LC Facility are guaranteed and secured by a first-priority pledge of the capital stock and other ownership interests of certain of our wholly owned domestic hospital subsidiaries on an equal ranking basis with our senior secured first lien notes. On September 15, 2016, we entered into an amendment to the existing letter of credit facility agreement in order to, among other things, (i) extend the scheduled maturity date of the LC Facility to March 7, 2021, (ii) reduce the margin payable with respect to unreimbursed drawings under letters of credit and undrawn letters of credit issued under the LC Facility, and (iii) reduce the commitment fee payable with respect to the undrawn portion of the commitments under the LC Facility.

Drawings under any letter of credit issued under the LC Facility that we have not reimbursed within three business days after notice thereof will accrue interest at a base rate plus a margin equal to 0.50% per annum. An unused commitment fee is payable at an initial rate of 0.25% per annum with a step up to 0.375% per annum should our secured-debt-to-EBITDA ratio equal or exceed 3.00 to 1.00 at the end of any fiscal quarter. A fee on the aggregate outstanding amount of issued but undrawn letters of credit will accrue at a rate of 1.50% per annum. An issuance fee equal to 0.125% per annum of the aggregate face amount of each outstanding letter of credit is payable to the account of the issuer of the related letter of credit. At September 30, 2017, we had approximately $105 million of standby letters of credit outstanding under the LC Facility.

XML

GUARANTEES

9 Months Ended

Sep. 30, 2017

Guarantees [Abstract]

GUARANTEES

GUARANTEES

At September 30, 2017, the maximum potential amount of future payments under our income guarantees to certain physicians who agree to relocate and revenue collection guarantees to hospital-based physician groups providing certain services at our hospitals was $172 million. We had a total liability of $139 million recorded for these guarantees included in other current liabilities at September 30, 2017.

At September 30, 2017, we also had issued guarantees of the indebtedness and other obligations of our investees to third parties, the maximum potential amount of future payments under which was approximately $23 million. Of the total, $17 million relates to the obligations of consolidated subsidiaries, which obligations are recorded in the accompanying Condensed Consolidated Balance Sheet at September 30, 2017.

XML

EMPLOYEE BENEFIT PLANS

9 Months Ended

Sep. 30, 2017

Defined Benefit Plan [Abstract]

EMPLOYEE BENEFIT PLANS

EMPLOYEE BENEFIT PLANS

In recent years, we have granted both options and restricted stock units to certain of our employees. Options have an exercise price equal to the fair market value of the shares on the date of grant and generally expire 10 years from the date of grant. A restricted stock unit is a contractual right to receive one share of our common stock or the equivalent value in cash in the future. Typically, options and time-based restricted stock units vest one-third on each of the first three anniversary dates of the grant; however, certain special retention awards may have longer vesting periods. In addition, we grant performance-based restricted stock units and performance-based options that vest subject to the achievement of specified performance goals within a specified time frame. At September 30, 2017, assuming outstanding performance-based restricted stock units and options for which performance has not yet been determined will achieve target performance, approximately 5.6 million shares of common stock were available under our 2008 Stock Incentive Plan for future stock option grants and other incentive awards, including restricted stock units (approximately 4.6 million shares remain available if we assume maximum performance for outstanding performance-based restricted stock units and options for which performance has not yet been determined).

Our Condensed Consolidated Statements of Operations for the nine months ended September 30, 2017 and 2016 include $44 million and $46 million, respectively, of pre-tax compensation costs related to our stock-based compensation arrangements.

Stock Options

The following table summarizes stock option activity during the nine months ended September 30, 2017:

	Options		Weighted Average Exercise Price Per Share		Aggregate Intrinsic Value		Weighted Average Remaining Life
					(In Millions)
Outstanding at December 31, 2016	1,435,921		$	22.87
Granted	1,396,307		18.24
Exercised	(16,525	)	4.56
Forfeited/Expired	(187,458	)	26.07
Outstanding at September 30, 2017	2,628,245		$	20.30	$	2	5.1 years
Vested and expected to vest at September 30, 2017	2,628,245		$	20.30	$	2	5.1 years
Exercisable at September 30, 2017	1,231,938		$	22.63	$	2	1.7 years

There were 16,525 and 110,715 stock options exercised during the nine months ended September 30, 2017 and 2016, respectively, with aggregate intrinsic values of less than $1 million and approximately $1 million, respectively.

At September 30, 2017, there were $9 million of total unrecognized compensation costs related to stock options. These costs are expected to be recognized over a weighted average period of 2.1 years.

In the three months ended March 31, 2017, we granted an aggregate of 987,781 stock options under our 2008 Stock Incentive Plan to certain of our senior officers. The stock options will all vest on the third anniversary of the grant date, subject to achieving a closing stock price of at least $23.74 (a 25% premium above the March 1, 2017 grant-date closing stock price of $18.99) for at least 20 consecutive trading days within three years of the grant date, and will expire on the tenth anniversary of the grant date. In the nine months ended September 30, 2016, there were no stock options granted.

The weighted average estimated fair value of stock options we granted in the three months ended March 31, 2017 was $8.52 per share. The fair values were calculated based on the grant date, using a Monte Carlo simulation with the following assumptions:

	Three Months Ended March 31, 2017
Expected volatility	49%
Expected dividend yield	0%
Expected life	6.2 years
Expected forfeiture rate	0%
Risk-free interest rate	2.15%

The expected volatility used in the Monte Carlo simulation incorporates historical and implied share-price volatility and is based on an analysis of historical prices of our stock and open-market exchanged options. The expected volatility reflects the historical volatility for a duration consistent with the contractual life of the options, and the volatility implied by the trading of options to purchase our stock on open-market exchanges. The historical share-price volatility excludes the movements in our stock price on two dates (April 8, 2011 and April 11, 2011) with unusual volatility due to an unsolicited acquisition proposal. The expected life of options granted is derived from Tenet’s historical stock option exercise behavior, adjusted for the exercisable period (i.e., from the third anniversary through the tenth anniversary of the grant date). The risk-free interest rates are based on zero-coupon United States Treasury yields in effect at the date of grant consistent with the expected exercise time frames.

On September 29, 2017, we granted our executive chairman 408,526 performance-based stock options with a grant date fair value of $5.63. The options vest on the first anniversary of the grant date and become exercisable only if the average closing price per share of the Company’s common stock, calculated over any period of 30 sequential trading days during the four-year period following the grant date, equals or exceeds $20.53.

The following table summarizes information about our outstanding stock options at September 30, 2017:

	Options Outstanding				Options Exercisable
Range of Exercise Prices	Number of Options	Weighted Average Remaining Contractual Life	Weighted Average Exercise Price		Number of Options	Weighted Average Exercise Price
$0.00 to $4.569	154,361	1.4 years	$	4.56	154,361	$	4.56
$4.57 to $19.759	1,396,607	8.1 years	18.24		300	14.52
$19.76 to $32.569	822,890	2.1 years	20.87		822,890	20.87
$32.57 to $42.529	254,387	0.4 years	39.31		254,387	39.31
	2,628,245	5.1 years	$	20.30	1,231,938	$	22.63

Restricted Stock Units

The following table summarizes restricted stock unit activity during the nine months ended September 30, 2017: 

	Restricted Stock Units		Weighted Average Grant Date Fair Value Per Unit
Unvested at December 31, 2016	3,174,533		$	38.75
Granted	643,329		18.65
Vested	(1,302,503	)	35.99
Forfeited	(93,618	)	37.62
Unvested at September 30, 2017	2,421,741		$	35.16

In the nine months ended September 30, 2017, we granted 643,329 restricted stock units, of which 630,426 will vest and be settled ratably over a three-year period from the grant date. The vesting of the remaining 12,903 restricted stock units is contingent on our achievement of specified performance goals for the years 2017 to 2019. Provided the goals are achieved, the performance-based restricted stock units will vest and settle on the third anniversary of the grant date. The actual number of performance-based restricted stock units that could vest will range from 0% to 200% of the 12,903 units granted, depending on our level of achievement with respect to the performance goals.

At September 30, 2017, there were $44 million of total unrecognized compensation costs related to restricted stock units. These costs are expected to be recognized over a weighted average period of 1.8 years.

Employee Retirement Plans

In both of the nine-month periods ended September 30, 2017 and 2016, we recognized (i) service cost related to one of our frozen nonqualified defined benefit pension plans of approximately $1 million in salaries, wages and benefits expense, and (ii) other components of net periodic pension cost and net periodic postretirement benefit cost related to our frozen qualified and nonqualified defined benefit plans of approximately $20 million in other non-operating income (expense), net, in the accompanying Condensed Consolidated Statements of Operations.

XML

EQUITY

9 Months Ended

Sep. 30, 2017

Stockholders' Equity Note [Abstract]

EQUITY

EQUITY

Changes in Shareholders’ Equity

The following table shows the changes in consolidated equity during the nine months ended September 30, 2017 and 2016 (dollars in millions, share amounts in thousands):

	Tenet Healthcare Corporation Shareholders’ Equity
	Common Stock			Additional Paid-In Capital			Accumulated Other Comprehensive Loss			Accumulated Deficit			Treasury Stock			Noncontrolling Interests			Total Equity
	Shares Outstanding	Issued Par Amount
Balances at December 31, 2016	99,686	$	7	$	4,827		$	(258	)	$	(1,742	)	$	(2,417	)	$	665		$	1,082
Net income (loss)	—	—		—			—			(475		)	—			99			(376		)
Distributions paid to noncontrolling interests	—	—		—			—			—			—			(93		)	(93		)
Other comprehensive income	—	—		—			20			—			—			—			20
Accretion of redeemable noncontrolling interests	—	—		(32		)	—			—			—			—			(32		)
Purchases (sales) of businesses and noncontrolling interests	—	—		(4		)	—			—			—			—			(4		)
Cumulative effect of accounting change	—	—		—			—			56			—			—			56
Stock-based compensation expense, tax benefit and issuance of common stock	1,145	—		44			—			—			(2		)	—			42
Balances at September 30, 2017	100,831	$	7	$	4,835		$	(238	)	$	(2,161	)	$	(2,419	)	$	671		$	695
Balances at December 31, 2015	98,495	$	7	$	4,815		$	(164	)	$	(1,550	)	$	(2,417	)	$	267		$	958
Net income (loss)	—	—		—			—			(113		)	—			96			(17		)
Distributions paid to noncontrolling interests	—	—		—			—			—			—			(82		)	(82		)
Other comprehensive loss	—	—		—			(36		)	—			—			—			(36		)
Purchases (sales) of businesses and noncontrolling interests	—	—		(43		)	—			—			—			119			76
Purchase accounting adjustments	—	—		—			—			—			—			237			237
Stock-based compensation expense and issuance of common stock	1,033	—		29			—			—			—			—			29
Balances at September 30, 2016	99,528	$	7	$	4,801		$	(200	)	$	(1,663	)	$	(2,417	)	$	637		$	1,165

Our noncontrolling interests balances at September 30, 2017 and December 31, 2016 were comprised of $70 million and $89 million, respectively, from our Hospital Operations and other segment, and $601 million and $576 million, respectively, from our Ambulatory Care segment. Our net income attributable to noncontrolling interests for the nine months ended September 30, 2017 and 2016 in the table above were comprised of $9 million and $8 million, respectively, from our Hospital Operations and other segment, and $90 million and $88 million, respectively, from our Ambulatory Care segment.

XML

PROPERTY AND PROFESSIONAL AND GENERAL LIABILITY INSURANCE

9 Months Ended

Sep. 30, 2017

PROPERTY AND PROFESSIONAL AND GENERAL LIABILITY INSURANCE

PROPERTY AND PROFESSIONAL AND GENERAL LIABILITY INSURANCE

PROPERTY AND PROFESSIONAL AND GENERAL LIABILITY INSURANCE

Property Insurance

We have property, business interruption and related insurance coverage to mitigate the financial impact of catastrophic events or perils that is subject to deductible provisions based on the terms of the policies. These policies are on an occurrence basis. For the policy period April 1, 2017 through March 31, 2018, we have coverage totaling $850 million per occurrence, after deductibles and exclusions, with annual aggregate sub-limits of $100 million for floods, $200 million for earthquakes and a per-occurrence sub-limit of $200 million for named windstorms with no annual aggregate. With respect to fires and other perils, excluding floods, earthquakes and named windstorms, the total $850 million limit of coverage per occurrence applies. Deductibles are 5% of insured values up to a maximum of $25 million for California earthquakes, floods and wind-related claims, and 2% of insured values for New Madrid fault earthquakes, with a maximum per claim deductible of $25 million. Floods and certain other covered losses, including fires and other perils, have a minimum deductible of $1 million.

Professional and General Liability Reserves

At September 30, 2017 and December 31, 2016, the aggregate current and long-term professional and general liability reserves in our accompanying Condensed Consolidated Balance Sheets were approximately $827 million and $794 million, respectively. These reserves include the reserves recorded by our captive insurance subsidiaries and our self-insured retention reserves recorded based on modeled estimates for the portion of our professional and general liability risks, including incurred but not reported claims, for which we do not have insurance coverage. We estimated the reserves for losses and related expenses using expected loss-reporting patterns discounted to their present value under a risk-free rate approach using a Federal Reserve seven-year maturity rate of 2.16% at September 30, 2017 and 2.25% at December 31, 2016.

If the aggregate limit of any of our professional and general liability policies is exhausted, in whole or in part, it could deplete or reduce the limits available to pay any other material claims applicable to that policy period.

Included in other operating expenses, net, in the accompanying Condensed Consolidated Statements of Operations is malpractice expense of $225 million and $233 million for the nine months ended September 30, 2017 and 2016, respectively.

XML

CLAIMS AND LAWSUITS

9 Months Ended

Sep. 30, 2017

Commitments and Contingencies Disclosure [Abstract]

CLAIMS AND LAWSUITS

CLAIMS AND LAWSUITS

We operate in a highly regulated and litigious industry. Healthcare companies are subject to numerous investigations by various governmental agencies. Further, private parties have the right to bring qui tam or “whistleblower” lawsuits against companies that allegedly submit false claims for payments to, or improperly retain overpayments from, the government and, in some states, private payers. We and our subsidiaries have received inquiries in recent years from government agencies, and we may receive similar inquiries in future periods. We are also subject to class action lawsuits, employment-related claims and other legal actions in the ordinary course of business. Some of these actions may involve large demands, as well as substantial defense costs. We cannot predict the outcome of current or future legal actions against us or the effect that judgments or settlements in such matters may have on us.

We are also subject to a non-prosecution agreement, as described in our Annual Report. If we fail to comply with this agreement, we could be subject to criminal prosecution, substantial penalties and exclusion from participation in federal healthcare programs, any of which could adversely impact our business, financial condition, results of operations or cash flows.

We record accruals for estimated losses relating to claims and lawsuits when available information indicates that a loss is probable and we can reasonably estimate the amount of the loss or a range of loss. Significant judgment is required in both the determination of the probability of a loss and the determination as to whether a loss is reasonably estimable. These determinations are updated at least quarterly and are adjusted to reflect the effects of negotiations, settlements, rulings, advice of legal counsel and technical experts, and other information and events pertaining to a particular matter. If a loss on a material matter is reasonably possible and estimable, we disclose an estimate of the loss or a range of loss. In cases where we have not disclosed an estimate, we have concluded that the loss is either not reasonably possible or the loss, or a range of loss, is not reasonably estimable, based on available information.

Securities Litigation

In February 2017, the U.S. District Court for the Northern District of Texas consolidated two previously disclosed lawsuits filed by purported shareholders of the Company’s common stock against the Company and several current and former executive officers into a single matter captioned In re Tenet Healthcare Corporation Securities Litigation. In April 2017, the four court-appointed lead plaintiffs filed a consolidated amended class action complaint asserting violations of the federal securities laws. The plaintiffs are seeking class certification on behalf of all persons who acquired the Company’s common stock between February 28, 2012 and August 1, 2016. The complaint alleges that false or misleading statements or omissions concerning the Company’s financial performance and compliance policies, specifically with respect to the previously disclosed civil qui tam litigation and parallel criminal investigation of the Company and certain of its subsidiaries (together, the “Clinica de la Mama matters”), caused the price of the Company’s common stock to be artificially inflated. In addition, the plaintiffs claim that the defendants violated GAAP by failing to disclose an estimate of the possible loss or a range of loss related to the Clinica de la Mama matters. The Company’s motion to dismiss the consolidated complaint on behalf of all defendants is pending with the court. The Company intends to continue to vigorously defend against the allegations in the purported shareholder class action.

Shareholder Derivative Litigation

In January 2017, the Dallas County District Court consolidated two previously disclosed shareholder derivative lawsuits filed by purported shareholders of the Company’s common stock on behalf of the Company against current and former officers and directors into a single matter captioned In re Tenet Healthcare Corporation Shareholder Derivative Litigation. The plaintiffs filed a consolidated shareholder derivative petition in February 2017. A separate shareholder derivative lawsuit, captioned Horwitz, derivatively on behalf of Tenet Healthcare Corporation, was filed in January 2017 in the U.S. District Court for the Northern District of Texas. The consolidated shareholder derivative petition and the Horowitz complaint generally track the allegations in the securities class action complaint described above and claim that the plaintiffs did not make demand on the Board of Directors to bring the lawsuits because such a demand would have been futile. Both shareholder derivative matters were stayed in the second quarter of 2017 pending the final resolution of the motion to dismiss in the consolidated securities litigation. The Company intends to vigorously defend against the allegations in the purported shareholder derivative lawsuits.

Antitrust Class Action Lawsuit Filed by Registered Nurses in San Antonio

In Maderazo, et al. v. VHS San Antonio Partners, L.P. d/b/a Baptist Health Systems, et al., filed in June 2006 in the U.S. District Court for the Western District of Texas, a purported class of registered nurses employed by three unaffiliated San Antonio-area hospital systems allege those hospital systems, including Baptist Health System, and other unidentified San Antonio regional hospitals violated Section §1 of the federal Sherman Act by conspiring to depress nurses’ compensation and exchanging compensation-related information among themselves in a manner that reduced competition and suppressed the wages paid to such nurses. The suit seeks unspecified damages (subject to trebling under federal law), interest, costs and attorneys’ fees. The case was stayed from 2008 through mid-2015. At this time, we are awaiting the court’s ruling on class certification and will continue to vigorously defend ourselves against the plaintiffs’ allegations. It remains impossible at this time to predict the outcome of these proceedings with any certainty; however, we believe that the ultimate resolution of this matter will not have a material effect on our business, financial condition or results of operations.

Ordinary Course Matters

We are also subject to other claims and lawsuits arising in the ordinary course of business, including potential claims related to, among other things, the care and treatment provided at our hospitals and outpatient facilities, the application of various federal and state labor laws, tax audits and other matters. Although the results of these claims and lawsuits cannot be predicted with certainty, we believe that the ultimate resolution of these ordinary course claims and lawsuits will not have a material effect on our business or financial condition.

New claims or inquiries may be initiated against us from time to time. These matters could (1) require us to pay substantial damages or amounts in judgments or settlements, which, individually or in the aggregate, could exceed amounts, if any, that may be recovered under our insurance policies where coverage applies and is available, (2) cause us to incur substantial expenses, (3) require significant time and attention from our management, and (4) cause us to close or sell hospitals or otherwise modify the way we conduct business.

The table below presents reconciliations of the beginning and ending liability balances in connection with legal settlements and related costs recorded during the nine months ended September 30, 2017 and 2016: 

	Balances at Beginning of Period		Litigation and Investigation Costs		Cash Payments			Balances at End of Period
Nine Months Ended September 30, 2017
Continuing operations	$	12	$	12	$	(14	)	$	10
Discontinued operations	—		—		—			—
	$	12	$	12	$	(14	)	$	10
Nine Months Ended September 30, 2016
Continuing operations	$	299	$	291	$	(59	)	$	531
Discontinued operations	—		—		—			—
	$	299	$	291	$	(59	)	$	531

For the nine months ended September 30, 2017 and 2016, we recorded costs of $12 million and $291 million, respectively, in continuing operations in connection with significant legal proceedings and governmental investigations.

XML

REDEEMABLE NONCONTROLLING INTERESTS IN EQUITY OF CONSOLIDATED SUBSIDIARIES

9 Months Ended

Sep. 30, 2017

Noncontrolling Interest [Abstract]

REDEEMABLE NONCONTROLLING INTERESTS IN EQUITY OF CONSOLIDATED SUBSIDIARIES

REDEEMABLE NONCONTROLLING INTERESTS IN EQUITY OF CONSOLIDATED SUBSIDIARIES

As previously disclosed, as part of the formation of our USPI joint venture in 2015, we entered into a put/call agreement (the “Put/Call Agreement”) with respect to the equity interests in the joint venture held by our joint venture partners. In January 2016, Welsh, Carson, Anderson & Stowe (“Welsh Carson”), on behalf of our joint venture partners, delivered a put notice for the minimum number of shares they were required to put to us in 2016 according to the Put/Call Agreement. In April 2016, we paid approximately $127 million to purchase those shares, which increased our ownership interest in the USPI joint venture to approximately 56.3%. On May 1, 2017, we amended and restated the Put/Call Agreement to provide for, among other things, the acceleration of our acquisition of certain shares of our USPI joint venture. Under the terms of the amendment, we agreed to pay Welsh Carson, on or before July 3, 2017, approximately $711 million to buy 23.7% of our USPI joint venture, which amount will be subject to adjustment for actual 2017 financial results in accordance with the terms of the Put/Call Agreement. On July 3, 2017, we paid approximately $716 million for the purchase of these shares, which increased our ownership interest in the USPI joint venture to 80.0%, as well as the final adjustment to the 2016 purchase price.

The amended and restated Put/Call Agreement also provides that the remaining 15% ownership interest in our USPI joint venture held by our Welsh Carson joint venture partners will be subject to put and call options in equal shares in each of 2018 and 2019. In the event our Welsh Carson joint venture partners do not exercise these put options, we will have the option, but not the obligation, to buy 7.5% of our USPI joint venture from them in 2018 and another 7.5% in 2019. In connection with such puts or calls, we will have the ability to choose whether to settle the purchase price in cash or shares of our common stock.

The following table shows the changes in redeemable noncontrolling interests in equity of consolidated subsidiaries during the nine months ended September 30, 2017 and 2016:

	Nine Months Ended September 30,
	2017			2016
Balances at beginning of period	$	2,393		$	2,266
Net income	155			170
Distributions paid to noncontrolling interests	(85		)	(69		)
Purchase accounting adjustments	—			(47		)
Accretion of redeemable noncontrolling interests	32			—
Purchases and sales of businesses and noncontrolling interests, net	(679		)	(13		)
Balances at end of period	$	1,816		$	2,307

The following tables show the composition by segment of our redeemable noncontrolling interests balances at September 30, 2017 and December 31, 2016, as well as our net income attributable to redeemable noncontrolling interests for the nine months ended September 30, 2017 and 2016:

	September 30, 2017		December 31, 2016
Hospital Operations and other	$	529	$	520
Ambulatory Care	1,090		1,715
Conifer	197		158
Redeemable noncontrolling interests	$	1,816	$	2,393

	Nine Months Ended September 30,
	2017		2016
Hospital Operations and other	$	14	$	16
Ambulatory Care	103		116
Conifer	38		38
Net income attributable to redeemable noncontrolling interests	$	155	$	170

XML

INCOME TAXES

9 Months Ended

Sep. 30, 2017

Income Tax Disclosure [Abstract]

INCOME TAXES

INCOME TAXES

During the three months ended September 30, 2017, we recorded an income tax benefit of $60 million in continuing operations on pre-tax loss of $348 million compared to income tax expense of $10 million on pre-tax income of $89 million during the three months ended September 30, 2016. During the nine months ended September 30, 2017, we recorded an income tax benefit of $105 million in continuing operations on pre-tax loss of $325 million compared to income tax expense of $61 million on pre-tax income of $219 million during the nine months ended September 30, 2016. Our provision for income taxes during interim reporting periods has historically been calculated by applying an estimate of the annual effective tax rate for the full year to “ordinary” income or loss (pre-tax income or loss excluding unusual or infrequently occurring discrete items) for the reporting period. However, we utilized the discrete effective tax rate method to calculate the interim period tax provision for the three and nine month periods ended September 30, 2017. We determined that, because minor fluctuations in estimated “ordinary” income would result in significant changes in the estimated annual effective tax rate, the historical method would not provide a reliable estimate for the three and nine month periods ended September 30, 2017. Due to Aspen being classified as held for sale, we have reversed our indefinite reinvestment assertion with respect to this investment outside the United States as of September 30, 2017, which resulted in an income tax benefit of $30 million in the three months ended September 30, 2017. The reconciliation between the amount of recorded income tax expense (benefit) and the amount calculated at the statutory federal tax rate is shown in the following table:

	Three Months Ended September 30,						Nine Months Ended September 30,
	2017			2016			2017			2016
Tax expense (benefit) at statutory federal rate of 35%	$	(122	)	$	31		$	(114	)	$	77
State income taxes, net of federal income tax benefit	8			3			13			10
Tax benefit attributable to noncontrolling interests	(25		)	(28		)	(79		)	(75		)
Nondeductible goodwill	104			—			104			29
Nontaxable gains	—			(1		)	—			(18		)
Nondeductible litigation	—			4			—			37
Change in tax contingency reserves, including interest	(1		)	(1		)	(3		)	(4		)
Stock-based compensation	—			—			9			—
Change in indefinite reinvestment assertion	(30		)	—			(30		)	—
Change in valuation allowance	(5		)	—			(5		)	—
Other items	11			2			—			5
	$	(60	)	$	10		$	(105	)	$	61

During the nine months ended September 30, 2017, we increased our estimated liabilities for uncertain tax positions by $33 million, net of related deferred tax assets. The total amount of unrecognized tax benefits at September 30, 2017 was $68 million, of which $65 million, if recognized, would impact our effective tax rate and income tax expense (benefit) from continuing operations. 

Our practice is to recognize interest and penalties related to income tax matters in income tax expense in our consolidated statements of operations. Total accrued interest and penalties on unrecognized tax benefits at September 30, 2017 were $4 million, all of which related to continuing operations.

At September 30, 2017, approximately $2 million of unrecognized federal and state tax benefits, as well as reserves for interest and penalties, may decrease in the next 12 months as a result of the settlement of audits, the filing of amended tax returns or the expiration of statutes of limitations.

XML

LOSS PER COMMON SHARE

9 Months Ended

Sep. 30, 2017

Earnings Per Share [Abstract]

LOSS PER COMMON SHARE

LOSS PER COMMON SHARE

The following table is a reconciliation of the numerators and denominators of our basic and diluted loss per common share calculations for our continuing operations for three and nine months ended September 30, 2017 and 2016. Loss attributable to our common shareholders is expressed in millions and weighted average shares are expressed in thousands.

	Loss Attributable to Common Shareholders (Numerator)			Weighted Average Shares (Denominator)	Per-Share Amount
Three Months Ended September 30, 2017
Net loss attributable to Tenet Healthcare Corporation common shareholders for basic loss per share	$	(366	)	100,812	$	(3.63	)
Effect of dilutive stock options, restricted stock units and deferred compensation units	—			—	—
Net loss attributable to Tenet Healthcare Corporation common shareholders for diluted loss per share	$	(366	)	100,812	$	(3.63	)
Three Months Ended September 30, 2016
Net loss attributable to Tenet Healthcare Corporation common shareholders for basic loss per share	$	(9	)	99,523	$	(0.09	)
Effect of dilutive stock options, restricted stock units and deferred compensation units	—			—	—
Net loss attributable to Tenet Healthcare Corporation common shareholders for diluted loss per share	$	(9	)	99,523	$	(0.09	)
Nine Months Ended September 30, 2017
Net loss attributable to Tenet Healthcare Corporation common shareholders for basic loss per share	$	(474	)	100,475	$	(4.72	)
Effect of dilutive stock options, restricted stock units and deferred compensation units	—			—	—
Net loss attributable to Tenet Healthcare Corporation common shareholders for diluted loss per share	$	(474	)	100,475	$	(4.72	)
Nine Months Ended September 30, 2016
Net loss attributable to Tenet Healthcare Corporation common shareholders for basic loss per share	$	(108	)	99,210	$	(1.09	)
Effect of dilutive stock options, restricted stock units and deferred compensation units	—			—	—
Net loss attributable to Tenet Healthcare Corporation common shareholders for diluted loss per share	$	(108	)	99,210	$	(1.09	)

All potentially dilutive securities were excluded from the calculation of diluted loss per share for the three and nine months ended September 30, 2017 and 2016 because we did not report income from continuing operations available to common shareholders in those periods. In circumstances where we do not have income from continuing operations available to common shareholders, the effect of stock options and other potentially dilutive securities is anti-dilutive, that is, a loss from continuing operations attributable to common shareholders has the effect of making the diluted loss per share less than the basic loss per share. Had we generated income from continuing operations available to common shareholders in the three and nine months ended September 30, 2017 and 2016, the effect (in thousands) of employee stock options, restricted stock units and deferred compensation units on the diluted shares calculation would have been an increase in shares of 711 and 1,455 for the three months ended September 30, 2017 and 2016, respectively, and 747 and 1,470 for the nine months ended September 30, 2017 and 2016, respectively.

XML

FAIR VALUE MEASUREMENTS

9 Months Ended

Sep. 30, 2017

Fair Value Disclosures [Abstract]

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS

Our financial assets and liabilities recorded at fair value on a recurring basis primarily relate to investments in available-for-sale securities held by our captive insurance subsidiaries. The following tables present information about our assets and liabilities that are measured at fair value on a recurring basis. The following tables also indicate the fair value hierarchy of the valuation techniques we utilized to determine such fair values. In general, fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. We consider a security that trades at least weekly to have an active market. Fair values determined by Level 2 inputs utilize data points that are observable, such as quoted prices, interest rates and yield curves. Fair values determined by Level 3 inputs are unobservable data points for the asset or liability, and include situations where there is little, if any, market activity for the asset or liability.

Investments	September 30, 2017		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Marketable debt securities — noncurrent	$	54	$	40	$	14	$	—
	$	54	$	40	$	14	$	—

Investments	December 31, 2016		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Marketable debt securities — noncurrent	$	49	$	23	$	26	$	—
	$	49	$	23	$	26	$	—

Our non-financial assets and liabilities not permitted or required to be measured at fair value on a recurring basis typically relate to long-lived assets held and used, long-lived assets held for sale and goodwill. We are required to provide additional disclosures about fair value measurements as part of our financial statements for each major category of assets and liabilities measured at fair value on a non-recurring basis. The following table presents this information and indicates the fair value hierarchy of the valuation techniques we utilized to determine such fair values. In general, fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities, which generally are not applicable to non-financial assets and liabilities. Fair values determined by Level 2 inputs utilize data points that are observable, such as definitive sales agreements, appraisals or established market values of comparable assets. Fair values determined by Level 3 inputs are unobservable data points for the asset or liability and include situations where there is little, if any, market activity for the asset or liability, such as internal estimates of future cash flows.

	September 30, 2017		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Long-lived assets held for sale	$	399	$	—	$	399	$	—
Other than temporarily impaired equity method investments	112		—		112		—
	$	511	$	—	$	511	$	—

	December 31, 2016		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Long-lived assets held and used	$	163	$	—	$	163	$	—
Other than temporarily impaired equity method investments	27		—		27		—
	$	190	$	—	$	190	$	—

As described in Note 4, in the nine months ended September 30, 2017, we recorded $294 million of impairment charges to write-down assets held for sale to their estimated fair value, less estimated costs to sell, for our Aspen and Philadelphia-area facilities, and a $29 million impairment charge related to certain of our equity method investments.

The fair value of our long-term debt (except for borrowings under the Credit Agreement) is based on quoted market prices (Level 1). The inputs used to establish the fair value of the borrowings outstanding under the Credit Agreement are considered to be Level 2 inputs, which include inputs other than quoted prices included in Level 1 that are observable, either directly or indirectly. At September 30, 2017 and December 31, 2016, the estimated fair value of our long-term debt was approximately 100.6% and 93.9%, respectively, of the carrying value of the debt.

XML

ACQUISITIONS

9 Months Ended

Sep. 30, 2017

Business Combinations [Abstract]

ACQUISITIONS

ACQUISITIONS

Preliminary purchase price allocations (representing the fair value of the consideration conveyed) for all acquisitions made during the nine months ended September 30, 2017 and 2016 are as follows:

	Nine Months Ended September 30,
	2017			2016
Current assets	$	4		$	42
Property and equipment	5			33
Other intangible assets	5			7
Goodwill	65			316
Other long-term assets	1			6
Current liabilities	(4		)	(25		)
Long-term liabilities	(1		)	(14		)
Redeemable noncontrolling interests	(18		)	(114		)
Noncontrolling interests	(13		)	(122		)
Cash paid, net of cash acquired	(41		)	(96		)
Gains on consolidations	$	3		$	33

The goodwill generated from these transactions, the majority of which will be deductible for income tax purposes, can be attributed to the benefits that we expect to realize from operating efficiencies and growth strategies. The goodwill total of $65 million from acquisitions completed during the nine months ended September 30, 2017 was recorded in our Ambulatory Care segment. Approximately $5 million in transaction costs related to prospective and closed acquisitions were expensed during both of the nine month periods ended September 30, 2017 and 2016, and are included in impairment and restructuring charges, and acquisition-related costs in the accompanying Condensed Consolidated Statement of Operations.

We are required to allocate the purchase prices of acquired businesses to assets acquired or liabilities assumed and, if applicable, noncontrolling interests based on their fair values. The excess of the purchase price allocation over those fair values is recorded as goodwill. We are in process of finalizing the purchase price allocations, including valuations of the acquired property and equipment, other intangible assets and noncontrolling interests for some of our 2016 acquisitions; therefore, those purchase price allocations are subject to adjustment once the valuations are completed.

During the nine months ended September 30, 2017 and 2016, we recognized gains totaling $3 million and $33 million, respectively, associated with stepping up our ownership interests in previously held equity investments, which we began consolidating after we acquired controlling interests.

XML

SEGMENT INFORMATION

9 Months Ended

Sep. 30, 2017

Segment Reporting [Abstract]

SEGMENT INFORMATION

SEGMENT INFORMATION

Our business consists of our Hospital Operations and other segment, our Ambulatory Care segment and our Conifer segment. The factors for determining the reportable segments include the manner in which management evaluates operating performance combined with the nature of the individual business activities.

Our Hospital Operations and other segment is comprised of our acute care hospitals, ancillary outpatient facilities, urgent care centers, microhospitals and physician practices. We also own various related healthcare businesses.

Our Ambulatory Care segment is comprised of the operations of our USPI joint venture and our nine Aspen facilities in the United Kingdom. At September 30, 2017, our USPI joint venture had interests in 244ambulatory surgery centers, 34urgent care centers, 22imaging centers and 20surgical hospitals in 27states. At September 30, 2017, we owned 80.0% of our USPI joint venture.

Our Conifer segment provides healthcare business process services in the areas of hospital and physician revenue cycle management and value-based care solutions to healthcare systems, as well as individual hospitals, physician practices, self-insured organizations, health plans and other entities. At September 30, 2017, Conifer provided services to more than 800 Tenet and non-Tenet hospitals and other clients nationwide. In 2012, we entered into agreements documenting the terms and conditions of various services Conifer provides to Tenet hospitals, as well as certain administrative services our Hospital Operations and other segment provides to Conifer. The pricing terms for the services provided by each party to the other under these contracts were based on estimated third-party pricing terms in effect at the time the agreements were signed. At September 30, 2017, we owned 76.2% of Conifer Health Solutions, LLC, which is the principal subsidiary of Conifer Holdings, Inc.

The following tables include amounts for each of our reportable segments and the reconciling items necessary to agree to amounts reported in the accompanying Condensed Consolidated Balance Sheets and Condensed Consolidated Statements of Operations:

	September 30, 2017		December 31, 2016
Assets:
Hospital Operations and other	$	16,249	$	17,871
Ambulatory Care	5,847		5,722
Conifer	1,112		1,108
Total	$	23,208	$	24,701

	Three Months Ended September 30,						Nine Months Ended September 30,
	2017			2016			2017			2016
Capital expenditures:
Hospital Operations and other	$	122		$	182		$	441		$	557
Ambulatory Care	16			14			37			42
Conifer	6			5			14			15
Total	$	144		$	201		$	492		$	614
Net operating revenues:
Hospital Operations and other total prior to inter-segment eliminations(1)	$	3,866		$	4,162		$	12,066		$	12,761
Ambulatory Care	468			448			1,395			1,319
Conifer
Tenet	149			159			463			488
Other customers	252			239			740			681
Total Conifer	401			398			1,203			1,169
Inter-segment eliminations	(149		)	(159		)	(463		)	(488		)
Total	$	4,586		$	4,849		$	14,201		$	14,761
Equity in earnings of unconsolidated affiliates:
Hospital Operations and other	$	4		$	3		$	4		$	6
Ambulatory Care	34			28			91			79
Total	$	38		$	31		$	95		$	85
Adjusted EBITDA:
Hospital Operations and other(2)	$	269		$	346		$	924		$	1,191
Ambulatory Care	159			157			476			432
Conifer	79			79			204			205
Total	$	507		$	582		$	1,604		$	1,828
Depreciation and amortization:
Hospital Operations and other	$	185		$	170		$	560		$	525
Ambulatory Care	22			22			66			69
Conifer	12			13			36			38
Total	$	219		$	205		$	662		$	632

	Three Months Ended September 30,						Nine Months Ended September 30,
	2017			2016			2017			2016
Adjusted EBITDA	$	507		$	582		$	1,604		$	1,828
Loss from divested and closed businesses (i.e., the Company’s health plan businesses)	(6		)	(6		)	(41		)	(8		)
Depreciation and amortization	(219		)	(205		)	(662		)	(632		)
Impairment and restructuring charges, and acquisition-related costs	(329		)	(31		)	(403		)	(81		)
Litigation and investigation costs	(6		)	(4		)	(12		)	(291		)
Interest expense	(257		)	(243		)	(775		)	(730		)
Loss from early extinguishment of debt	(138		)	—			(164		)	—
Other non-operating expense, net	(4		)	(7		)	(14		)	(18		)
Gains on sales, consolidation and deconsolidation of facilities	104			3			142			151
Net income (loss) from continuing operations before income taxes	$	(348	)	$	89		$	(325	)	$	219

(1) Hospital Operations and other revenues includes health plan revenues of $10 million and $100 million for the three and nine months ended September 30, 2017, respectively, and $122 million and $385 million for the three and nine months ended September 30, 2016, respectively.

(2) Hospital Operations and other Adjusted EBITDA excludes health plan EBITDA of $(6) million and $(41) million for the three and nine months ended September 30, 2017, respectively, and $(6) million and $(8) million for the three and nine months ended September 30, 2016, respectively.

XML

RECENT ACCOUNTING STANDARDS

9 Months Ended

Sep. 30, 2017

New Accounting Pronouncements and Changes in Accounting Principles [Abstract]

RECENT ACCOUNTING STANDARDS

RECENT ACCOUNTING STANDARDS

In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers (Topic 606)”

(“ASU 2014-09”). In August 2015, the FASB amended the guidance to defer the effective date of this standard by one year. ASU 2014-09 affects any entity that either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets unless those contracts are within the scope of other standards. The core principle of the guidance in ASU 2014-09 is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. We have substantially completed our evaluation of the requirements of the new standard to insure that we have processes, systems and internal controls in place to collect the necessary information to implement the standard, which will be effective for us beginning in 2018. It is our current intention to use a modified retrospective method of application to adopt ASU 2014-09. For our Hospital Operations and other and Ambulatory Care segments, we will use a portfolio approach to apply the new model to classes of payers with similar characteristics and will analyze cash collection trends over an appropriate collection look-back period of 18 to 36 months depending on the payer. Adoption of ASU 2014-09 will result in changes to our presentation for and disclosure of revenue related to uninsured or underinsured patients. Currently, a significant portion of our provision for doubtful accounts relates to self-pay patients, as well as co-pays and deductibles owed to us by patients with insurance, in our Hospital Operations and other segment. Under ASU 2014-09, the estimated uncollectable amounts due from these patients will generally be considered a direct reduction to net operating revenues and, correspondingly, will result in a material reduction in the amounts presented separately as provision for doubtful accounts. We have also substantially completed our process of assessing the impact of the new standard on various reimbursement programs that represent variable consideration.  These include supplemental state Medicaid programs, disproportionate share payments and settlements with third party payers. The payment mechanisms for these types of programs often vary by state. During July 2017, industry guidance surrounding these programs was issued by the American Institute of Certified Public Accountants’ Financial Reporting Executive Committee. Our implementation team reviewed the guidance and concluded it was substantially consistent with our existing accounting processes. For our Conifer segment, we expect the adoption of ASU 2014-09 will result in changes to our presentation and disclosure of customer contract assets and liabilities and variable consideration. While the adoption of ASU 2014-09 will have a material effect on the presentation of net operating revenues in our consolidated statements of operations and on certain of our disclosures, we do not expect it to materially impact our financial position, results of operations or cash flows. We believe that the cumulative effect of the change in accounting principle effective January 1, 2018, if any, will be immaterial.

In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842)” (“ASU 2016-02”), which affects any entity that enters into a lease (as that term is defined in ASU 2016-02), with some specified scope exceptions. The main difference between the guidance in ASU 2016-02 and current GAAP is the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under current GAAP. Recognition of these assets and liabilities will have a material impact to our consolidated balance sheets upon adoption. Under ASU 2016-02, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach, which includes a number of optional practical expedients. We are currently evaluating the potential impact of this guidance, which will be effective for us beginning in 2019, including performing an assessment of the quantity of and contractual provisions in various leasing arrangements to guide our implementation plan related to processes, systems and internal controls and the conclusion on the use of the optional practical expedients.

In January 2017, the FASB issued ASU 2017-04, “Intangibles—Goodwill and Other (Topic 350)” (“ASU 2017-04”), which affects public business and other entities that have goodwill reported in their financial statements and have not elected the private company alternative for the subsequent measurement of goodwill. The amendments in ASU 2017-04 modify the concept of impairment from the condition that exists when the carrying amount of goodwill exceeds its implied fair value to the condition that exists when the carrying amount of a reporting unit exceeds its fair value. An entity no longer will determine goodwill impairment by calculating the implied fair value of goodwill by assigning the fair value of a reporting unit to all of its assets and liabilities as if that reporting unit had been acquired in a business combination. Because these amendments eliminate Step 2 from the goodwill impairment test, they should reduce the cost and complexity of evaluating goodwill for impairment. It is our intention to early adopt ASU 2017-04 for our annual goodwill impairment tests for the year ending December 31, 2017. As of September 30, 2017, we do not expect the adoption of this guidance to materially impact our financial position, results of operations or cash flows.

XML

BASIS OF PRESENTATION (Policies)

9 Months Ended

Sep. 30, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Description of Business and Basis of Presentation

Description of Business and Basis of Presentation

Tenet Healthcare Corporation (together with our subsidiaries, referred to herein as “Tenet,” “we” or “us”) is a diversified healthcare services company. At September 30, 2017, we operated 77 hospitals, 20 surgical hospitals and over 460 outpatient centers in the United States, as well as nine facilities in the United Kingdom, through our subsidiaries, partnerships and joint ventures, including USPI Holding Company, Inc. (“USPI joint venture”). Our Conifer Holdings, Inc. (“Conifer”) subsidiary provides healthcare business process services in the areas of hospital and physician revenue cycle management and value-based care solutions to healthcare systems, as well as individual hospitals, physician practices, self-insured organizations, health plans and other entities.

This quarterly report supplements our Annual Report on Form 10-K for the year ended December 31, 2016 (“Annual Report”). As permitted by the Securities and Exchange Commission for interim reporting, we have omitted certain notes and disclosures that substantially duplicate those in our Annual Report. For further information, refer to the audited Consolidated Financial Statements and notes included in our Annual Report. Unless otherwise indicated, all financial and statistical data included in these notes to our Condensed Consolidated Financial Statements relate to our continuing operations, with dollar amounts expressed in millions (except per-share amounts).  In addition to the impact of the new accounting standards discussed below, certain prior-year amounts have also been reclassified to conform to the current-year presentation, primarily related to the detail of other intangible assets in Note 1 and the line items presented in the changes in shareholders’ equity table in Note 8.

Effective January 1, 2017, we adopted the Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) 2016-09, “Compensation—Stock Compensation (Topic 718) Improvements to Employee Share-Based Payment Accounting” (“ASU 2016-09”), which affects all entities that issue share-based payment awards to their employees. The guidance in ASU 2016-09 simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. Upon adoption of ASU 2016-09, we recorded previously unrecognized excess tax benefits of approximately $56 million as a deferred tax asset and a cumulative effect adjustment to retained earnings as of January 1, 2017. Prospectively, all excess tax benefits and deficiencies will be recognized as income tax benefit or expense in our consolidated statement of operations when awards vest.

Also effective January 1, 2017, we early adopted ASU 2017-07, “Compensation—Retirement Benefits (Topic 715) Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost” (“ASU 2017-07”), which the FASB issued in March 2017. The amendments in ASU 2017-07 apply to all employers that offer to their employees defined benefit pension plans, other postretirement benefit plans, or other types of benefits accounted for under Topic 715 of the FASB Accounting Standards Codification. The guidance in ASU 2017-07 requires that an employer report the service cost component in the same line item or items as other compensation costs arising from services rendered by the pertinent employees during the period. The other components of net benefit cost are required to be presented in the statement of operations separately from the service cost component and outside a subtotal of income from operations. The line item or items used in the statement of operations to present the other components of net benefit cost must be disclosed. The amendments in ASU 2017-07 must be applied retrospectively for the presentation of the service cost component and the other components of net periodic pension cost and net periodic postretirement benefit cost in the statement of operations. As a result of the adoption of ASU 2017-07, we reclassified approximately $20 million of net benefit cost from salaries, wages and benefits expense to other non-operating income (expense), net, in the accompanying Condensed Consolidated Statement of Operations for both of the nine month periods ended September 30, 2017 and 2016. Upon adoption of ASU 2017-07, we also reclassified approximately $8 million of net benefit cost from salaries, wages and benefits expense to other non-operating income (expense), net for the three months ended December 31, 2016, and we reclassified approximately $21 million of net benefit cost from salaries, wages and benefits expense to other non-operating income (expense), net for the year ended December 31, 2015.

Although the Condensed Consolidated Financial Statements and related notes within this document are unaudited, we believe all adjustments considered necessary for a fair presentation have been included and are of a normal recurring nature. In preparing our financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”), we are required to make estimates and assumptions that affect the amounts reported in our Condensed Consolidated Financial Statements and these accompanying notes. We regularly evaluate the accounting policies and estimates we use. In general, we base the estimates on historical experience and on assumptions that we believe to be reasonable given the particular circumstances in which we operate. Actual results may vary from those estimates. Financial and statistical information we report to other regulatory agencies may be prepared on a basis other than GAAP or using different assumptions or reporting periods and, therefore, may vary from amounts presented herein. Although we make every effort to ensure that the information we report to those agencies is accurate, complete and consistent with applicable reporting guidelines, we cannot be responsible for the accuracy of the information they make available to the public.

Operating results for the three and nine month periods ended September 30, 2017 are not necessarily indicative of the results that may be expected for the full year. Reasons for this include, but are not limited to: overall revenue and cost trends, particularly the timing and magnitude of price changes; fluctuations in contractual allowances and cost report settlements and valuation allowances; managed care contract negotiations, settlements or terminations and payer consolidations; changes in Medicare and Medicaid regulations; Medicaid and other supplemental funding levels set by the states in which we operate; the timing of approval by the Centers for Medicare and Medicaid Services of Medicaid provider fee revenue programs; trends in patient accounts receivable collectability and associated provisions for doubtful accounts; fluctuations in interest rates; levels of malpractice insurance expense and settlement trends; the timing of when we meet the criteria to recognize electronic health record incentives; impairment of long-lived assets and goodwill; restructuring charges; losses, costs and insurance recoveries related to natural disasters and other weather-related occurrences; litigation and investigation costs; gains (losses) on sales, consolidation and deconsolidation of facilities; income tax rates and deferred tax asset valuation allowance activity; changes in estimates of accruals for annual incentive compensation; the timing and amounts of stock option and restricted stock unit grants to employees and directors; gains or losses from early extinguishment of debt; and changes in occupancy levels and patient volumes. Factors that affect patient volumes and, thereby, the results of operations at our hospitals and related healthcare facilities include, but are not limited to: the business environment, economic conditions and demographics of local communities in which we operate; the number of uninsured and underinsured individuals in local communities treated at our hospitals; seasonal cycles of illness; climate and weather conditions; physician recruitment, retention and attrition; advances in technology and treatments that reduce length of stay; local healthcare competitors; managed care contract negotiations or terminations; the number of patients with high-deductible health insurance plans; any unfavorable publicity about us, or our joint venture partners, that impacts our relationships with physicians and patients; changes in healthcare regulations and the participation of individual states in federal programs; and the timing of elective procedures. These considerations apply to year-to-year comparisons as well.

Translation of Foreign Currencies

Translation of Foreign Currencies

The accounts of European Surgical Partners Limited (“Aspen”) were measured in its local currency (the pound sterling) and then translated into U.S. dollars. All assets and liabilities were translated using the current rate of exchange at the balance sheet date. Results of operations were translated using the average rates prevailing throughout the period of operations. Translation gains or losses resulting from changes in exchange rates are accumulated in shareholders’ equity.

Net Operating Revenues Before Provision for Doubtful Accounts

Net Operating Revenues Before Provision for Doubtful Accounts

We recognize net operating revenues before provision for doubtful accounts in the period in which our services are performed. Net operating revenues before provision for doubtful accounts primarily consist of net patient service revenues that are recorded based on established billing rates (i.e., gross charges), less estimated discounts for contractual and other allowances, principally for patients covered by Medicare, Medicaid, managed care and other health plans, as well as certain uninsured patients under our Compact with Uninsured Patients and other uninsured discount and charity programs.

Cash and Cash Equivalents

Cash and Cash Equivalents

We treat highly liquid investments with original maturities of three months or less as cash equivalents.

Investments in Unconsolidated Affiliates

Investments in Unconsolidated Affiliates

We control 220 of the facilities within our Ambulatory Care segment and, therefore, consolidate their results. We account for many of the facilities our Ambulatory Care segment operates (109 of 329 at September 30, 2017) and four of the hospitals our Hospital Operations and other segment operates, as well as 11 additional facilities in which our Hospital Operations and other segment holds ownership interests, under the equity method as investments in unconsolidated affiliates and report only our share of net income attributable to the investee as equity in earnings of unconsolidated affiliates in the accompanying Condensed Consolidated Statements of Operations.

Recent Accounting Standards

RECENT ACCOUNTING STANDARDS

In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers (Topic 606)”

(“ASU 2014-09”). In August 2015, the FASB amended the guidance to defer the effective date of this standard by one year. ASU 2014-09 affects any entity that either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets unless those contracts are within the scope of other standards. The core principle of the guidance in ASU 2014-09 is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. We have substantially completed our evaluation of the requirements of the new standard to insure that we have processes, systems and internal controls in place to collect the necessary information to implement the standard, which will be effective for us beginning in 2018. It is our current intention to use a modified retrospective method of application to adopt ASU 2014-09. For our Hospital Operations and other and Ambulatory Care segments, we will use a portfolio approach to apply the new model to classes of payers with similar characteristics and will analyze cash collection trends over an appropriate collection look-back period of 18 to 36 months depending on the payer. Adoption of ASU 2014-09 will result in changes to our presentation for and disclosure of revenue related to uninsured or underinsured patients. Currently, a significant portion of our provision for doubtful accounts relates to self-pay patients, as well as co-pays and deductibles owed to us by patients with insurance, in our Hospital Operations and other segment. Under ASU 2014-09, the estimated uncollectable amounts due from these patients will generally be considered a direct reduction to net operating revenues and, correspondingly, will result in a material reduction in the amounts presented separately as provision for doubtful accounts. We have also substantially completed our process of assessing the impact of the new standard on various reimbursement programs that represent variable consideration.  These include supplemental state Medicaid programs, disproportionate share payments and settlements with third party payers. The payment mechanisms for these types of programs often vary by state. During July 2017, industry guidance surrounding these programs was issued by the American Institute of Certified Public Accountants’ Financial Reporting Executive Committee. Our implementation team reviewed the guidance and concluded it was substantially consistent with our existing accounting processes. For our Conifer segment, we expect the adoption of ASU 2014-09 will result in changes to our presentation and disclosure of customer contract assets and liabilities and variable consideration. While the adoption of ASU 2014-09 will have a material effect on the presentation of net operating revenues in our consolidated statements of operations and on certain of our disclosures, we do not expect it to materially impact our financial position, results of operations or cash flows. We believe that the cumulative effect of the change in accounting principle effective January 1, 2018, if any, will be immaterial.

In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842)” (“ASU 2016-02”), which affects any entity that enters into a lease (as that term is defined in ASU 2016-02), with some specified scope exceptions. The main difference between the guidance in ASU 2016-02 and current GAAP is the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under current GAAP. Recognition of these assets and liabilities will have a material impact to our consolidated balance sheets upon adoption. Under ASU 2016-02, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach, which includes a number of optional practical expedients. We are currently evaluating the potential impact of this guidance, which will be effective for us beginning in 2019, including performing an assessment of the quantity of and contractual provisions in various leasing arrangements to guide our implementation plan related to processes, systems and internal controls and the conclusion on the use of the optional practical expedients.

In January 2017, the FASB issued ASU 2017-04, “Intangibles—Goodwill and Other (Topic 350)” (“ASU 2017-04”), which affects public business and other entities that have goodwill reported in their financial statements and have not elected the private company alternative for the subsequent measurement of goodwill. The amendments in ASU 2017-04 modify the concept of impairment from the condition that exists when the carrying amount of goodwill exceeds its implied fair value to the condition that exists when the carrying amount of a reporting unit exceeds its fair value. An entity no longer will determine goodwill impairment by calculating the implied fair value of goodwill by assigning the fair value of a reporting unit to all of its assets and liabilities as if that reporting unit had been acquired in a business combination. Because these amendments eliminate Step 2 from the goodwill impairment test, they should reduce the cost and complexity of evaluating goodwill for impairment. It is our intention to early adopt ASU 2017-04 for our annual goodwill impairment tests for the year ending December 31, 2017. As of September 30, 2017, we do not expect the adoption of this guidance to materially impact our financial position, results of operations or cash flows.

XML

BASIS OF PRESENTATION (Tables)

9 Months Ended

Sep. 30, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of sources of net operating revenues before provision for doubtful accounts

The table below shows the sources of net operating revenues before provision for doubtful accounts from continuing operations:

	Three Months Ended September 30,						Nine Months Ended September 30,
	2017			2016			2017			2016
Hospital Operations and other:
Net patient revenues from acute care hospitals, related outpatient facilities and physician practices
Medicare	$	809		$	844		$	2,563		$	2,658
Medicaid	256			339			822			1,009
Managed care	2,524			2,729			7,867			8,031
Indemnity, self-pay and other	442			328			1,316			1,264
Net patient revenues(1)	4,031			4,240			12,568			12,962
Health plans	10			122			100			385
Revenue from other sources	171			158			480			482
Hospital Operations and other total prior to inter-segment eliminations	4,212			4,520			13,148			13,829
Ambulatory Care	477			457			1,422			1,346
Conifer	401			398			1,203			1,169
Inter-segment eliminations	(149		)	(159		)	(463		)	(488		)
Net operating revenues before provision for doubtful accounts	$	4,941		$	5,216		$	15,310		$	15,856

(1) Net patient revenues include revenues from physician practices of $171 million and $179 million for the three months ended September 30, 2017 and 2016, respectively, and $551 million and $558 million for the nine months ended September 30, 2017 and 2016, respectively.

Schedule of other intangible assets

The following tables provide information regarding other intangible assets, which are included in the accompanying Condensed Consolidated Balance Sheets at September 30, 2017 and December 31, 2016:

	Gross Carrying Amount		Accumulated Amortization			Net Book Value
At September 30, 2017:
Capitalized software costs	$	1,537	$	(721	)	$	816
Trade names	105		—			105
Contracts	855		(55		)	800
Other	108		(65		)	43
Total	$	2,605	$	(841	)	$	1,764

	Gross Carrying Amount		Accumulated Amortization			Net Book Value
At December 31, 2016:
Capitalized software costs	$	1,572	$	(681	)	$	891
Trade names	106		—			106
Contracts	845		(43		)	802
Other	94		(48		)	46
Total	$	2,617	$	(772	)	$	1,845

Schedule of estimated future amortization of intangibles with finite useful lives

Estimated future amortization of intangibles with finite useful lives at September 30, 2017 is as follows:

			Three Months Ending		Years Ending								Later Years
			December 31,
	Total		2017		2018		2019		2020		2021
Amortization of intangible assets	$	1,097	$	47	$	152	$	135	$	104	$	92	$	567

Schedule of equity method investments

Summarized financial information for the equity method investees within our Ambulatory Care segment and the four equity method investee hospitals operated by our Hospital Operations and other segment are included in the following table. For investments acquired during the reported periods, amounts reflect 100% of the investee’s results beginning on the date of our acquisition of the investment.

	Three Months Ended September 30,				Nine Months Ended September 30,
	2017		2016		2017		2016
Net operating revenues	$	635	$	610	$	1,819	$	1,803
Net income	$	143	$	129	$	376	$	364
Net income attributable to the investees	$	93	$	83	$	242	$	241

XML

ACCOUNTS RECEIVABLE AND ALLOWANCE FOR DOUBTFUL ACCOUNTS (Tables)

9 Months Ended

Sep. 30, 2017

Accounts Receivable Additional Disclosures [Abstract]

Schedule of components of accounts receivable

The principal components of accounts receivable are shown in the table below: 

	September 30, 2017			December 31, 2016
Continuing operations:
Patient accounts receivable	$	3,371		$	3,799
Allowance for doubtful accounts	(934		)	(1,031		)
Estimated future recoveries	130			141
Net cost reports and settlements payable and valuation allowances	(2		)	(14		)
	2,565			2,895
Discontinued operations	2			2
Accounts receivable, net	$	2,567		$	2,897

Schedule of estimated costs for charity care and self-pay patients

The table below shows our estimated costs (based on selected operating expenses, which include salaries, wages and benefits, supplies and other operating expenses and which exclude the costs of our health plan businesses) of caring for our self-pay patients and charity care patients, and revenues attributable to Medicaid DSH and other supplemental revenues we recognized in three and nine months ended September 30, 2017 and 2016:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2017		2016		2017		2016
Estimated costs for:
Self-pay patients	$	164	$	158	$	484	$	453
Charity care patients	29		36		92		104
Total	$	193	$	194	$	576	$	557
Medicaid DSH and other supplemental revenues	$	140	$	249	$	462	$	691

XML

ASSETS AND LIABILITIES HELD FOR SALE ASSETS AND LIABILITIES HELD FOR SALE (Tables)

9 Months Ended

Sep. 30, 2017

Discontinued Operation, Additional Disclosures [Abstract]

Assets and liabilities classified as held for sale

Assets and liabilities classified as held for sale at September 30, 2017 were comprised of the following:

Accounts receivable	$	178
Other current assets	100
Investments and other long-term assets	20
Property and equipment	456
Other intangible assets	8
Goodwill	80
Current liabilities	(107		)
Long-term liabilities	(300		)
Net assets held for sale	$	435

XML

LONG-TERM DEBT AND LEASE OBLIGATIONS (Tables)

9 Months Ended

Sep. 30, 2017

Long-term Debt and Capital Lease Obligations [Abstract]

Summary of long-term debt

The table below shows our long-term debt at September 30, 2017 and December 31, 2016:

	September 30, 2017			December 31, 2016
Senior unsecured notes:
5.000% due 2019	$	—		$	1,100
5.500% due 2019	500			500
6.750% due 2020	300			300
8.000% due 2020	—			750
8.125% due 2022	2,800			2,800
6.750% due 2023	1,900			1,900
7.000% due 2025	500			—
6.875% due 2031	430			430
Senior secured notes:
6.250% due 2018	—			1,041
4.750% due 2020	500			500
6.000% due 2020	1,800			1,800
Floating % due 2020	—			900
4.500% due 2021	850			850
4.375% due 2021	1,050			1,050
7.500% due 2022	750			750
4.625% due 2024	1,870			—
5.125% due 2025	1,410			—
Capital leases	377			735
Mortgage notes	85			84
Unamortized issue costs, note discounts and premiums	(241		)	(235		)
Total long-term debt	14,881			15,255
Less current portion	140			191
Long-term debt, net of current portion	$	14,741		$	15,064

XML

EMPLOYEE BENEFIT PLANS (Tables)

9 Months Ended

Sep. 30, 2017

Defined Benefit Plan [Abstract]

Summary of stock option activity

The following table summarizes stock option activity during the nine months ended September 30, 2017:

	Options		Weighted Average Exercise Price Per Share		Aggregate Intrinsic Value		Weighted Average Remaining Life
					(In Millions)
Outstanding at December 31, 2016	1,435,921		$	22.87
Granted	1,396,307		18.24
Exercised	(16,525	)	4.56
Forfeited/Expired	(187,458	)	26.07
Outstanding at September 30, 2017	2,628,245		$	20.30	$	2	5.1 years
Vested and expected to vest at September 30, 2017	2,628,245		$	20.30	$	2	5.1 years
Exercisable at September 30, 2017	1,231,938		$	22.63	$	2	1.7 years

Schedule of assumptions used to determine fair value of stock options

The fair values were calculated based on the grant date, using a Monte Carlo simulation with the following assumptions:

	Three Months Ended March 31, 2017
Expected volatility	49%
Expected dividend yield	0%
Expected life	6.2 years
Expected forfeiture rate	0%
Risk-free interest rate	2.15%

Summary of information about stock options by range of exercise prices

The following table summarizes information about our outstanding stock options at September 30, 2017:

	Options Outstanding				Options Exercisable
Range of Exercise Prices	Number of Options	Weighted Average Remaining Contractual Life	Weighted Average Exercise Price		Number of Options	Weighted Average Exercise Price
$0.00 to $4.569	154,361	1.4 years	$	4.56	154,361	$	4.56
$4.57 to $19.759	1,396,607	8.1 years	18.24		300	14.52
$19.76 to $32.569	822,890	2.1 years	20.87		822,890	20.87
$32.57 to $42.529	254,387	0.4 years	39.31		254,387	39.31
	2,628,245	5.1 years	$	20.30	1,231,938	$	22.63

Summary of restricted stock unit activity

The following table summarizes restricted stock unit activity during the nine months ended September 30, 2017: 

	Restricted Stock Units		Weighted Average Grant Date Fair Value Per Unit
Unvested at December 31, 2016	3,174,533		$	38.75
Granted	643,329		18.65
Vested	(1,302,503	)	35.99
Forfeited	(93,618	)	37.62
Unvested at September 30, 2017	2,421,741		$	35.16

XML

EQUITY (Tables)

9 Months Ended

Sep. 30, 2017

Stockholders' Equity Note [Abstract]

Schedule of changes in consolidated equity

The following table shows the changes in consolidated equity during the nine months ended September 30, 2017 and 2016 (dollars in millions, share amounts in thousands):

	Tenet Healthcare Corporation Shareholders’ Equity
	Common Stock			Additional Paid-In Capital			Accumulated Other Comprehensive Loss			Accumulated Deficit			Treasury Stock			Noncontrolling Interests			Total Equity
	Shares Outstanding	Issued Par Amount
Balances at December 31, 2016	99,686	$	7	$	4,827		$	(258	)	$	(1,742	)	$	(2,417	)	$	665		$	1,082
Net income (loss)	—	—		—			—			(475		)	—			99			(376		)
Distributions paid to noncontrolling interests	—	—		—			—			—			—			(93		)	(93		)
Other comprehensive income	—	—		—			20			—			—			—			20
Accretion of redeemable noncontrolling interests	—	—		(32		)	—			—			—			—			(32		)
Purchases (sales) of businesses and noncontrolling interests	—	—		(4		)	—			—			—			—			(4		)
Cumulative effect of accounting change	—	—		—			—			56			—			—			56
Stock-based compensation expense, tax benefit and issuance of common stock	1,145	—		44			—			—			(2		)	—			42
Balances at September 30, 2017	100,831	$	7	$	4,835		$	(238	)	$	(2,161	)	$	(2,419	)	$	671		$	695
Balances at December 31, 2015	98,495	$	7	$	4,815		$	(164	)	$	(1,550	)	$	(2,417	)	$	267		$	958
Net income (loss)	—	—		—			—			(113		)	—			96			(17		)
Distributions paid to noncontrolling interests	—	—		—			—			—			—			(82		)	(82		)
Other comprehensive loss	—	—		—			(36		)	—			—			—			(36		)
Purchases (sales) of businesses and noncontrolling interests	—	—		(43		)	—			—			—			119			76
Purchase accounting adjustments	—	—		—			—			—			—			237			237
Stock-based compensation expense and issuance of common stock	1,033	—		29			—			—			—			—			29
Balances at September 30, 2016	99,528	$	7	$	4,801		$	(200	)	$	(1,663	)	$	(2,417	)	$	637		$	1,165

XML

CLAIMS AND LAWSUITS (Tables)

9 Months Ended

Sep. 30, 2017

Commitments and Contingencies Disclosure [Abstract]

Reconciliations of legal settlements and related costs

The table below presents reconciliations of the beginning and ending liability balances in connection with legal settlements and related costs recorded during the nine months ended September 30, 2017 and 2016: 

	Balances at Beginning of Period		Litigation and Investigation Costs		Cash Payments			Balances at End of Period
Nine Months Ended September 30, 2017
Continuing operations	$	12	$	12	$	(14	)	$	10
Discontinued operations	—		—		—			—
	$	12	$	12	$	(14	)	$	10
Nine Months Ended September 30, 2016
Continuing operations	$	299	$	291	$	(59	)	$	531
Discontinued operations	—		—		—			—
	$	299	$	291	$	(59	)	$	531

XML

REDEEMABLE NONCONTROLLING INTERESTS IN EQUITY OF CONSOLIDATED SUBSIDIARIES (Tables)

9 Months Ended

Sep. 30, 2017

Noncontrolling Interest [Abstract]

Schedule of changes in redeemable noncontrolling interests in equity of consolidated subsidiaries

The following table shows the changes in redeemable noncontrolling interests in equity of consolidated subsidiaries during the nine months ended September 30, 2017 and 2016:

	Nine Months Ended September 30,
	2017			2016
Balances at beginning of period	$	2,393		$	2,266
Net income	155			170
Distributions paid to noncontrolling interests	(85		)	(69		)
Purchase accounting adjustments	—			(47		)
Accretion of redeemable noncontrolling interests	32			—
Purchases and sales of businesses and noncontrolling interests, net	(679		)	(13		)
Balances at end of period	$	1,816		$	2,307

The following tables show the composition by segment of our redeemable noncontrolling interests balances at September 30, 2017 and December 31, 2016, as well as our net income attributable to redeemable noncontrolling interests for the nine months ended September 30, 2017 and 2016:

	September 30, 2017		December 31, 2016
Hospital Operations and other	$	529	$	520
Ambulatory Care	1,090		1,715
Conifer	197		158
Redeemable noncontrolling interests	$	1,816	$	2,393

	Nine Months Ended September 30,
	2017		2016
Hospital Operations and other	$	14	$	16
Ambulatory Care	103		116
Conifer	38		38
Net income attributable to redeemable noncontrolling interests	$	155	$	170

XML

INCOME TAXES (Tables)

9 Months Ended

Sep. 30, 2017

Income Tax Disclosure [Abstract]

Schedule of reconciliation between reported income tax expense (benefit) and income taxes calculated by the statutory federal income tax rate

	Three Months Ended September 30,						Nine Months Ended September 30,
	2017			2016			2017			2016
Tax expense (benefit) at statutory federal rate of 35%	$	(122	)	$	31		$	(114	)	$	77
State income taxes, net of federal income tax benefit	8			3			13			10
Tax benefit attributable to noncontrolling interests	(25		)	(28		)	(79		)	(75		)
Nondeductible goodwill	104			—			104			29
Nontaxable gains	—			(1		)	—			(18		)
Nondeductible litigation	—			4			—			37
Change in tax contingency reserves, including interest	(1		)	(1		)	(3		)	(4		)
Stock-based compensation	—			—			9			—
Change in indefinite reinvestment assertion	(30		)	—			(30		)	—
Change in valuation allowance	(5		)	—			(5		)	—
Other items	11			2			—			5
	$	(60	)	$	10		$	(105	)	$	61

XML

LOSS PER COMMON SHARE (Tables)

9 Months Ended

Sep. 30, 2017

Earnings Per Share [Abstract]

Schedule of reconciliation of numerators and denominators of our basic and diluted loss per common share

The following table is a reconciliation of the numerators and denominators of our basic and diluted loss per common share calculations for our continuing operations for three and nine months ended September 30, 2017 and 2016. Loss attributable to our common shareholders is expressed in millions and weighted average shares are expressed in thousands.

	Loss Attributable to Common Shareholders (Numerator)			Weighted Average Shares (Denominator)	Per-Share Amount
Three Months Ended September 30, 2017
Net loss attributable to Tenet Healthcare Corporation common shareholders for basic loss per share	$	(366	)	100,812	$	(3.63	)
Effect of dilutive stock options, restricted stock units and deferred compensation units	—			—	—
Net loss attributable to Tenet Healthcare Corporation common shareholders for diluted loss per share	$	(366	)	100,812	$	(3.63	)
Three Months Ended September 30, 2016
Net loss attributable to Tenet Healthcare Corporation common shareholders for basic loss per share	$	(9	)	99,523	$	(0.09	)
Effect of dilutive stock options, restricted stock units and deferred compensation units	—			—	—
Net loss attributable to Tenet Healthcare Corporation common shareholders for diluted loss per share	$	(9	)	99,523	$	(0.09	)
Nine Months Ended September 30, 2017
Net loss attributable to Tenet Healthcare Corporation common shareholders for basic loss per share	$	(474	)	100,475	$	(4.72	)
Effect of dilutive stock options, restricted stock units and deferred compensation units	—			—	—
Net loss attributable to Tenet Healthcare Corporation common shareholders for diluted loss per share	$	(474	)	100,475	$	(4.72	)
Nine Months Ended September 30, 2016
Net loss attributable to Tenet Healthcare Corporation common shareholders for basic loss per share	$	(108	)	99,210	$	(1.09	)
Effect of dilutive stock options, restricted stock units and deferred compensation units	—			—	—
Net loss attributable to Tenet Healthcare Corporation common shareholders for diluted loss per share	$	(108	)	99,210	$	(1.09	)

XML

FAIR VALUE MEASUREMENTS (Tables)

9 Months Ended

Sep. 30, 2017

Fair Value Disclosures [Abstract]

Schedule of assets and liabilities measured at fair value on a recurring basis

The following tables present information about our assets and liabilities that are measured at fair value on a recurring basis. The following tables also indicate the fair value hierarchy of the valuation techniques we utilized to determine such fair values. In general, fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. We consider a security that trades at least weekly to have an active market. Fair values determined by Level 2 inputs utilize data points that are observable, such as quoted prices, interest rates and yield curves. Fair values determined by Level 3 inputs are unobservable data points for the asset or liability, and include situations where there is little, if any, market activity for the asset or liability.

Investments	September 30, 2017		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Marketable debt securities — noncurrent	$	54	$	40	$	14	$	—
	$	54	$	40	$	14	$	—

Investments	December 31, 2016		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Marketable debt securities — noncurrent	$	49	$	23	$	26	$	—
	$	49	$	23	$	26	$	—

Our non-financial assets and liabilities not permitted or required to be measured at fair value on a recurring basis typically relate to long-lived assets held and used, long-lived assets held for sale and goodwill. We are required to provide additional disclosures about fair value measurements as part of our financial statements for each major category of assets and liabilities measured at fair value on a non-recurring basis. The following table presents this information and indicates the fair value hierarchy of the valuation techniques we utilized to determine such fair values. In general, fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities, which generally are not applicable to non-financial assets and liabilities. Fair values determined by Level 2 inputs utilize data points that are observable, such as definitive sales agreements, appraisals or established market values of comparable assets. Fair values determined by Level 3 inputs are unobservable data points for the asset or liability and include situations where there is little, if any, market activity for the asset or liability, such as internal estimates of future cash flows.

	September 30, 2017		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Long-lived assets held for sale	$	399	$	—	$	399	$	—
Other than temporarily impaired equity method investments	112		—		112		—
	$	511	$	—	$	511	$	—

	December 31, 2016		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Long-lived assets held and used	$	163	$	—	$	163	$	—
Other than temporarily impaired equity method investments	27		—		27		—
	$	190	$	—	$	190	$	—

XML

ACQUISITIONS (Tables)

9 Months Ended

Sep. 30, 2017

Business Combinations [Abstract]

Schedule of preliminary purchase price allocation

Preliminary purchase price allocations (representing the fair value of the consideration conveyed) for all acquisitions made during the nine months ended September 30, 2017 and 2016 are as follows:

	Nine Months Ended September 30,
	2017			2016
Current assets	$	4		$	42
Property and equipment	5			33
Other intangible assets	5			7
Goodwill	65			316
Other long-term assets	1			6
Current liabilities	(4		)	(25		)
Long-term liabilities	(1		)	(14		)
Redeemable noncontrolling interests	(18		)	(114		)
Noncontrolling interests	(13		)	(122		)
Cash paid, net of cash acquired	(41		)	(96		)
Gains on consolidations	$	3		$	33

XML

SEGMENT INFORMATION (Tables)

9 Months Ended

Sep. 30, 2017

Segment Reporting [Abstract]

Reconciliation of assets by reportable segment to consolidated assets

The following tables include amounts for each of our reportable segments and the reconciling items necessary to agree to amounts reported in the accompanying Condensed Consolidated Balance Sheets and Condensed Consolidated Statements of Operations:

	September 30, 2017		December 31, 2016
Assets:
Hospital Operations and other	$	16,249	$	17,871
Ambulatory Care	5,847		5,722
Conifer	1,112		1,108
Total	$	23,208	$	24,701

Reconciliation of other significant reconciling items from segments to consolidated

	Three Months Ended September 30,						Nine Months Ended September 30,
	2017			2016			2017			2016
Capital expenditures:
Hospital Operations and other	$	122		$	182		$	441		$	557
Ambulatory Care	16			14			37			42
Conifer	6			5			14			15
Total	$	144		$	201		$	492		$	614
Net operating revenues:
Hospital Operations and other total prior to inter-segment eliminations(1)	$	3,866		$	4,162		$	12,066		$	12,761
Ambulatory Care	468			448			1,395			1,319
Conifer
Tenet	149			159			463			488
Other customers	252			239			740			681
Total Conifer	401			398			1,203			1,169
Inter-segment eliminations	(149		)	(159		)	(463		)	(488		)
Total	$	4,586		$	4,849		$	14,201		$	14,761
Equity in earnings of unconsolidated affiliates:
Hospital Operations and other	$	4		$	3		$	4		$	6
Ambulatory Care	34			28			91			79
Total	$	38		$	31		$	95		$	85
Adjusted EBITDA:
Hospital Operations and other(2)	$	269		$	346		$	924		$	1,191
Ambulatory Care	159			157			476			432
Conifer	79			79			204			205
Total	$	507		$	582		$	1,604		$	1,828
Depreciation and amortization:
Hospital Operations and other	$	185		$	170		$	560		$	525
Ambulatory Care	22			22			66			69
Conifer	12			13			36			38
Total	$	219		$	205		$	662		$	632

	Three Months Ended September 30,						Nine Months Ended September 30,
	2017			2016			2017			2016
Adjusted EBITDA	$	507		$	582		$	1,604		$	1,828
Loss from divested and closed businesses (i.e., the Company’s health plan businesses)	(6		)	(6		)	(41		)	(8		)
Depreciation and amortization	(219		)	(205		)	(662		)	(632		)
Impairment and restructuring charges, and acquisition-related costs	(329		)	(31		)	(403		)	(81		)
Litigation and investigation costs	(6		)	(4		)	(12		)	(291		)
Interest expense	(257		)	(243		)	(775		)	(730		)
Loss from early extinguishment of debt	(138		)	—			(164		)	—
Other non-operating expense, net	(4		)	(7		)	(14		)	(18		)
Gains on sales, consolidation and deconsolidation of facilities	104			3			142			151
Net income (loss) from continuing operations before income taxes	$	(348	)	$	89		$	(325	)	$	219

(1) Hospital Operations and other revenues includes health plan revenues of $10 million and $100 million for the three and nine months ended September 30, 2017, respectively, and $122 million and $385 million for the three and nine months ended September 30, 2016, respectively.

(2) Hospital Operations and other Adjusted EBITDA excludes health plan EBITDA of $(6) million and $(41) million for the three and nine months ended September 30, 2017, respectively, and $(6) million and $(8) million for the three and nine months ended September 30, 2016, respectively.

XML

BASIS OF PRESENTATION (Details)	9 Months Ended
	Sep. 30, 2017 hospital center
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of hospitals	77
Number of surgical hospitals	20
Number of outpatient centers | center	460

XML

BASIS OF PRESENTATION - ASU Adoption (Details) - USD ($) $ in Millions	3 Months Ended			9 Months Ended		12 Months Ended
	Sep. 30, 2017	Dec. 31, 2016	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2015	Jan. 01, 2017
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Deferred income tax assets	$ 783	$ 871		$ 783
Retained earnings	(2,161)	(1,742)		(2,161)
Salaries, wages and benefits	2,264		$ 2,308	6,990	$ 7,012
Other non-operating expense, net	$ (4)		$ (7)	(14)	(18)
Accounting Standards Update 2016 09
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Deferred income tax assets							$ 56
Retained earnings							$ 56
Accounting Standards Update 2017 07 | Adjustments for New Accounting Principle, Early Adoption
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Salaries, wages and benefits		(8)		(20)	(20)	$ (21)
Other non-operating expense, net		$ 8		$ 20	$ 20	$ 21

XML

BASIS OF PRESENTATION - Revenues (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Supplemental payments and net operating revenues
Net operating revenues before provision for doubtful accounts	$ 4,941	$ 5,216	$ 15,310	$ 15,856
Operating segments | Hospital Operations and other
Supplemental payments and net operating revenues
Net operating revenues before provision for doubtful accounts	4,212	4,520	13,148	13,829
Operating segments | Hospital Operations and other | Medicare
Supplemental payments and net operating revenues
Net operating revenues before provision for doubtful accounts	809	844	2,563	2,658
Operating segments | Hospital Operations and other | Medicaid
Supplemental payments and net operating revenues
Net operating revenues before provision for doubtful accounts	256	339	822	1,009
Operating segments | Hospital Operations and other | Managed care
Supplemental payments and net operating revenues
Net operating revenues before provision for doubtful accounts	2,524	2,729	7,867	8,031
Operating segments | Hospital Operations and other | Indemnity, self-pay and other
Supplemental payments and net operating revenues
Net operating revenues before provision for doubtful accounts	442	328	1,316	1,264
Operating segments | Hospital Operations and other | Net patient revenues
Supplemental payments and net operating revenues
Net operating revenues before provision for doubtful accounts	4,031	4,240	12,568	12,962
Operating segments | Hospital Operations and other | Health plans
Supplemental payments and net operating revenues
Net operating revenues before provision for doubtful accounts	10	122	100	385
Operating segments | Hospital Operations and other | Revenue from other sources
Supplemental payments and net operating revenues
Net operating revenues before provision for doubtful accounts	171	158	480	482
Operating segments | Hospital Operations and other | Physician practices
Supplemental payments and net operating revenues
Net operating revenues before provision for doubtful accounts	171	179	551	558
Operating segments | Ambulatory Care | Ambulatory Care
Supplemental payments and net operating revenues
Net operating revenues before provision for doubtful accounts	477	457	1,422	1,346
Operating segments | Conifer | Conifer
Supplemental payments and net operating revenues
Net operating revenues before provision for doubtful accounts	401	398	1,203	1,169
Inter-segment eliminations
Supplemental payments and net operating revenues
Net operating revenues before provision for doubtful accounts	$ (149)	$ (159)	$ (463)	$ (488)

XML

BASIS OF PRESENTATION - Cash and Cash Equivalents (Details) - USD ($) $ in Millions	9 Months Ended		12 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016	Dec. 31, 2015
Cash and Cash Equivalents
Cash and cash equivalents	$ 429	$ 649	$ 716	$ 356
Accrued property and equipment purchases for items received but not yet paid	89		179
Non-cancellable capital leases primarily for buildings and equipment	82	$ 110
Captive insurance subsidiaries
Cash and Cash Equivalents
Cash and cash equivalents	167		147
Health plan-related businesses
Cash and Cash Equivalents
Cash and cash equivalents	62		85
Accounts payable
Cash and Cash Equivalents
Book overdrafts classified as accounts payable	240		279
Accrued property and equipment purchases for items received but not yet paid	$ 57		$ 141

XML

BASIS OF PRESENTATION - Intangible Assets Summary (Details) - USD ($) $ in Millions	Sep. 30, 2017	Dec. 31, 2016
Other intangible assets
Gross Carrying Amount	$ 2,605	$ 2,617
Accumulated Amortization	(841)	(772)
Net Book Value	1,764	1,845
Capitalized software costs
Other intangible assets
Gross Carrying Amount	1,537	1,572
Accumulated Amortization	(721)	(681)
Net Book Value	816	891
Trade names
Other intangible assets
Gross Carrying Amount	105	106
Accumulated Amortization	0	0
Net Book Value	105	106
Contracts
Other intangible assets
Gross Carrying Amount	855	845
Accumulated Amortization	(55)	(43)
Net Book Value	800	802
Other
Other intangible assets
Gross Carrying Amount	108	94
Accumulated Amortization	(65)	(48)
Net Book Value	$ 43	$ 46

XML

BASIS OF PRESENTATION - Amortization of Intangible Assets (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Estimated future amortization of intangibles with finite useful lives
Total	$ 1,097
2017	47
2018	152
2019	135
2020	104
2021	92
Later Years	567
Amortization expense	$ 125	$ 111

XML

BASIS OF PRESENTATION - Investments in Unconsolidated Affiliates (Details) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2017 USD ($)	Sep. 30, 2016 USD ($)	Sep. 30, 2017 USD ($) hospital center	Sep. 30, 2016 USD ($)
Schedule of Equity Method Investments [Line Items]
Number of outpatient centers | center			460
Investee results reflected			1
Net operating revenues | $	$ 635	$ 610	$ 1,819	$ 1,803
Net income | $	143	129	376	364
Net income attributable to the investees | $	$ 93	$ 83	$ 242	$ 241
Ambulatory Care
Schedule of Equity Method Investments [Line Items]
Number of outpatient centers recorded not using equity method			220
Number of outpatient centers recorded using equity method			109
Number of outpatient centers			329
Hospital Operations and other
Schedule of Equity Method Investments [Line Items]
Number of outpatient centers recorded using equity method			11
Number of hospitals recorded using equity method			4

XML

ACCOUNTS RECEIVABLE AND ALLOWANCE FOR DOUBTFUL ACCOUNTS - Components (Details) - USD ($) $ in Millions	Sep. 30, 2017	Dec. 31, 2016
Accounts receivable and allowance for doubtful accounts
Accounts receivable, net	$ 2,567	$ 2,897
Continuing operations
Accounts receivable and allowance for doubtful accounts
Patient accounts receivable	3,371	3,799
Allowance for doubtful accounts	(934)	(1,031)
Estimated future recoveries	130	141
Net cost reports and settlements payable and valuation allowances	(2)	(14)
Accounts receivable, net	2,565	2,895
Discontinued operations
Accounts receivable and allowance for doubtful accounts
Accounts receivable, net	$ 2	$ 2

XML

ACCOUNTS RECEIVABLE AND ALLOWANCE FOR DOUBTFUL ACCOUNTS - Allowance (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Accounts receivable and allowance for doubtful accounts
Allowance for doubtful accounts as a percent of patients accounts receivable			27.70%		27.10%
Estimated costs of caring	$ 193	$ 194	$ 576	$ 557
Self-pay patients
Accounts receivable and allowance for doubtful accounts
Estimated costs of caring	164	158	484	453
Charity care patients
Accounts receivable and allowance for doubtful accounts
Estimated costs of caring	29	36	92	104
Medicaid DSH and other supplemental revenues
Accounts receivable and allowance for doubtful accounts
Estimated costs of caring	$ 140	$ 249	$ 462	$ 691

XML

ACCOUNTS RECEIVABLE AND ALLOWANCE FOR DOUBTFUL ACCOUNTS - Other Receivables (Details) - USD ($) $ in Millions	Sep. 30, 2017	Dec. 31, 2016
Accounts receivable and allowance for doubtful accounts
Receivables	$ 2,567	$ 2,897
Payables	1,100	1,329
California's Provider Fee Program | Other current assets
Accounts receivable and allowance for doubtful accounts
Receivables	375	537
California's Provider Fee Program | Other current liabilities
Accounts receivable and allowance for doubtful accounts
Payables	$ 56	$ 139

XML

ASSETS AND LIABILITIES HELD FOR SALE (Details) $ in Millions			3 Months Ended		9 Months Ended
	Aug. 01, 2017 USD ($)	Mar. 31, 2016 USD ($)	Sep. 30, 2017 USD ($) hospital	Sep. 30, 2016 USD ($)	Sep. 30, 2017 USD ($) hospital	Sep. 30, 2016 USD ($)	Dec. 31, 2016 USD ($)
Current Assets and Liabilities Held for Sale
Number of hospitals | hospital					77
Impairment charges					$ 3	$ 2
Proceeds from sales of facilities and other assets					826	573
Gain on sale			$ 104	$ 3	142	$ 151
Net receivables			2,567		2,567		$ 2,897
Philadelphia Facilities | Discontinued Operations, Held-for-sale
Current Assets and Liabilities Held for Sale
Assets held for sale			222		222
Liabilities held for sale			52		52
Impairment charges			235
Chicago Facilities | Discontinued Operations, Held-for-sale
Current Assets and Liabilities Held for Sale
Assets held for sale			222		222
Liabilities held for sale			33		33
United Kingdom Facilities | Discontinued Operations, Held-for-sale
Current Assets and Liabilities Held for Sale
Assets held for sale			398		398
Liabilities held for sale			$ 322		$ 322
Number of hospitals | hospital			9
Impairment charges			$ 59
Houston, Texas Facilities | Disposal Group, Disposed of by Sale, Not Discontinued Operations
Current Assets and Liabilities Held for Sale
Proceeds from sales of facilities and other assets	$ 750
Gain on sale	$ 111
Michigan Facilities | Disposal Group, Disposed of by Sale, Not Discontinued Operations
Current Assets and Liabilities Held for Sale
Proceeds from sales of facilities and other assets			20
Gain on sale			3
Arizona Facilities | Disposal Group, Disposed of by Sale, Not Discontinued Operations
Current Assets and Liabilities Held for Sale
Proceeds from sales of facilities and other assets			13
Gain on sale			13
Texas Facilities | Disposal Group, Disposed of by Sale, Not Discontinued Operations
Current Assets and Liabilities Held for Sale
Proceeds from sales of facilities and other assets			12
Gain on sale			$ 10
Georgia Facilities | Disposal Group, Disposed of by Sale, Not Discontinued Operations
Current Assets and Liabilities Held for Sale
Proceeds from sales of facilities and other assets		$ 575
Gain on sale		113
Net receivables		$ 17

XML

ASSETS AND LIABILITIES HELD FOR SALE - Net Assets Held For Sale (Details) - USD ($) $ in Millions	Sep. 30, 2017	Dec. 31, 2016
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Current liabilities	$ (407)	$ (9)
Hospital Operations and other | Discontinued Operations, Held-for-sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Accounts receivable	178
Other current assets	100
Investments and other long-term assets	20
Property and equipment	456
Other intangible assets	8
Goodwill	80
Current liabilities	(107)
Long-term liabilities	(300)
Net assets held for sale	$ 435

XML

IMPAIRMENT AND RESTRUCTURING CHARGES, AND ACQUISITION-RELATED COSTS (Details) $ in Millions	9 Months Ended
	Sep. 30, 2017 USD ($) segment investment	Sep. 30, 2016 USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net impairment and restructuring charges and acquisition-related costs	$ 403	$ 81
Impairment charges	3	2
Equity method investment impairment	$ 29
Number of impaired equity method investments | investment	2
Employee severance costs	$ 40	26
Contract and lease termination costs	8	4
Restructuring costs	13	9
Acquisition costs	16	40
Acquisition-related transaction costs	5	5
Acquisition integration charges	$ 11	$ 35
Number of continuing operating segments | segment	3
Hospital Operations and other
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net impairment and restructuring charges and acquisition-related costs	$ 319
Ambulatory Care
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net impairment and restructuring charges and acquisition-related costs	70
Conifer
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net impairment and restructuring charges and acquisition-related costs	14
Discontinued Operations, Held-for-sale | Aspen And Philadelphia Area Facilities
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Impairment charges	$ 294

XML

LONG-TERM DEBT AND LEASE OBLIGATIONS - Schedule of Debt (Details) - USD ($) $ in Millions	Sep. 30, 2017	Sep. 11, 2017	Aug. 01, 2017	Jul. 14, 2017	Jun. 14, 2017	Dec. 31, 2016
LONG-TERM DEBT AND LEASE OBLIGATIONS
Capital leases	$ 377					$ 735
Mortgage notes	85					84
Unamortized issue costs, note discounts and premiums	(241)					(235)
Total long-term debt	14,881					15,255
Less current portion	140					191
Long-term debt, net of current portion	$ 14,741					15,064
Senior Notes | 5.000% due 2019
LONG-TERM DEBT AND LEASE OBLIGATIONS
Interest rate, stated percentage	5.00%			5.00%
Carrying amount	$ 0					1,100
Senior Notes | 5.500% due 2019
LONG-TERM DEBT AND LEASE OBLIGATIONS
Interest rate, stated percentage	5.50%
Carrying amount	$ 500					500
Senior Notes | 6.750% due 2020
LONG-TERM DEBT AND LEASE OBLIGATIONS
Interest rate, stated percentage	6.75%
Carrying amount	$ 300					300
Senior Notes | 8.000% due 2020
LONG-TERM DEBT AND LEASE OBLIGATIONS
Interest rate, stated percentage	8.00%	8.00%	8.00%
Carrying amount	$ 0					750
Senior Notes | 8.125% due 2022
LONG-TERM DEBT AND LEASE OBLIGATIONS
Interest rate, stated percentage	8.125%
Carrying amount	$ 2,800					2,800
Senior Notes | 6.750% due 2023
LONG-TERM DEBT AND LEASE OBLIGATIONS
Interest rate, stated percentage	6.75%
Carrying amount	$ 1,900					1,900
Senior Notes | 7.000% due 2025
LONG-TERM DEBT AND LEASE OBLIGATIONS
Interest rate, stated percentage	7.00%				7.00%
Carrying amount	$ 500					0
Senior Notes | 6.875% due 2031
LONG-TERM DEBT AND LEASE OBLIGATIONS
Interest rate, stated percentage	6.875%
Carrying amount	$ 430					430
Senior Notes | 6.250% due 2018
LONG-TERM DEBT AND LEASE OBLIGATIONS
Interest rate, stated percentage	6.25%			6.25%
Carrying amount	$ 0					1,041
Senior Notes | 4.750% due 2020
LONG-TERM DEBT AND LEASE OBLIGATIONS
Interest rate, stated percentage	4.75%
Carrying amount	$ 500					500
Senior Notes | 6.000% due 2020
LONG-TERM DEBT AND LEASE OBLIGATIONS
Interest rate, stated percentage	6.00%
Carrying amount	$ 1,800					1,800
Senior Notes | Floating % due 2020
LONG-TERM DEBT AND LEASE OBLIGATIONS
Carrying amount	$ 0					900
Senior Notes | 4.500% due 2021
LONG-TERM DEBT AND LEASE OBLIGATIONS
Interest rate, stated percentage	4.50%
Carrying amount	$ 850					850
Senior Notes | 4.375% due 2021
LONG-TERM DEBT AND LEASE OBLIGATIONS
Interest rate, stated percentage	4.375%
Carrying amount	$ 1,050					1,050
Senior Notes | 7.500% due 2022
LONG-TERM DEBT AND LEASE OBLIGATIONS
Interest rate, stated percentage	7.50%
Carrying amount	$ 750					750
Senior Notes | 4.625% due 2024
LONG-TERM DEBT AND LEASE OBLIGATIONS
Interest rate, stated percentage	4.625%				4.625%
Carrying amount	$ 1,870					0
Senior Notes | 5.125% due 2025
LONG-TERM DEBT AND LEASE OBLIGATIONS
Interest rate, stated percentage	5.125%				5.125%
Carrying amount	$ 1,410					$ 0

XML

LONG-TERM DEBT AND LEASE OBLIGATIONS - Senior Secured and Senior Secured Notes (Details) - USD ($)	3 Months Ended			9 Months Ended
	Sep. 30, 2017	Jun. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Sep. 11, 2017	Aug. 01, 2017	Jul. 14, 2017	Jun. 14, 2017
LONG-TERM DEBT AND LEASE OBLIGATIONS
Loss from early extinguishment of debt	$ 138,000,000		$ 0	$ 164,000,000	$ 0
Senior Notes
LONG-TERM DEBT AND LEASE OBLIGATIONS
Loss from early extinguishment of debt		$ 26,000,000
Senior Notes | 4.625% due 2024
LONG-TERM DEBT AND LEASE OBLIGATIONS
Aggregate principal amount									$ 830,000,000
Interest rate, stated percentage	4.625%			4.625%					4.625%
Senior Notes | Floating % due 2020
LONG-TERM DEBT AND LEASE OBLIGATIONS
Repurchased face amount									$ 900,000,000
Loss from early extinguishment of debt	$ 138,000,000
Senior Notes | Escrow Secured First Lien Notes
LONG-TERM DEBT AND LEASE OBLIGATIONS
Aggregate principal amount									$ 1,040,000,000.000
Interest rate, stated percentage									4.625%
Senior Notes | 5.125% due 2025
LONG-TERM DEBT AND LEASE OBLIGATIONS
Aggregate principal amount									$ 1,410,000,000.000
Interest rate, stated percentage	5.125%			5.125%					5.125%
Senior Notes | 7.000% due 2025
LONG-TERM DEBT AND LEASE OBLIGATIONS
Aggregate principal amount									$ 500,000,000
Interest rate, stated percentage	7.00%			7.00%					7.00%
Senior Notes | 6.250% due 2018
LONG-TERM DEBT AND LEASE OBLIGATIONS
Interest rate, stated percentage	6.25%			6.25%				6.25%
Repurchased face amount								$ 1,041,000,000
Senior Notes | 5.000% due 2019
LONG-TERM DEBT AND LEASE OBLIGATIONS
Interest rate, stated percentage	5.00%			5.00%				5.00%
Repurchased face amount								$ 1,100,000,000
Senior Notes | 8.000% due 2020
LONG-TERM DEBT AND LEASE OBLIGATIONS
Interest rate, stated percentage	8.00%			8.00%		8.00%	8.00%
Repurchased face amount						$ 250,000,000	$ 500,000,000

XML

LONG-TERM DEBT AND LEASE OBLIGATIONS - Credit Agreement and Letter of Credit Facility (Details)	9 Months Ended
	Sep. 30, 2017 USD ($)
Credit Agreement
LONG-TERM DEBT AND LEASE OBLIGATIONS
Revolving credit facility, maximum borrowing capacity (up to)	$ 1,000,000,000
Line of credit facility, subfacility maximum available capacity	300,000,000
Borrowings outstanding	0
Standby letters of credit outstanding	2,000,000
Amount available for borrowing under revolving credit facility	$ 998,000,000
Credit Agreement | Minimum
LONG-TERM DEBT AND LEASE OBLIGATIONS
Unused commitment fee	0.25%
Credit Agreement | Maximum
LONG-TERM DEBT AND LEASE OBLIGATIONS
Unused commitment fee	0.375%
Credit Agreement | Base rate | Minimum
LONG-TERM DEBT AND LEASE OBLIGATIONS
Margin on variable rate	0.25%
Credit Agreement | Base rate | Maximum
LONG-TERM DEBT AND LEASE OBLIGATIONS
Margin on variable rate	0.75%
Credit Agreement | LIBOR | Minimum
LONG-TERM DEBT AND LEASE OBLIGATIONS
Margin on variable rate	1.25%
Credit Agreement | LIBOR | Maximum
LONG-TERM DEBT AND LEASE OBLIGATIONS
Margin on variable rate	1.75%
Letter of Credit Facility
LONG-TERM DEBT AND LEASE OBLIGATIONS
Revolving credit facility, maximum borrowing capacity (up to)	$ 180,000,000
Unused commitment fee	0.25%
Standby letters of credit outstanding	$ 105,000,000
Borrowing capacity after increase subject to certain conditions (up to)	$ 200,000,000
Secured debt to EBITDA ratio	3.00
Issuance fee	1.50%
Issuance fee, based on face amount	0.125%
Letter of Credit Facility | Maximum
LONG-TERM DEBT AND LEASE OBLIGATIONS
Number of business days after notice, for reimbursement of amount drawn	3 days
Unused commitment fee after step down (up to)	0.375%
Letter of Credit Facility | Base rate
LONG-TERM DEBT AND LEASE OBLIGATIONS
Margin on variable rate	0.50%

XML

GUARANTEES (Details) $ in Millions	Sep. 30, 2017 USD ($)
Income and Revenue Collection Guarantee
GUARANTEES
Maximum potential amount of future payments under guarantees	$ 172
Income and Revenue Collection Guarantee | Other current liabilities
GUARANTEES
Liability for the fair value of guarantees	139
Guaranteed Investees Of Third Parties
GUARANTEES
Liability for the fair value of guarantees	23
Guaranteed Investees Of Third Parties | Other current liabilities
GUARANTEES
Guarantee obligations for consolidated subsidiaries	$ 17

XML

EMPLOYEE BENEFIT PLANS (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
EMPLOYEE BENEFIT PLANS
Stock-based compensation costs, pretax	$ 44	$ 46
2008 Stock Incentive Plan
EMPLOYEE BENEFIT PLANS
Shares available for issuance under the plan (in shares)	5,600,000
Shares available assuming maximum performance (in shares)	4,600,000
Stock Options
EMPLOYEE BENEFIT PLANS
Expiration period from the date of grant	10 years
Portion of awards vesting on each of the first three anniversary dates of the grant	33.33%
Vesting period	3 years
Restricted Stock Units
EMPLOYEE BENEFIT PLANS
Contractual right to receive shares of common stock for a stock based award (in shares)	1
Portion of awards vesting on each of the first three anniversary dates of the grant	33.33%
Vesting period	3 years

XML

EMPLOYEE BENEFIT PLANS - Stock Options (Details) - USD ($) $ / shares in Units, $ in Millions		3 Months Ended	9 Months Ended
	Sep. 29, 2017	Mar. 31, 2017	Sep. 30, 2017	Sep. 30, 2016
Weighted Average Remaining Life
Weighted average estimated fair value of awards granted (in dollars per share)		$ 8.52
Assumptions used to calculate fair value of awards granted to top eleven employees
Expected volatility		49.00%
Expected dividend yield		0.00%
Expected life		6 years 2 months 12 days
Expected forfeiture rate		0.00%
Risk-free interest rate		2.15%
Stock Options
Options
Outstanding at the beginning of the period (in shares)		1,435,921	1,435,921
Granted (in shares)			1,396,307
Exercised (in shares)			(16,525)	(110,715)
Forfeited/Expired (in shares)			(187,458)
Outstanding at the end of the period (in shares)			2,628,245
Vested and expected to vest at the end of the period (in shares)			2,628,245
Exercisable at the end of the period (in shares)			1,231,938
Weighted Average Exercise Price Per Share
Outstanding at the beginning of the period (in dollars per share)		$ 22.87	$ 22.87
Granted (in dollars per share)			18.24
Exercised (in dollars per share)			4.56
Forfeited/Expired (in dollars per share)			26.07
Outstanding at the end of the period (in dollars per share)			20.30
Vested and expected to vest at the end of the period (in dollars per share)			20.30
Exercisable at the end of the period (in dollars per share)			$ 22.63
Aggregate Intrinsic Value
Outstanding at the end of the period			$ 2
Vested and expected to vest at the end of the period			2
Exercisable at the end of the period			$ 2
Weighted Average Remaining Life
Outstanding at the end of the period			5 years 1 month 7 days
Vested and expected to vest at the end of the period			5 years 1 month 7 days
Exercisable at the end of the period			1 year 7 months 29 days
Aggregate Intrinsic value of awards exercised (less than $1 million - 2017)			$ 1	$ 1
Unrecognized compensation costs			$ 9
Period for recognition of unrecognized compensation costs			2 years 22 days
Granted (in shares)				0
Vesting period			3 years
Stock Options | 2008 Stock Incentive Plan | Senior Officers
Options
Granted (in shares)		987,781
Weighted Average Remaining Life
Target closing stock price (in dollars per share)		$ 23.74
Stock price premium		25.00%
Share price (in dollars per share)		$ 18.99
Number of consecutive trading days (at least)		20 days
Vesting date of grant anniversary subject to specific conditions		3 years
Performance Shares | 2008 Stock Incentive Plan | Executive Chairman
Options
Granted (in shares)	408,526
Weighted Average Remaining Life
Number of consecutive trading days (at least)	30 days
Vesting date of grant anniversary subject to specific conditions	4 years
Weighted average estimated fair value of awards granted (in dollars per share)	$ 5.63
Weighted average estimated fair value of awards granted subject to conditions (in dollars per share)	$ 20.53

XML

EMPLOYEE BENEFIT PLANS - Range of Exercise Prices (Details) - Stock Options	9 Months Ended
	Sep. 30, 2017 $ / shares shares
Options Outstanding
Number of Options Outstanding (in shares) | shares	2,628,245
Weighted Average Remaining Contractual Life	5 years 1 month 6 days
Weighted Average Exercise Price (in dollars per share)	$ 20.30
Options Exercisable
Number of Options Exercisable (in shares) | shares	1,231,938
Weighted Average Exercise Price (in dollars per share)	$ 22.63
$0.00 to $4.569
Summary information about outstanding stock options
Exercise price per share, low end of the range (in dollars per share)	0
Exercise price per share, high end of the range (in dollars per share)	$ 4.569
Options Outstanding
Number of Options Outstanding (in shares) | shares	154,361
Weighted Average Remaining Contractual Life	1 year 4 months 28 days
Weighted Average Exercise Price (in dollars per share)	$ 4.56
Options Exercisable
Number of Options Exercisable (in shares) | shares	154,361
Weighted Average Exercise Price (in dollars per share)	$ 4.56
$4.57 to $19.759
Summary information about outstanding stock options
Exercise price per share, low end of the range (in dollars per share)	4.57
Exercise price per share, high end of the range (in dollars per share)	$ 19.759
Options Outstanding
Number of Options Outstanding (in shares) | shares	1,396,607
Weighted Average Remaining Contractual Life	8 years 1 month 17 days
Weighted Average Exercise Price (in dollars per share)	$ 18.24
Options Exercisable
Number of Options Exercisable (in shares) | shares	300
Weighted Average Exercise Price (in dollars per share)	$ 14.52
$19.76 to $32.569
Summary information about outstanding stock options
Exercise price per share, low end of the range (in dollars per share)	19.76
Exercise price per share, high end of the range (in dollars per share)	$ 32.569
Options Outstanding
Number of Options Outstanding (in shares) | shares	822,890
Weighted Average Remaining Contractual Life	2 years 1 month 5 days
Weighted Average Exercise Price (in dollars per share)	$ 20.87
Options Exercisable
Number of Options Exercisable (in shares) | shares	822,890
Weighted Average Exercise Price (in dollars per share)	$ 20.87
$32.57 to $42.529
Summary information about outstanding stock options
Exercise price per share, low end of the range (in dollars per share)	32.57
Exercise price per share, high end of the range (in dollars per share)	$ 42.529
Options Outstanding
Number of Options Outstanding (in shares) | shares	254,387
Weighted Average Remaining Contractual Life	5 months
Weighted Average Exercise Price (in dollars per share)	$ 39.31
Options Exercisable
Number of Options Exercisable (in shares) | shares	254,387
Weighted Average Exercise Price (in dollars per share)	$ 39.31

XML

EMPLOYEE BENEFIT PLANS - Restricted Stock Units (Details) - Restricted Stock Units $ / shares in Units, $ in Millions	9 Months Ended
	Sep. 30, 2017 USD ($) $ / shares shares
Restricted Stock Units
Unvested at the beginning of the period (in shares)	3,174,533
Granted (in shares)	643,329
Vested (in shares)	(1,302,503)
Forfeited (in shares)	(93,618)
Unvested at the end of the period (in shares)	2,421,741
Weighted Average Grant Date Fair Value Per Unit
Unvested at the beginning of the period (in dollars per share) | $ / shares	$ 38.75
Granted (in dollars per share) | $ / shares	18.65
Vested (in dollars per share) | $ / shares	35.99
Forfeited (in dollars per share) | $ / shares	37.62
Unvested at the end of the period (in dollars per share) | $ / shares	$ 35.16
Vesting period	3 years
Unrecognized compensation costs | $	$ 44
Period for recognition of unrecognized compensation costs	1 year 9 months 18 days
Time-vesting
Restricted Stock Units
Granted (in shares)	643,329
Weighted Average Grant Date Fair Value Per Unit
Restricted stock that will vest and be settled over a three-year period from the grant date (in shares)	630,426
Vesting period	3 years
Performance-based vesting
Weighted Average Grant Date Fair Value Per Unit
Restricted stock that will vest and be settled over a three-year period from the grant date (in shares)	12,903
Performance-based vesting | Minimum
Weighted Average Grant Date Fair Value Per Unit
Percentage of restricted stock units, which will vest three years from the grant date	0.00%
Performance-based vesting | Maximum
Weighted Average Grant Date Fair Value Per Unit
Percentage of restricted stock units, which will vest three years from the grant date	200.00%

XML

EMPLOYEE BENEFIT PLANS - Employee Retirement Plans (Details) $ in Millions	9 Months Ended
	Sep. 30, 2017 USD ($) plan	Sep. 30, 2016 USD ($) plan
Employee Retirement Plans
Number of frozen plans | plan	1	1
Salaries, wages and benefits expense
Employee Retirement Plans
Service costs	$ 1	$ 1
Other non-operating income (expense), net
Employee Retirement Plans
Other components	$ 20	$ 20

XML

EQUITY - Changes in Shareholders' Equity (Details) - USD ($) shares in Thousands, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Changes in Shareholders' Equity
Balance, beginning of period			$ 1,082	$ 958
Net income (loss)			(376)	(17)
Distributions paid to noncontrolling interests			(93)	(82)
Other comprehensive income (loss)	$ 4	$ 3	20	(36)
Accretion of redeemable noncontrolling interests			(32)
Purchases (sales) of businesses and noncontrolling interests			(4)	76
Cumulative effect of accounting change	56		56
Purchase accounting adjustments				237
Stock-based compensation expense and issuance of common stock			42	29
Balance, end of period	$ 695	$ 1,165	$ 695	$ 1,165
Common Stock
Changes in Shareholders' Equity
Balances, beginning of period (in shares)			99,686	98,495
Balance, beginning of period			$ 7	$ 7
Stock-based compensation expense and issuance of common stock (in shares)			1,145	1,033
Balances, end of period (in shares)	100,831	99,528	100,831	99,528
Balance, end of period	$ 7	$ 7	$ 7	$ 7
Additional Paid-In Capital
Changes in Shareholders' Equity
Balance, beginning of period			4,827	4,815
Accretion of redeemable noncontrolling interests			(32)
Purchases (sales) of businesses and noncontrolling interests			(4)	(43)
Stock-based compensation expense and issuance of common stock			44	29
Balance, end of period	4,835	4,801	4,835	4,801
Accumulated Other Comprehensive Loss
Changes in Shareholders' Equity
Balance, beginning of period			(258)	(164)
Other comprehensive income (loss)			20	(36)
Balance, end of period	(238)	(200)	(238)	(200)
Accumulated Deficit
Changes in Shareholders' Equity
Balance, beginning of period			(1,742)	(1,550)
Net income (loss)			(475)	(113)
Cumulative effect of accounting change	56		56
Balance, end of period	(2,161)	(1,663)	(2,161)	(1,663)
Treasury Stock
Changes in Shareholders' Equity
Balance, beginning of period			(2,417)	(2,417)
Stock-based compensation expense and issuance of common stock			(2)	0
Balance, end of period	(2,419)	(2,417)	(2,419)	(2,417)
Noncontrolling Interests
Changes in Shareholders' Equity
Balance, beginning of period			665	267
Net income (loss)			99	96
Distributions paid to noncontrolling interests			(93)	(82)
Purchases (sales) of businesses and noncontrolling interests			0	119
Purchase accounting adjustments				237
Balance, end of period	$ 671	$ 637	$ 671	$ 637

XML

EQUITY - Changes in Shareholders' Equity - Noncontrolling interests (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016	Dec. 31, 2015
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stockholders equity balance	$ 695	$ 1,165	$ 1,082	$ 958
Net income	(376)	(17)
Noncontrolling Interests
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stockholders equity balance	671	637	665	$ 267
Net income	99	96
Noncontrolling Interests | Hospital Operations and other
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stockholders equity balance	70		89
Net income	9	8
Noncontrolling Interests | Ambulatory Care
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stockholders equity balance	601		$ 576
Net income	$ 90	$ 88

XML

PROPERTY AND PROFESSIONAL AND GENERAL LIABILITY INSURANCE (Details)	9 Months Ended
	Sep. 30, 2017 USD ($)
Insurance coverage
Insurance coverage, aggregate limit	$ 850,000,000
Flood and Earthquake
Insurance coverage
Insurance, maximum coverage per incident	100,000,000
Windstorms
Insurance coverage
Insurance, maximum coverage per incident	$ 200,000,000
Flood, earthquake and windstorm
Insurance coverage
Insurance deductible as a percent	5.00%
Flood, earthquake and windstorm | Maximum
Insurance coverage
Insurance deductible	$ 25,000,000
New Madrid fault earthquakes
Insurance coverage
Insurance deductible as a percent	2.00%
New Madrid fault earthquakes | Maximum
Insurance coverage
Insurance deductible	$ 25,000,000
Fire and other perils | Minimum
Insurance coverage
Insurance deductible	$ 1,000,000

XML

PROPERTY AND PROFESSIONAL AND GENERAL LIABILITY INSURANCE - Professional and General Liability Reserves (Details) - USD ($) $ in Millions	9 Months Ended		12 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Other operating expense, net
Insurance coverage
Malpractice expense	$ 225	$ 233
Professional and General Liability Reserves
Insurance coverage
Self insurance reserve	$ 827		$ 794
Loss contingency discount rate, maturity rate period	7 years		7 years
Risk-free discount rate	2.16%		2.25%

XML

CLAIMS AND LAWSUITS (Details)	1 Months Ended	9 Months Ended
	Apr. 30, 2017 plantiff	Sep. 30, 2017 system	Feb. 28, 2017 lawsuit	Jan. 31, 2017 lawsuit
Securities Litigation
Loss Contingencies
Consolidated lawsuits			2
Number of plaintiffs | plantiff	4
Shareholder Derivative Litigation
Loss Contingencies
Consolidated lawsuits				2
Antitrust Class Action Lawsuit
Loss Contingencies
Number of hospital systems alleging violation | system		3

XML

CLAIMS AND LAWSUITS - Reconciliations (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Loss Contingency Accrual [Roll Forward]
Litigation and Investigation Costs	$ 6	$ 4	$ 12	$ 291
Claims, lawsuits, and regulatory proceedings
Loss Contingency Accrual [Roll Forward]
Litigation reserve, Balances at Beginning of Period			12	299
Litigation and Investigation Costs			12	291
Cash Payments			(14)	(59)
Litigation reserve, Balances at End of Period	10	531	10	531
Claims, lawsuits, and regulatory proceedings | Continuing operations
Loss Contingency Accrual [Roll Forward]
Litigation reserve, Balances at Beginning of Period			12	299
Litigation and Investigation Costs			12	291
Cash Payments			(14)	(59)
Litigation reserve, Balances at End of Period	10	531	10	531
Claims, lawsuits, and regulatory proceedings | Discontinued operations
Loss Contingency Accrual [Roll Forward]
Litigation reserve, Balances at Beginning of Period			0	0
Litigation and Investigation Costs			0	0
Cash Payments			0	0
Litigation reserve, Balances at End of Period	$ 0	$ 0	$ 0	$ 0

XML

REDEEMABLE NONCONTROLLING INTERESTS IN EQUITY OF CONSOLIDATED SUBSIDIARIES - Ownership percentage (Details) - United Surgical Partners International - Redeemable noncontrolling interests - USD ($) $ in Millions			1 Months Ended
	Jul. 03, 2017	May 01, 2017	Apr. 30, 2016	Sep. 30, 2017
REDEEMABLE NONCONTROLLING INTEREST
Payment made to purchase shares in joint venture	$ 716	$ 711	$ 127
Joint venture ownership	80.00%		56.30%	15.00%
Joint venture, ownership percentage acquired		23.70%
Joint venture, put option, percentage ownership purchase option, next fiscal year				7.50%
Joint venture, put option, percentage ownership purchase option, in two years				7.50%

XML

REDEEMABLE NONCONTROLLING INTERESTS IN EQUITY OF CONSOLIDATED SUBSIDIARIES - Changes in Redeemable Noncontrolling Interests (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Changes in redeemable noncontrolling interests in equity of consolidated subsidiaries
Distributions paid to noncontrolling interests	$ (93)	$ (82)
Purchase accounting adjustments		237
Accretion of redeemable noncontrolling interests	32	0
Redeemable noncontrolling interests
Changes in redeemable noncontrolling interests in equity of consolidated subsidiaries
Balances at beginning of period	2,393	2,266
Net income	155	170
Distributions paid to noncontrolling interests	(85)	(69)
Purchase accounting adjustments	0	(47)
Purchases and sales of businesses and noncontrolling interests, net	(679)	(13)
Balances at end of period	$ 1,816	$ 2,307

XML

REDEEMABLE NONCONTROLLING INTERESTS IN EQUITY OF CONSOLIDATED SUBSIDIARIES - Segment Details (Details) - Redeemable noncontrolling interests - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016	Dec. 31, 2015
REDEEMABLE NONCONTROLLING INTEREST
Redeemable noncontrolling interests	$ 1,816	$ 2,307	$ 2,393	$ 2,266
Net income attributable to redeemable noncontrolling interests	155	170
Hospital Operations and other
REDEEMABLE NONCONTROLLING INTEREST
Redeemable noncontrolling interests	529		520
Net income attributable to redeemable noncontrolling interests	14	16
Ambulatory Care
REDEEMABLE NONCONTROLLING INTEREST
Redeemable noncontrolling interests	1,090		1,715
Net income attributable to redeemable noncontrolling interests	103	116
Conifer
REDEEMABLE NONCONTROLLING INTEREST
Redeemable noncontrolling interests	197		$ 158
Net income attributable to redeemable noncontrolling interests	$ 38	$ 38

XML

INCOME TAXES (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Income Taxes
Income tax expense (benefit)	$ (60)	$ 10	$ (105)	$ 61
Continued operations pre-tax earnings	(348)	89	(325)	219
Reduction in estimated liabilities for uncertain tax positions			(33)
Unrecognized tax benefits	68		68
Unrecognized tax benefits which, if recognized, would impact effective tax rate	65		65
Unrecognized federal and state tax benefits and reserves for interest and penalties, which may decrease in the next 12 months	2		2
Discontinued Operations, Held-for-sale | United Kingdom Facilities
Income Taxes
Income tax expense (benefit)	(30)
Continuing operations
Income Taxes
Income tax expense (benefit)	$ (60)	$ 10	(105)	$ 61
Interest and penalties related to accrued liabilities for uncertain tax positions, recognized			$ 4

XML

INCOME TAXES - Federal Tax Reconciliation (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Reconciliation between reported income tax expense (benefit) and income taxes calculated by the statutory federal income tax rate
Tax expense (benefit) at statutory federal rate of 35%	$ (122)	$ 31	$ (114)	$ 77
State income taxes, net of federal income tax benefit	8	3	13	10
Tax benefit attributable to noncontrolling interests	(25)	(28)	(79)	(75)
Nondeductible goodwill	104	0	104	29
Nontaxable gains	0	(1)	0	(18)
Nondeductible litigation	0	4	0	37
Change in tax contingency reserves, including interest	(1)	(1)	(3)	(4)
Stock-based compensation	0	0	9	0
Change in indefinite reinvestment assertion	(30)	0	(30)	0
Change in valuation allowance	(5)	0	(5)	0
Other items	11	2	0	5
Income tax expense (benefit)	$ (60)	$ 10	$ (105)	$ 61
Statutory federal rate			35.00%

XML

LOSS PER COMMON SHARE (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Loss Attributable to Common Shareholders (Numerator)
Net loss attributable to Tenet Healthcare Corporation common shareholders for basic loss per share	$ (366)	$ (9)	$ (474)	$ (108)
Effect of dilutive stock options, restricted stock units and deferred compensation units	0	0	0	0
Net loss attributable to Tenet Healthcare Corporation common shareholders for diluted loss per share	$ (366)	$ (9)	$ (474)	$ (108)
Weighted Average Shares (Denominator)
Net loss attributable to Tenet Healthcare Corporation common shareholders for basic loss per share (in shares)	100,812	99,523	100,475	99,210
Effect of dilutive stock options, restricted stock units and deferred compensation units (in shares)	0	0	0	0
Net loss attributable to Tenet Healthcare Corporation common shareholders for diluted loss per share (in shares)	100,812	99,523	100,475	99,210
Per-Share Amount
Net loss attributable to Tenet Healthcare Corporation common shareholders for basic loss per share (in dollars per share)	$ (3.63)	$ (0.09)	$ (4.72)	$ (1.09)
Effect of dilutive stock options, restricted stock units and deferred compensation units (in dollars per share)	0.00	0.00	0.00	0.00
Net loss attributable to Tenet Healthcare Corporation common shareholders for diluted loss per share (in dollars per share)	$ (3.63)	$ (0.09)	$ (4.72)	$ (1.09)

XML

LOSS PER COMMON SHARE - Antidilutive securities (Details) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Employee stock options, restricted stock units and deferred compensation units
Antidilutive securities
Anti-dilutive securities excluded from computation of earnings per share (in shares)	711	1,455	747	1,470

XML

FAIR VALUE MEASUREMENTS (Details) $ in Millions	9 Months Ended
	Sep. 30, 2017 USD ($) hospital	Sep. 30, 2016 USD ($)	Dec. 31, 2016 USD ($)
Fair value of assets and liabilities measured on recurring basis
Impairment charges	$ 3	$ 2
Number of hospitals | hospital	77
Equity method investment impairment	$ 29
Aspen And Philadelphia Area Facilities | Discontinued Operations, Held-for-sale
Fair value of assets and liabilities measured on recurring basis
Impairment charges	294
Recurring basis
Fair value of assets and liabilities measured on recurring basis
Marketable debt securities — noncurrent	54		$ 49
Investments	54		49
Recurring basis | Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair value of assets and liabilities measured on recurring basis
Marketable debt securities — noncurrent	40		23
Investments	$ 40		$ 23
Estimated fair value of the long-term debt instrument as a percentage of carrying value	100.60%		93.90%
Recurring basis | Significant Other Observable Inputs (Level 2)
Fair value of assets and liabilities measured on recurring basis
Marketable debt securities — noncurrent	$ 14		$ 26
Investments	14		26
Nonrecurring
Fair value of assets and liabilities measured on recurring basis
Long-lived assets held for sale	399
Long-lived assets held and used			163
Other than temporarily impaired equity method investments	112		27
Investments	511		190
Nonrecurring | Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair value of assets and liabilities measured on recurring basis
Long-lived assets held for sale	0
Long-lived assets held and used			0
Other than temporarily impaired equity method investments	0		0
Investments	0		0
Nonrecurring | Significant Other Observable Inputs (Level 2)
Fair value of assets and liabilities measured on recurring basis
Long-lived assets held for sale	399
Long-lived assets held and used			163
Other than temporarily impaired equity method investments	112		27
Investments	$ 511		$ 190

XML

ACQUISITIONS - Purchase Price Allocation (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Final purchase price allocations
Goodwill	$ 7,022		$ 7,425
Series of individual business acquisitions
Final purchase price allocations
Current assets	4	$ 42
Property and equipment	5	33
Other intangible assets	5	7
Goodwill	65	316
Other long-term assets	1	6
Current liabilities	(4)	(25)
Long-term liabilities	(1)	(14)
Redeemable noncontrolling interests	(18)	(114)
Noncontrolling interests	(13)	(122)
Cash paid, net of cash acquired	(41)	(96)
Gains on consolidations	3	33
Transaction costs related to prospective and closed acquisitions	$ 5	$ 5

XML

SEGMENT INFORMATION - General Information and Customer Concentration (Details)	9 Months Ended
	Sep. 30, 2017 hospital state
SEGMENT INFORMATION
Number of surgical hospitals	20
Conifer
SEGMENT INFORMATION
Ownership percentage by parent	76.20%
Minimum | Conifer
SEGMENT INFORMATION
Number of hospitals to which segment of the entity provides revenue cycle services	800
United Surgical Partners International
SEGMENT INFORMATION
Number of ambulatory surgery centers	244
Number of urgent care centers	34
Number of diagnostic imaging centers	22
Number of states where operations occur | state	27
Ownership percentage by parent	80.00%
European Surgical Partners Ltd
SEGMENT INFORMATION
Number of facilities owned by subsidiaries	9

XML

SEGMENT INFORMATION - Reconciling Items (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
SEGMENT INFORMATION
Assets	$ 23,208		$ 23,208		$ 24,701
Capital expenditures	144	$ 201	492	$ 614
Net operating revenues	4,586	4,849	14,201	14,761
Equity in earnings of unconsolidated affiliates	38	31	95	85
Adjusted EBITDA	507	582	1,604	1,828
Depreciation and amortization	219	205	662	632
Adjusted EBITDA and Other Reconciling Items
Adjusted EBITDA	507	582	1,604	1,828
Loss from divested and closed businesses (i.e., the Company’s health plan businesses)	(6)	(6)	(41)	(8)
Depreciation and amortization	(219)	(205)	(662)	(632)
Impairment and restructuring charges, and acquisition-related costs	(329)	(31)	(403)	(81)
Litigation and investigation costs	(6)	(4)	(12)	(291)
Interest expense	(257)	(243)	(775)	(730)
Loss from early extinguishment of debt	(138)	0	(164)	0
Other non-operating expense, net	(4)	(7)	(14)	(18)
Gains on sales, consolidation and deconsolidation of facilities	104	3	142	151
Net income (loss) from continuing operations, before income taxes	(348)	89	(325)	219
Inter-segment eliminations
SEGMENT INFORMATION
Net operating revenues	(149)	(159)	(463)	(488)
Hospital Operations and other
SEGMENT INFORMATION
Assets	16,249		16,249		17,871
Adjusted EBITDA and Other Reconciling Items
Health plan revenues	10	122	100	385
Hospital Operations and other | Operating segments
SEGMENT INFORMATION
Capital expenditures	122	182	441	557
Net operating revenues	3,866	4,162	12,066	12,761
Equity in earnings of unconsolidated affiliates	4	3	4	6
Adjusted EBITDA	269	346	924	1,191
Depreciation and amortization	185	170	560	525
Adjusted EBITDA and Other Reconciling Items
Adjusted EBITDA	269	346	924	1,191
Depreciation and amortization	(185)	(170)	(560)	(525)
Ambulatory Care
SEGMENT INFORMATION
Assets	5,847		5,847		5,722
Ambulatory Care | Operating segments
SEGMENT INFORMATION
Capital expenditures	16	14	37	42
Net operating revenues	468	448	1,395	1,319
Equity in earnings of unconsolidated affiliates	34	28	91	79
Adjusted EBITDA	159	157	476	432
Depreciation and amortization	22	22	66	69
Adjusted EBITDA and Other Reconciling Items
Adjusted EBITDA	159	157	476	432
Depreciation and amortization	(22)	(22)	(66)	(69)
Conifer
SEGMENT INFORMATION
Assets	1,112		1,112		$ 1,108
Conifer | Operating segments
SEGMENT INFORMATION
Capital expenditures	6	5	14	15
Net operating revenues	401	398	1,203	1,169
Adjusted EBITDA	79	79	204	205
Depreciation and amortization	12	13	36	38
Adjusted EBITDA and Other Reconciling Items
Adjusted EBITDA	79	79	204	205
Depreciation and amortization	(12)	(13)	(36)	(38)
Conifer | Operating segments | Tenet
SEGMENT INFORMATION
Net operating revenues	149	159	463	488
Conifer | Operating segments | Other customers
SEGMENT INFORMATION
Net operating revenues	$ 252	$ 239	$ 740	$ 681